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Although Lyme disease is the most frequently reported vector-borne illness in the United 
States, recent evidence from the CDC suggests that Lyme disease incidence in the United 
States may be much higher than reported. Lyme disease symptoms can be mistaken for a 
wide variety of diseases, which can complicate the diagnosis. To date, no diagnostic 
criteria analysis has been conducted examining the association between 
sociodemographic variables (sex and age) and seasonality of infection with the severity 
and symptomology found in Lyme disease cases. Using the CDC’s outbreak investigation 
model, a primary case/control study was conducted using the ROSS Scale to collect data. 
Comparisons were made between a Lyme disease-diagnosed group (n = 203) and a 
convenience sample of non-Lyme disease patients (n = 388). Novel symptom patterns 
were found to significantly predict a diagnosis of Lyme disease. Odds ratio results 
revealed a positive association between musculoskeletal (OR = 11; 95% CI), neurological 
(OR = 12; 95% CI), cognitive (OR = 10; 95% CI), and cutaneous (OR = 144; 95% CI) 
symptoms frequency and severity and the diagnosis of Lyme disease. In addition, overall 
symptom frequency and severity scores displayed significant differences between cases 
and controls, between males and females, and among certain age groups. No correlation 
was found between symptom frequency and severity with the seasonality of infection. 
Current diagnostic tools search for antibodies to the Borrelia bacteria, but antibody 
production takes a few weeks. The results of this study help identify at-risk patients based 
on the presentation and severity of Lyme disease symptoms when antibodies are not 
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Chapter 1: Introduction to the Study 
Problem Statement 
Lyme disease is a tick-borne illness caused by the spirochete Borrelia burgdorferi 
(Borchers, Keen, Huntley, & Gershwin, 2015; Deluca, Eisendle, & Zelger, 2013; Henry 
et al., 2011; Mead, 2015). Currently, Lyme disease is reported more frequently than any 
other tick-borne illness (Binder, Telschow, & Meyer-Hermann, 2012; Mead, 2015). 
According to the most recent surveillance data provided by the Centers for Disease 
Control and Prevention (CDC), there were 33,461 cases of Lyme disease reported in the 
United States in 2014 (CDC, 2015). These cases represent a 38% increase over the 
previous year’s total. In addition, reported and confirmed Lyme disease cases show a 
bimodal distribution with children between the ages 5-9 years and adults between 40-50 
years showing the highest incidence rates. Males account for 54% of reported cases and, 
except in the 70-plus age groups, consistently have a higher incidence of confirmed Lyme 
disease (CDC, 2007). Based on preliminary data reported from three ongoing CDC 
research studies, Lyme disease may be underreported across all ages by a factor as high 
as 12-to-1 resulting in 300,000 actual cases yearly (Aucott & Seifter, 2011; Borchers et 
al., 2015; CDC, 2015; Johnson, Aylward, & Stricker, 2011; Mead, 2015). The cause of 
this underreporting remains unclear.  
Sex differences in symptom presentation could be a possible reason why Lyme 
disease is underreported. In a study conducted in Slovenia (2013), sex differences existed 
with the presentation and appearance of the erythema migrans (EM) rash (Strle et al., 
2013). The Slovenia study (2013) examined three specific symptoms commonly found in 




differences. The results of the Slovenia study showed that of the 10,539 patients who 
displayed the EM rash, 58% were women, while males (42%) tended to present with 
other noncutaneous symptoms (Strle et al., 2013). In addition, the women who presented 
with the EM rash were 15 years younger than those women who presented with other 
cutaneous symptoms (Strle et al., 2013). In the same study, men were more likely to 
display Lyme arthritis and Lyme neuroborreliosis (later stage symptoms) than women 
(Strle et al., 2013).These results may be related to the specific type of Borrelia species 
found in Europe, which differs from the Borrelia species found in the United States. 
Because of these species variations, further study in the United States is warranted. 
According to the Institute of Medicine’s (IOM) report (2001), sex differences are 
based on factors related to being male or female. These differences result from biological 
differences at the genetic level, cellular level, and/or via hormonal variations between 
males and females (Wizeman & Pardue, 2001). Prior to puberty and the production of the 
sex hormones (estrogen, progesterone, and testosterone), male to female sex differences 
are related only to the anatomical differences present. This study will focus on adult male 
and female subjects. 
Sex differences in symptom presentation have been reported in many chronic and 
autoimmune diseases. For example, coronary heart disease (CHD), stroke, Parkinson’s 
disease, rheumatoid arthritis (RA), multiple sclerosis (MS), and fibromyalgia show 
distinct male to female differences in disease presentation (Casimir et al., 2010; Caracta, 
2003; Hassan, Gordon, & Einstein, 2016; Hirsch, Jette, Frolkis, Steeves, & Pringsheim, 
2016; Kure et al., 2016; Maselli et al., 2016; Ngo, Steyn, & McCombeet, 2014; Quintero, 




disease is caused by a bacterium, long term infection mimics a few autoimmune disorders 
such as RA, MS, and systemic lupus erythematosus (SLE) (Savely, 2010). 
Sex differences may also be found in recreational or occupational exposure to 
ticks. Studies have been conducted examining both recreational and occupational risk of 
contracting Lyme disease, but none have examined this risk based on sex (Borchers et al., 
2015; Finch et al., 2014; Piacentino & Schwartz, 2002). In addition, seasonality of 
infection may be important because exposure to ticks and risk for contraction of Lyme 
disease may increase based on outdoor exposure to the Ixodes tick during peak tick 
growth seasons (CDC, 2015; Borchers et al., 2015; Finch et al., 2014; Mead, 2015). 
Age variations in Lyme disease presentation have also been reported. According 
to CDC data for the years 2000-2010, males in the age group 5-9 years contain the most 
reported confirmed cases of Lyme disease (Borchers et al., 2015; CDC, 2015). A second 
spike in the number of cases during the same time frame occurs in both males and 
females age 40-50 years old (Borchers et al., 2015; CDC, 2015). This bimodal 
distribution is also seen in Europe and was supported by a study in Germany (Borchers et 
al., 2015; Dehnert et al., 2012). Why do these age variations exist? Are these variations 
related to sex differences in symptom presentation? 
Gender differences, although the term is often used interchangeably with sex 
differences, are related to an individual’s interactions with and expectations from their 
social environment (Sieck, 2015; Wizeman & Pardue, 2001).According to the World 
Health Organization’s report on sex and gender differences in epidemic-prone infectious 
diseases (2007), gender roles can determine exposure possibilities and treatment seeking 




increased based on occupational and recreational exposures (Borchers et al., 2015; Finch 
et al., 2014; McKenna, Faustini, Nowakowski, & Wormser, 2004). Gender differences 
can be seen in many occupational and recreational choices. While occupational and 
recreational choices as part of the risk of exposure to the Ixodes tick were considered, the 
focus of this study remained on differences in symptom presentation based on biological 
sex and not on gender roles. 
In addition, Lyme disease shows seasonality in incidence rates. According to the 
CDC (2015), the highest number of reported cases for Lyme disease occur between the 
months of May and August. This time frame corresponds directly with the life cycle of 
the Ixodes scapularis tick (Aucott & Seifter, 2011; Borchers et al., 2015; CDC, 2015; 
Mead, 2015). Although incidence data is collected and reported by the CDC, an analysis 
based on sociodemographic and clinical factors, including sex, age, time since exposure 
to the Ixodes tick, month of case confirmation, symptomology, and severity of symptoms, 
has not been performed. Factors associated with seasonality of infection, sex, and age 
could provide insight into the risk of exposure to Lyme disease and whether these factors 
play a role in the underreporting of Lyme disease. 
Lastly, severity of reported symptoms must be considered. While the severity of 
the EM rash or Bell’s palsy may not prevent someone from performing daily tasks, the 
changes in appearance may prevent a person from going to work, school, or out in public 
(Fu, Bundy, & Sadiq, 2011). In addition, some of the other symptoms of Lyme disease 
may significantly impact day-to-day activities.  
Arthritic pain in the major joints can prevent sufferers from performing normal 




symptoms of Lyme disease in the United States (Borchers et al., 2015; Feder, Abeles, 
Bernstein, Whitaker-Worth, & Grant-Kels, 2006; Mead, 2015; Nadelman, & Schwartz, 
2012; Wormser et al., 2006). According to the Arthritis Foundation (2014), arthritis is the 
leading cause of disability in the United States. Severity of arthritis pain in the joints due 
to B. burgdorferi infection is no different than that caused by RA or osteoarthritis and can 
lead to similar levels of disability (Borchers et al., 2015; Nadelman, & Schwartz, 2012; 
Wormser et al., 2006). 
Symptom severity may lead to additional negative outcomes. These negative 
outcomes may include, but are not limited to, inability to work, loss of job, and loss of 
insurance coverage (Chandra, Keilp, & Fallon, 2013; Johnson et al., 2011). The more 
severe the symptom experienced, the more functional impact Lyme disease can have on 
the individual. 
Significance 
Lyme disease has been classified into three phases of infection: early localized 
Lyme disease, early disseminated Lyme disease, and late Lyme disease (Binder et al., 
2012; Borchers et al., 2015; Donta, 2012; Girschick, Morbach, & Tappe, 2009; Wormser 
et al., 2006). In addition to the three accepted phases of Lyme disease, posttreatment 
Lyme disease syndrome and chronic Lyme disease have also been reported (Aucott, 
Rebman, Crowder, & Kortte, 2012; Cairns & Goodwin, 2005; Cameron, 2010). In early 
or localized Lyme disease, symptoms include mild flu-like symptoms, malaise, fatigue, 
headache and the erythema migrans (EM) rash that begins around the site of the tick bite 
and slowly increases in size to a typical diameter of at least 5 cm (Binder et al., 2012; 




rash occurs more frequently with B. burgdorferi sensu stricto, which is the bacterial 
species found in the United States, than in Lyme disease cases in Europe caused by other 
species of the bacterium (Borchers et al., 2015; Mead, 2015; Girschick et al., 2009).  
In 50 – 80% of all cases of Lyme disease, the erythema migrans (EM) rash is 
present and can be used as a primary method for diagnosis (Aucott, Crowder, Yedlin, & 
Kortte, 2012; CDC, 2015; Miraflor et al., 2016). The EM rash can serve as a strong 
clinical marker for diagnosis according to the case definition of the National Notifiable 
Diseases Surveillance System (CDC, 2008). Correct identification of this rash is vital to 
the diagnosis of early Lyme disease because current diagnostic tools result in negative 
tests 60% of the time in patients who show up for treatment during the earliest stage of 
infection (Aucott et al., 2009). Inaccurate identification of this rash can lead to delayed 
treatment or treatment with antibiotics that would have no effect on the organism leading 
to long term, serious effects on the patient (Aucott et al., 2009). 
Early disseminated Lyme disease signals the spread of the bacteria from the initial 
site of infection. The hallmark of this stage of infection is nervous system symptoms such 
as meningitis and cranial nerve palsies (Binder et al., 2012; Borchers et al., 2015; Donta, 
2012; Girschick et al., 2009; Wormser et al., 2006). In some cases, secondary EM lesions 
may appear at sites not near the initial tick bite (Binder et al., 2012; Borchers et al., 2015; 
Donta, 2012; Girschick et al., 2009; Wormser et al., 2006). Secondary EM lesions have 
been seen in approximately 40% of children who show up for treatment but are less 
common in adults (Girschick et al., 2009). In addition, mild musculoskeletal system 
symptoms have been reported during this phase, especially in the United States (Borchers 




Late Lyme disease may occur many months after the initial tick bite and results 
from systemic spread of the bacteria (Binder et al., 2012; Borchers et al., 2015; Donta, 
2012; Girschick et al., 2009; Wormser et al., 2006). Typical manifestations of this stage 
include arthritis, especially in the large joints of the arms and legs, polyneuropathy, 
cranial neuropathy, cardiac complications, and encephalomyelitis (Binder et al., 2012; 
Borchers et al., 2015; Donta, 2012; Girschick et al., 2009; Wormser et al., 2006). 
If left untreated or inadequately treated, early Lyme disease can progress quickly 
to late phase infection and the serious complications that come with this phase of the 
disease. Most research suggests that earlier treatment provides the patient’s best chance 
for a full recovery (Cameron, 2007; Donta, 2012; Johnson & Stricker, 2004; Miraflor et 
al., 2016). Once treatment is initiated, 80-90% of patients significantly improve (CDC, 
2015). Delaying treatment can be costly, both in patient health costs and in reduced 
quality of life (Johnson et al., 2011). Zhang et al. (2006) determined that the annual 
health care costs associated with late Lyme disease treatment ($16,199 per person) can be 
12 times higher than those costs associated with early Lyme disease treatment ($1,310 
per person).  
During the early stage of infection, treatment with beta-lactam antibiotics is 
highly successful at killing the bacteria and stopping the progression of the infection 
(Binder et al., 2012; Borchers et al., 2015; Cameron, 2007; Donta, 2012; Girschick et al., 
2009; Wormser et al., 2006). Late phase infections may require longer term or 
intravenous treatments with antibiotics (Binder et al., 2012; Cameron, 2007; Donta, 2012; 
Girschick et al., 2009; Wormser et al., 2006). Unfortunately, antibiotic treatment for late 




et al., 2013; Johnson et al., 2011). It is in these instances that post-treatment Lyme 
disease syndrome and/or chronic Lyme disease may be the diagnosis. 
Because late phase manifestations can be incapacitating, adults could be burdened 
with “functional impacts” of Lyme disease (Aucott et al., 2013, p 2). Functional impacts 
occur when patients experience symptoms and/or increased severity of symptoms that 
prevent them from completing daily activities (Aucott et al., 2013). These functional 
impacts may include loss of job, loss of productivity, lapse of insurance coverage, and 
disability (Johnson et al., 2011). In fact, loss of productivity makes up more than half the 
costs of late Lyme disease infection (Johnson et al., 2011). Early, accurate diagnosis of 
Lyme disease can prevent all of these impacts by stopping the spread of the infection 
before the serious complications of late Lyme disease occur (Miraflor et al., 2016). 
In cases of misdiagnosis in children and adults, the burden of Lyme disease may 
be measured in more than just the financial burden. In a study conducted by Tager et al. 
(2001), children diagnosed with Lyme disease showed many cognitive difficulties even 
after the completion of treatment. These cognitive difficulties included attention and 
organizational deficits, as well as memory and IQ issues (Tager et al., 2001). Similar 
cognitive difficulties have also been reported for adult patients with late Lyme disease 
(Borchers et al., 2015; Cairns & Godwin, 2005). Early, accurate diagnosis is vital to 
prevent these long term cognitive changes (Tager et al., 2001). 
Identification of the comorbidities that alter the symptom presentation of Lyme 
disease would be helpful in ensuring the accurate diagnosis and appropriate treatment at 
the earliest stage of infection of Lyme disease. In chronic diseases such as cardiovascular 




been identified (Fairweather, Petri, Coronado & Cooper, 2012; Hassan et al., 2016; 
Hirsch et al., 2016; Kure et al., 2016; Maselli et al., 2016; Ngo et al., 2014; Quintero et 
al., 2012). In autoimmune diseases such as RA and SLE, females are more likely to be 
affected than males based on the specific mechanisms of the female immune system 
(Fairweather et al., 2012; Ngo et al., 2014; Quintero et al., 2012). According to Dey et al. 
(2009), women with acute coronary syndromes were more likely to have a milder form of 
the disease and to report atypical symptoms, such as jaw pain and nausea, when seeking 
treatment. The study by Dey et al. supported the findings of a previous study on sex 
differences in symptom presentation for cardiovascular disease (Polk & Naqvi, 2005).  
In Parkinson’s disease, both age and sex differences play a role in the progression 
of the disease (Hirsch et al., 2016; Haaxma et al., 2007). Women develop symptoms 2.2 
years later than men (Hirsch et al., 2016; Haaxma et al., 2007). After disease onset, 
women displayed different symptoms than men at initial diagnosis; women seemed to 
display the “tremor dominant form” of the disease (Haaxma et al., 2007, p. 822).  
Understanding of these differences has led to targeted prevention and education 
programs for both patients and physicians, and timely administration of treatment for 
women who present with nonclassical symptoms of disease. These advances can be 
realized for Lyme disease as well if potential differences in symptom presentation can be 
identified. 
Background 
Lyme disease is caused by the spirochete Borrelia burgdorferi sensu lato 
(Borchers et al., 2015; Deluca et al., 2013; Mead., 2015; Miraflor et al., 2016). This 




genospecies based on the bacterial genome, geographical location, tick vector, reservoir 
animal, and Lyme disease symptoms produced (Borchers et al., 2015; Deluca et al., 2013; 
Mead et al., 2015; Pritt et al., 2016). The five most commonly found pathogenic 
genospecies include B. burgdorferi sensu stricto found in North America and Europe; B. 
garinii and B. afzelii found in Europe; B. japonica found in Japan; and B. andersonii 
found in North America (Borchers et al., 2015; Mead, 2015; Pritt et al., 2016). A new 
genospecies of Borrelia was recently discovered in the Midwestern United States, 
specifically Minnesota, North Dakota, and Wisconsin (CDC, 2015; Pritt et al., 2016). 
This new genospecies, proposed name Borrelia mayonii, has similar symptoms to 
Borrelia burgdorferi (Pritt et al., 2016). Signs and symptoms of infection vary based on 
the Borrelia species causing the infection (Borchers et al., 2015; Deluca et al., 2013; 
Mead, 2015). 
Lyme disease is transmitted through the bite of the Ixodes tick (Arsnoe, Hickling, 
Ginsburg, McElreath, & Tsao, 2015; Borchers et al., 2015; Deluca et al., 2013; Mead, 
2015; Miraflor et al., 2016). The tick vector varies based on the geographic area where 
the tick is found. In the United States, the primary vectors of Lyme disease are Ixodes 
scapularis in the Eastern states and Ixodes pacificus on the West coast (Arsnoe et al., 
2015; Borchers et al., 2015; Deluca et al., 2013; Mead, 2015). In order for Lyme disease 
to be transmitted to a human host, the tick must first be infected with B. burgdorferi 
while feeding from an infected animal host (Arsnoe et al., 2015; Deluca et al., 2013). 
Typical animal reservoirs for B. burgdorferi include small rodents like the white-footed 
mouse, hares, small birds, and white-tailed deer (CDC, 2015; Deluca et al., 2013). 




human host for 24-48 hours to pass on the infection (Borchers et al., 2015; CDC, 2015; 
Hynote, Mervine, & Stricker, 2012).   
Clinical manifestations of Lyme disease occur in three phases (Binder et al., 2012; 
Borchers et al., 2015; Deluca et al., 2013; Girschick et al., 2009; Johnson & Feder Jr., 
2010). These phases include early or localized Lyme disease, early disseminated Lyme 
disease, and late Lyme disease (Binder et al., 2012; Borchers et al., 2015; Deluca et al., 
2013; Girschick et al., 2009; Johnson & Feder Jr., 2010). In addition, posttreatment Lyme 
disease syndrome and chronic Lyme disease have been discussed in the literature. Each 
phase has typical signs and symptoms associated with movement of the bacteria from the 
initial tick bite to a systemic infection (Binder et al., 2012; Borchers et al., 2015; Deluca 
et al., 2013; Girschick et al., 2009; Johnson & Feder Jr., 2010).  
Signs and symptoms include, but are not limited to, flu-like symptoms such as 
malaise, fatigue, fever, arthralgia, myalgia; arthritis; neuropathy including Bell’s Palsy; 
meningitis and encephalitis; cardiac symptoms including atrial block; and erythema 
migrans (EM) rash (Binder et al., 2012; Borchers et al., 2015; Deluca et al., 2013; 
Girschick et al., 2009; Johnson & Feder Jr., 2010; Miraflor et al., 2016).   
The classic bull’s eye EM rash is the most widely known symptom associated 
with Lyme disease (Aucott et al., 2012a; Borchers et al., 2015; Miraflor et al., 2016). Key 
features of the EM rash include a shape that is round to oval; a red to bluish-red color; a 
clearly defined edge; occurs at the location of the tick bite; and increases in size over time 
from 5 cm to 16 cm (Moore, 2015; Muellegger, 2004). Typical locations for the EM rash 
appear to coincide with common tick bite locations. In adults, EM usually occurs on the 




the scalp/hairline (Muellegger, 2004). With the new genospecies Borrelia mayonii, the 
rash is more diffuse and distributed and does not take on the typical bulls-eye appearance 
(Pritt et al., 2016). In children, head and neck lesions are more common than in adults 
(Muellegger, 2004). Unfortunately, some of these sites are not conducive to finding the 
tick or viewing the EM rash, so patients may not seek treatment during the early phase of 
infection. 
Because some form of the EM rash is present in 50 – 80% of reported cases, the 
EM rash alone can be used to definitely diagnose Lyme disease without any additional 
testing (Johnson & Stricker, 2004; Miraflor et al., 2016; Moore, 2015). The EM rash 
provides the best clinical marker for Lyme borreliosis (Moore, 2015; Muellegger, 2004). 
According to the National Notifiable Disease Surveillance System (NNDSS) case 
definition, a diagnosis can be made based on the presence of the EM rash or positive two-
tiered serology testing with ELISA and Western blot (CDC, 2008). Unfortunately, the 
classic appearance of the bull’s eye EM rash (concentric rings with a central clear area) is 
present only 20% of the time with Borrelia burgdorferi infections and not at all with 
Borrelia mayonii infections (Aucott et al., 2012a; Pritt et al., 2016). 
Other manifestations of this rash can be present and can significantly confuse the 
accurate diagnosis of Lyme disease in the early stages. These manifestations include 
homogenous red lesions with no central clearing; secondary lesions; vesiculopustular 
lesions; lesions with bruising, which typically occur on the calves; and a “diffuse macular 
rash” occurring all over the body including the palms of the hands and soles of the feet 
(Aucott et al., 2012a ; Pritt et al., 2016, pg. 7;). In addition, other skin lesions may be 




(spider or mosquito); immediate allergic inflammatory responses to the initial tick bite 
which decreases in size over time; poison ivy rash; shingles rash; cellulitis; hand-foot-
mouth disease; and S. aureus infection (Aucott et al., 2012a; Tibbles & Edlow, 2007). 
Lipsker, Lieber-Mbomeyo, and Hedelin (2004) found that almost 72% of physicians in 
Lyme endemic areas could not correctly diagnose the EM rash (Aucott et al., 2012a; 
Brett, Hickley, Zielinski-Gutierrez, & Mead, 2014). Early diagnosis is necessary to 
ensure full recovery from infection (Brett et al., 2014). 
Lyme disease can be successfully treated with a 21 day course of oral antibiotics 
as long as neurological or cardiac symptoms are not present (Borchers et al., 2015; 
Gerstenblith & Stern, 2014; Johnson & Feder Jr., 2010). Neurological or cardiac 
symptoms may require up to 28 days of IV antibiotics (Borchers et al., 2015; Johnson & 
Feder Jr., 2010). The earlier this treatment begins, the more likely a full recovery will 
occur (Borchers et al., 2015; Brett et al., 2014; Johnson & Stricker, 2004; Mead, 2015). 
Delayed treatment may lead to more chronic symptoms and may require longer courses 
of antibiotics (Cameron, 2007; Johnson & Stricker, 2004). In addition, the direct and 
indirect medical costs may pose problems for patients over the long term. Zhang et al. 
(2006) found that the economic impact of Lyme disease nationwide was more than $200 
million in direct and indirect medical costs, as well as nonmedical costs like loss of 
productivity. This cost can be avoided with accurate diagnosis in the early stages of 
infection so that appropriate treatment can be implemented. 
Tager et al. (2001) discuss the cognitive deficits found in children with late phase 
Lyme disease. These deficits can lessen quality of life and increase the burden assumed 




memory and IQ deficiencies, attention and concentration disorders, and withdrawal from 
social situations (Tager et al., 2001). Similar cognitive defects have also been found in 
adults in the later stages of the infection (Cairns & Godwin, 2005). 
Posttreatment Lyme disease (PTLD) syndrome occurs when patients have been 
diagnosed with Lyme disease via the traditional methods of EM rash identification or 
enzyme immunosorbent assay (EIA) and Western blot, treated with a 21-day course of 
antibiotics, and still display symptoms like fatigue, arthralgia, myalgia, and memory and 
concentration issues (Lantos, 2011; Nichols & Windemuth, 2013). While rare, PTLD 
syndrome does occur more frequently in patients who are diagnosed in the later stages of 
infection or had severe symptoms at diagnosis (Lantos, 2011; Nichols & Windemuth, 
2013).  
Lastly, the controversy surrounding chronic Lyme disease must be presented. The 
controversy is centered on the existence of chronic Lyme disease. On one side of the 
controversy are the physicians and researchers who believe that chronic Lyme disease 
does not exist; that Lyme disease is rarely found in the general population, is not easily 
acquired, and is simple to cure with the standard course of antibiotics (Johnson et al., 
2011; Stricker & Johnson, 2007). On the other side of the controversy are the physicians 
and researchers who believe that chronic Lyme disease exists and is extremely difficult to 
treat and cure (Johnson et al., 2011; Stricker & Johnson, 2007). 
An important component of this controversy stems from the fact that the 
Infectious Diseases Society of America (IDSA) is influential in determining treatment 
regimens for Lyme and other infectious diseases in the United States (Johnson et al., 




recommendations set forth do not cover treatment for long term infection, providing 
barriers to health care access and increased disease burden for those diagnosed with 
chronic Lyme disease (Johnson et al., 2011).  
The International Lyme and Associated Diseases Society (ILADS) is on the 
opposite side of this controversy. ILADS was formed by a group of physicians and 
researchers to advance the options available for chronic Lyme disease sufferers (ILADS, 
2009). This group has also offered a case definition of chronic Lyme disease with 
diagnostic criteria and treatment recommendations. The ILADS case definition is broader 
and covers many more presentations of symptoms (ILADS, 2009; Lantos, 2011). In 
addition, diagnostic criteria take into consideration the expertise of the physician and do 
not rely exclusively on the EM rash, EIA, and/or Western blot tests (ILADS, 2009; 
Lantos, 2011). Lastly, treatment options are expanded to allow for extended antibiotic 
treatment as needed (ILADS, 2009; Lantos, 2011). Although the existence of chronic 
Lyme disease remains controversial, identification of sex differences in symptom 
presentation may help inform this issue more fully. 
Sex differences in symptom presentation have been seen in many other diseases. 
In coronary heart disease (CHD), women often do not present with chest pain as their 
primary symptom (Dey et al., 2008; Fairweather et al., 2012; Kure et al., 2016; Polk & 
Naqvi, 2005; Wizeman & Pardue, 2001). However, males experiencing CHD most often 
report chest pain as a primary symptom (Dey et al., 2008; Fairweather et al., 2012; Polk 
& Naqvi, 2005; Wizeman & Pardue, 2001). According to the American Heart 
Association (2015), a woman is likely to experience shortness of breath and/or pain and 




pain may prevent a woman from seeking help, since it is an accepted convention that 
heart attacks present with chest pain. 
Parkinson’s disease is another example where women and men present with 
different symptoms. Parkinson’s disease is more common in men than women, where 
women tend to present with symptoms at an older age (Haaxma et al., 2006; Hirsch et al., 
2016). In addition, women are more likely to present with the classic tremors associated 
with Parkinson’s disease while men tend to present with rigidity and bradykinesia, which 
is slow, limited movement (Haaxma et al, 2006; Hirsch et al., 2016). 
Observed advantages for women in both CHD and Parkinson’s disease may be 
related to estrogen levels circulating in the bloodstream. Differences in symptoms of both 
CHD and Parkinson’s disease between males and females seem to equal out after 
menopause (Haaxma et al., 2006; Hirsch et al., 2016; Kure et al., 2016; Wizeman & 
Pardue, 2001). While age of onset and estrogen levels may affect symptom presentation 
for CHD and Parkinson’s disease, autoimmune diseases are another example where 
symptom presentation differs between males and females and estrogen levels may not be 
the cause. For many autoimmune diseases, the prevalence in women is 60 – 75% higher 
than it is in men (Maselli et al., 2016; Ngo et al., 2014; Quintero et al., 2012; Whitacre, 
2001). 
Late Lyme disease mimics a few autoimmune diseases and is often misdiagnosed 
as MS, SLE, and RA (Hassan et al., 2016; Ngo et al., 2014; Quintero et al., 2012; Savely, 
2010). Some symptom similarities between MS and Lyme disease include confusion, 
weakness, peripheral nerve numbness, dizziness, and malaise (Savely, 2010). Joint and 




not receive a diagnosis of MS (Savely, 2010). Unfortunately, in SLE and RA, joint and 
muscle pain and malaise are primary symptoms (Hassan et al., 2016; Savely, 2010). 
Lastly, autoimmune diseases tend to present later in life, so misdiagnosis with 
autoimmune diseases versus Lyme disease may occur more frequently in older patients 
than in children (Savely, 2010; Whitacre, 2001).   
Because Lyme disease displays a bimodal distribution when considering age as a 
variable, it becomes important to identify why this distribution occurs (Dehnert et al., 
2012; Esposito, Bosis, Sabatini, Tagliaferri, & Principi, 2013). Are these variations due to 
sex differences in recreational behaviors and occupational exposures? While studies have 
been conducted on outdoor worker exposure and tick counts/types in recreational areas, 
no studies have looked at Lyme disease, occupational and/or recreational exposure, and 
sex (Belongia et al., 1999; Finch et al., 2014; Piacentino & Schwartz, 2002; Schwartz & 
Goldstein, 1990; Smith, Benach, White, Stroup, & Morse, 1988). Most of these studies 
collected sex (male/female) information, but none of the studies analyzed sex as a 
variable for study. This study will include a sex comparison in the collection and analysis 
of data.  
In addition, none of the described studies examined seasonality of infection in 
relation to either sex or age. Seasonality of infection could be directly related to outdoor 
activities because exposure to the Ixodes scapularis tick occurs outdoors during certain 
stages of the tick’s life cycle. Month of diagnosis and potential month of tick exposure 
will be collected from the medical records and ROSS scale surveys in order to make 





An appropriate theoretical framework for this study is the CDC’s outbreak 
investigation model (Rohrer, 2013). Although Lyme disease is not considered a typical 
outbreak type of disease (like Salmonella or E. coli), the outbreak investigation model 
can still apply. This model allows for examining the relationship between a variable 
under consideration and a disease like Lyme disease (Reingold, 1998). This model also 
allows for the expansion of the variables studied as more information becomes available 
(Roher, 2013). In addition, the outbreak investigation model fits well with the case-
control study design. Independent variables to be studied include socio-demographic 
characteristics like age and sex; seasonality of infection characteristics like month of 
infection and month of diagnosis; and time since tick exposure; dependent variables to be 
studied include symptoms present at diagnosis and severity of symptoms as reported by 
the patient (Table 1). 
Table 1 
Study Variables 
Independent variables Dependent variables 






Age Month of tick 
exposure 
Musculoskeletal Not affected Never 




  Cognitive Minor but 
noticeable 
3-4 days 
State of Residence**  General Moderate 5-6 days 
 Cardiac  Major 7 days 
Cutaneous disabling  
*See Appendix A for a complete list of symptoms.  





The CDC outbreak investigation model has 10 components, but only seven were 
applied to this study (Reingold, 1998). The three components that were not applicable to 
the current study included environmental sampling and testing, controlling the spread of 
infection, and dissemination of information via the press to the public (Reingold, 1998). 
Dissemination of information on the finding of this study will occur in public forums at 
the completion of the study. The steps of the model that were applied include the 
following: 
First, a case definition was established to ensure that all cases met specific, 
consistent criteria for inclusion in the study. Cases (n = 203) were defined as adult 
subjects (≥ 18 years of age) that met one of the following diagnostic criteria: (a) patient 
presented with a physician confirmed EM rash; (b) patient had a positive EIA and/or 
Western Blot laboratory result for IgG and IgM antibodies to B. burgdorferi surface 
proteins; or (c) patient had a score of 5 or higher on the Burrascano Diagnostic Criteria 
for Lyme Disease scale (Burrascano, 2005).  
Controls (n = 388) were selected from adult subjects (≥ 18 years of age) from the 
primary care clinic who did not suffer from Lyme disease, family members of Lyme 
disease patients at the primary care clinic, and employees and students at a small, liberal 
arts college. Subjects who suffered from illnesses other than Lyme disease were not 
excluded from the study. All controls were Lyme disease free at the time of selections as 
determined by: (a) never having had a tick bite; (b) having no evidence of EM rash; or (c) 
no prior laboratory testing for or diagnosis of Lyme disease by a physician. Controls were 
selected at an approximate 1:2 case/control ratio to address the sampling bias introduced 




Removal of participants who did not meet the established case criteria was 
performed. Cases were removed based on age (participant must be over 18 years old), 
missing data for date of birth, and state of residence. Because state of residence was used 
to match cases and controls, participants were required to live in a Lyme endemic state 
for this study to equalize the risk of exposure to the Ixodes tick vector. Additional 
information on case inclusion and exclusion criteria can be found in chapters 3 and 4. 
Next, case confirmation was performed by a qualified physician who specialized 
in the treatment of Lyme disease. Completed forms were reviewed with the primary care 
physician to verify inclusion as a case or control for this study from a clinical standpoint. 
Because controls must NOT be Lyme disease positive, any indicators from the symptom 
checklist for a potential undiagnosed Lyme disease patient were reviewed carefully for 
appropriate case/control placement or exclusion from the study. No undiagnosed Lyme 
diseases cases were identified through this review. 
Incidence rates for Lyme disease were established for all states of residence used 
in the study. This data was collected from the CDC, which reports data received via the 
National Notifiable Disease Surveillance System. Lyme disease is a vector-borne disease 
that, if caught early, can be cured with a 21-28 day course of antibiotics (Gerstenblith & 
Stern, 2014). Lyme disease is therefore reported in incidence rates because each case 
reported to the National Notifiable Disease Surveillance System (NNDSS) represents a 
newly diagnosed infection. 
Cases and controls were enrolled from two sites – a primary care clinic that 
specializes in the treatment of Lyme disease and a small, liberal arts college campus. At 




Because sex and age were two variables of interest in this study, matching between cases 
and controls based on sex or age could not occur. Matching based on state of residence 
was done to insure that exposure to the Ixodes scapularis tick was the same between 
cases and controls. In addition, both cases and controls had to be available from a 
particular state to be considered for inclusion in the study. 
Descriptive data was collected and analyzed. Data collected included, but was not 
limited to: sex, date of birth, state of residence, education level, date of tick bite, and date 
of diagnosis. These demographic characteristics allowed for the establishment of person, 
place, and time variables. Cases consisted of both females (n = 130) and males (n = 73) 
ranging in age from 18 years to 75+ years. Controls consisted of both females (n = 268) 
and males (n = 120) also ranging in age from 18 years to 75+ years. States of residence 
for both cases and controls included Connecticut, Massachusetts, New Hampshire, New 
Jersey, New York, Pennsylvania, and Vermont. All of these states are considered Lyme-
endemic states by the CDC (2015). 
Overall, 51% of the study population had at least a high school diploma and 44% 
of the population had completed at least a baccalaureate degree. Cases occurred in all 
twelve months; the majority of cases occurred in May (n = 34) and June (n = 29) and the 
fewest number of cases occurred in March (n = 3). Twenty one cases did not list a month 
of tick exposure or month of diagnosis, so they were excluded from the analysis for 
seasonality of infection only. 
Research Questions 
Five research questions were formulated, each with a null and alternate hypothesis 




review of the published literature. These research questions were an important guide for 
the inquiry into specific factors that ultimately affect the diagnosis of Lyme disease. 
Symptom presentation and severity were compared to defined sociodemographic 
variables, seasonality of infection variables, and time since tick exposure to identify areas 
to expand health providers’ knowledge and awareness of Lyme disease which can lead to 
earlier diagnosis and treatment, reduced treatment costs and improved health outcomes 
for Lyme disease patients. 
RQ1: Is the presentation of symptoms in Lyme disease-positive patients 
associated with the sociodemographic variables age and sex as assessed by patient 
medical record and ROSS Scale survey review? 
H01: Lyme disease symptom presentation is not associated with the 
sociodemographic variables age and sex as assessed by patient reported 
symptoms recorded in patient medical records or on the ROSS Scale survey. 
Ha1: Lyme disease symptom presentation is associated with the 
sociodemographic variables age and sex as assessed by patient reported 
symptoms recorded in patient medical records or on the ROSS Scale survey. 
RQ2: Is the severity of symptoms in Lyme disease positive patients associated 
with the sociodemographic variables age and sex as assessed by patient medical 
record and ROSS Scale survey review? 
H02: Lyme disease symptom severity is not associated with the 
sociodemographic variables age and sex as assessed by patient reported 




Ha2: Lyme disease symptom severity is associated with the sociodemographic 
variables age and sex as assessed by patient reported symptoms recorded in 
patient medical records or on the ROSS Scale survey. 
RQ3: Is the presentation of symptoms associated with the diagnosis of Lyme 
disease as assessed by patient medical record and ROSS Scale survey review? 
H03: Lyme disease symptom presentation is not associated with the diagnosis 
of Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
Ha3: Lyme disease symptom presentation is associated with the diagnosis of 
Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
RQ4: Is the severity of symptoms associated with the diagnosis of Lyme disease 
as assessed by patient medical record and ROSS Scale survey review? 
H04: Lyme disease symptom severity is not associated with the diagnosis of 
Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
Ha4: Lyme disease symptom severity is associated with the diagnosis of Lyme 
disease as assessed by patient reported symptoms recorded in patient medical 
records or on the ROSS Scale survey. 
RQ5: Is Lyme disease symptom presentation and severity associated with 
seasonality of infection variables as assessed by medical record and the ROSS 




H05: Lyme disease symptom presentation and severity are not associated with 
the seasonality of infection variables as assessed by patient medical record 
and the ROSS Scale survey review. 
Ha5: Lyme disease symptom presentation and severity are associated with the 
seasonality of infection variables as assessed by patient medical record and 
the ROSS Scale survey review. 
Nature of the Study 
In this study, I followed a quantitative approach to data collection. Patient records 
and ROSS scales were examined for symptoms present at time of doctor’s appointment 
for Lyme disease; severity of symptoms present as described by the patient; sex of 
patient; age at diagnosis; time elapsed between tick exposure and diagnosis; and month of 
possible tick exposure and month of initial diagnosis. Because sex is a nominal variable, 
age, month of exposure and month of diagnosis can be measured using an interval scale, 
and symptom severity is an ordinal variable, quantitative analysis of the data will be 
performed using SPSS (version 21). 
Statistical tests performed include the Chi-square test (if the data are normally 
distributed) or the Kruskal-Wallis test (if the data are not normally distributed), which 
allowed for comparisons between the control group and the study population. The Chi-
square test and the Kruskal-Wallis test can be performed because the sample size is well 
over 60 participants and there was more than five participants in each age category. 
Analysis of Variance (ANOVA) was performed on normally distributed data samples, 
both with and without the Tukey Post-hoc analysis as needed, to compare the various age 




included in the study. Lastly, a receiver operating characteristic (ROC) curve was 
generated to analyze the usefulness of the symptom index score as a diagnostic tool. 
In addition to the described univariate and bivariate statistical analyses, multiple 
linear regression analysis was conducted on sex and age variables in comparison to the 
symptom index score. The independent variables of age and sex were included in the 
analysis regardless of their association with the dependent variables after bivariate 
analysis based on evidence from previous literature (Katz, 2006).  
Since the goal of this research was to identify additional potential factors to use 
for the earliest possible diagnosis of Lyme disease, an analysis based on the use of the 
information from this study for diagnosis was performed. Once associations between 
symptoms and/or symptom severity and the independent variables were determined, the 
sensitivity, specificity, positive predictive value, and the negative predictive values were 
calculated for the groups of symptoms. These values describe the ability of the test to 
identify correctly those individuals who have a disease. A ROC plot was also generated 
determine the diagnostic value of the symptom index score for Lyme disease. 
Possible Types and Sources of Information or Data 
1. ROSS Scale surveys from patient records from a primary care medical 
practice. 
2. ROSS Scale surveys distributed and collected at a small, rural liberal-arts 
college. 
Definition of Terms 





Age: A numerical value distinguishing the number of years an individual has been 
alive, beginning at birth and ending with death (Free Dictionary, 2013). 
Chronic Lyme disease: Persistent symptoms of Lyme disease despite 30 days of 
treatment or a recurrence or relapse of symptoms without evidence of a new tick bite or 
incidence of EM rash (Cameron et al., 2004). 
Early disseminated Lyme disease: The stage of Lyme disease infection associated 
with the spread of the B. burgdorferi bacteria from the initial site of infection as 
associated with neurological symptoms, like cranial nerve palsies and meningitis, and 
initial musculoskeletal complaints (Binder et al., 2012; Donta, 2012; Franz & Krause, 
2003; Girschick et al., 2009; Wormser et al., 2006). 
Early localized Lyme disease: The stage of Lyme disease infection signaled by 
symptoms that include mild flu-like symptoms, malaise, fatigue, headache and the 
erythema migrans (EM) rash that begins around the site of the tick bite and slowly 
increases in size to a typical diameter of at least 5 cm (Binder et al., 2012; Donta, 2012; 
Franz & Krause, 2003; Girschick et al., 2009; Wormser et al., 2006). Neurological 
symptoms, including Bell’s palsy, may be present as well (Binder et al., 2012; Donta, 
2012; Franz & Krause, 2003; Girschick et al., 2009; Wormser et al., 2006;). 
Erythema migrans (EM) rash: A characteristic rash of early localized Lyme 
disease with the key features that include a shape that is round to oval; a red to bluish-red 
color; a clearly defined edge; occurs at the location of the tick bite; and increases in size 




Sex: For the purposes of this research, the term sex will be used to describe male 
or female biological sex, as well as the individual’s interactions with and expectations 
from their social environment (Wizeman & Pardue, 2001). 
Late Lyme disease: The stage of Lyme disease infection characterized by 
musculoskeletal complaints including arthritis, especially in the large joints of the arms 
and legs, polyneuropathy, cranial neuropathy, cardiac complications, and 
encephalomyelitis (Binder et al., 2012; Donta, 2012; Franz & Krause, 2003; Girschick et 
al., 2009; Wormser et al., 2006).  
Posttreatment Lyme disease syndrome: The stage of Lyme disease characterized 
by the continuation or return of symptoms after a standard course of treatment for the 
disease (Aucott, Crowder, & Kortte, 2013).  
Symptom presentation: The subjective signs of Lyme disease as reported by the 
patient (Free Dictionary, 2013). 
Symptom severity: The intensity of the subjective signs of Lyme disease as 
reported by the patient (Free Dictionary, 2013).  
Limitations 
One of the main limitations for this study is related to sampling bias. The patient 
records examined all came from one clinic in New York. The patient records do not 
represent a random sampling of individuals because this study focuses on those 
individuals who have already been diagnosed with Lyme disease. In addition, all of these 
patients have access to health care and have health insurance, so results may not be 




Controls were selected by convenience sampling, which can lead to a reduction of 
external validity (Mann, 2003; McDermott, 2011; Pannucci & Wilkins, 2010). The 
convenience sample was chosen despite this reduction because the medical clinic treats 
patients from a broad sampling of states within the Lyme endemic region of the United 
States and the college also has students and staff from these same Lyme endemic regions. 
According to the CDC surveillance data, 97% of all reported Lyme disease cases come 
from only 14 states (CDC, 2015). These states include: Connecticut, Delaware, Maine, 
Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin (CDC, 2015). The 
medical clinic is centrally located and within driving distance from Connecticut, New 
York, Pennsylvania, and New Jersey. The college is located two hours west from the 
medical clinic. This central location provided the opportunity for both Lyme disease and 
non-Lyme disease participants to be chosen as both cases and controls. In addition, the 
age distribution of controls from the college was well matched to the age distribution of 
the medical clinic. 
To address this non-random sampling bias, a ratio of 1:2 cases to controls was 
used. Frequency matching was used to insure that cases and controls had a similar 
percentage of participants that fell into the male/female and the selected age categories. 
Because age and sex are variables under investigation in this study, matching could not 
occur on these variables, but to make meaningful comparisons on these variables, there 
must be similar numbers of cases and controls for each sex and age category 
(McDermott, 2011; Pannucci & Wilkins, 2010; Zondervan, Cardon, & Kennedy, 2002). 




residence. Because Lyme disease is endemic to only 14 states in the United States, 
matching of cases and controls on their state of residence insures that potential exposure 
to the Ixodes tick is equal in both groups. 
Recall bias is a potential problem with case-control study designs (Mann, 2003; 
McDermot, 2011; Pannucci & Wilkins, 2010; Schulz & Grimes, 2002). Because this 
study collected data through medical record review and via the ROSS Scale survey, recall 
bias was minimized. Cases reported signs and symptoms experienced at the time of their 
medical office visit. Controls reported symptoms experienced within the previous week 
from the date the ROSS scale was filled out. The ROSS Scale survey collects data on 
symptoms for the week prior to filling out the survey. Recalling information from the 
past seven days helped to minimize recall bias considerably.  
Lastly, confounding must be addressed. Because matching of cases with controls 
and stratification were difficult due to age and sex being variables under study, potential 
confounders were dealt with in the analysis portion of the study through multivariate 
regression analysis (McDermott, 2011; Schlesselman, 1982; Schulz & Grimes, 2002).  
Statement of Positive Social Change Implications 
The implications of this research for positive social change include increased 
knowledge of the sex differences found in Lyme disease; prevention of delays in 
diagnosis and treatment for patients with Lyme disease; decreased expenses associated 
with late Lyme disease due to increased diagnosis in the early stage of infection; and 





This chapter outlined the key components of this research project. Research 
questions and hypotheses were identified. Key definitions were provided. Significant 
background for and descriptions of Lyme disease were provided to show the importance 
of studying factors that could increase the accurate diagnosis and early treatment of Lyme 
disease. Further evidence to support the importance of studying Lyme disease is provided 





Chapter 2: Literature Review 
Introduction 
This chapter provides a review of the literature in support of an examination of 
the factors that affect the presentation of Lyme disease. First, I provide a description of 
Borrelia burgdorferi, the causative agent of Lyme disease. Because Lyme disease is a 
tick-borne disease, Ixodes scapularis and Ixodes pacificus, the tick vectors found in the 
United States, must be described as well. In addition, I review the complex lifecycle of 
both Borrelia burgdorferi and Ixodes scapularis.  
Next, I establish evidence for sex differences in other chronic and infectious 
diseases. These established differences, although not well studied in Lyme disease in the 
United States, can be utilized as support for identifying the same differences in Lyme 
disease. In addition, I review comparisons between the male and female immune 
response. I also discuss age differences in the incidence of Lyme disease. Lyme disease 
symptoms are clearly defined to provide the necessary basis for study measurements. 
Finally, I discuss the theoretical framework for the study. 
I identified pertinent literature using Google and Google Scholar search engines, 
as well as Science Direct, PubMED, and ProQuest databases. Search terms included 
Lyme disease, symptoms of Lyme disease, sex differences + Lyme disease, gender 
differences + Lyme disease, age + Lyme disease, sex differences + immune response, 
gender differences + immune response, sex differences + chronic disease, gender 
differences + chronic disease, sex differences + cardiovascular disease, gender 




differences + autoimmune disease, sex differences + infectious disease, gender 
differences + infectious disease, Lyme disease + children, behavior risk factors + Lyme 
disease, occupational exposure + Lyme disease, recreational activity + Lyme disease, 
symptom severity  + Lyme disease, and environmental risk factors + Lyme disease. Both 
sex differences and gender differences were searched separately because these terms are 
often used interchangeably.  
The Causative Agent 
The causative agent for Lyme disease, as it is known in the United States, or 
Lyme borreliosis, as it is known in Europe and Asia, was discovered in 1981 by Dr. 
Willy Burgdorfer, an entomologist who studied ticks and the organisms who lived inside 
them (Sternbach & Dibble, 1996). This bacterium, Borrelia burgdorferi sensu lato, has 
been separated into more than 20 distinct species to date, not all of which cause disease in 
humans (Borchers et al., 2015; Caimano, Hu, Radolf, & Stevenson, 2012; Mead, 2015). 
The primary disease causing agents for Lyme disease are Borrelia burgdorferi sensu 
stricto, found in the United States and Europe, Borrelia garinii, and Borrelia afzelii, 
found in Europe and Asia, and the recently discovered Borrelia mayonii, found only in 
the Midwestern United States (Borchers et al., 2015; Caimano et al., 2012; Mead et al., 
2015; Pritt et al., 2016). Because the patient sample for this research will be in the eastern 
United States, the focus of this literature review will be on Borrelia burgdorferi sensu 
stricto. 
Borrelia burgdorferi sensu stricto is a Gram negative, microaerophilic member of 
the family Spirochaetaceae (Johnson, Schmid, Hyde, Steigerwalt, & Brenner, 1984; 




flexible spiral shape of other members of the Spirochaetaceae family with both inner and 
outer protective membranes that enclose the periplasmic flagella which allow the 
organism to be motile by either rotational or translational movement (Johnson et al., 
1984; Rosa et al., 2005). The cell wall of B. burgdorferi is missing lipopolysaccharides, a 
unique characteristic for a Gram negative organism, since most Gram negative cell walls 
contain a high concentration of lipopolysaccharides (Rosa et al., 2005). In addition, the 
peptidoglycan layer of the cell wall contains a high concentration of ornithine (Johnson et 
al., 1984). Peptidoglycan composition is important since peptidoglycan is a typical 
antimicrobial target for treatments. 
The cell wall encloses a unique genome. First, the genome contains both a 
segmented linear chromosome and between 13 and 21 linear and circular plasmids 
(Brisson et al., 2012; Caimano et al., 2011; Rosa et al., 2005; Schutzer et al., 2011). 
While the linear chromosome contains much of the structural and metabolic information 
necessary for survival, this information is carried repeatedly on many different genes 
(Brisson et al., 2012; Caimano et al., 2011; Schutzer et al., 2011). In fact, many of the 
genes in the Borrelia genome are identical (Brisson et al., 2012; Schutzer et al., 2011). 
Bacterial plasmids generally carry information for virulence, exotoxins, endotoxins, or 
special enzymes. Borrelia plasmids carry information vital for survival, including the 
outer surface protein genes (Brisson et al., 2012; Caimano et al., 2011; Schutzer et al., 
2011). In addition, no virulence factors have been discovered on any of the known 
plasmids (Brisson et al., 2012; Rosa et al., 2005).  
Additional components of the bacterial cell wall and membrane with functional 




have been identified, but only three have identified functions in the infection cycle 
(Kenedy, Lenhart, & Akins, 2012; Pal et al., 2000). Outer surface protein A (OspA) plays 
a role in replication in and infection of the Ixodes tick vector (Hartiala et al., 2008; 
Kenedy, Lenhart, & Akins, 2012; Pal et al., 2000). This protein is only produced when 
Borrelia is in the tick’s gut and plays a role in binding to TROPSA receptors in the mid-
gut region of the tick (de Silva, Fish, Burkot, Zhang, &Fikrig, 1997; de Silva, Telford III, 
Brunet, Barthold, &Fikrig, 1996; Hartiala et al., 2008; Kenedy, Lenhart, & Akins, 2012; 
Pal et al., 2004a; Schwan, Piesman, Golde, Dolan, & Rosa, 1995). Once the tick begins 
feeding on either the natural host or the human host, production of OspA stops and 
Borrelia no longer expresses this protein on the surface (de Silva et al., 1997; de Silva et 
al., 1996; Hartiala et al., 2008; Kenedy, Lenhart, & Akins, 2012; Schwan et al., 1995). 
OspA was a target for the Lyme vaccine because OspA is found only in the tick stage of 
infection, but the vaccine is no longer produced due to poor sales in the United States (de 
Silva et al., 1997; de Silva et al., 1996; Schwan et al., 1995).  
Outer surface protein B (OspB) is found in conjunction with OspA on the 
bacterial cell surface when Borrelia is in the mid-gut of the Ixodes tick (de Silva et al., 
1997; de Silva et al., 1996; Hartiala et al., 2008; Kenedy, Lenhart, & Akins, 2012; 
Neelakanta et al., 2007; Schwan et al., 1995). While not much is known about the 
function of OspB, a study by Neelakanta et al. (2007) confirmed the importance of OspB 
in binding of Borrelia burgdorferi to the epithelial lining of the Ixodes tick. In addition, 
Hartiala et al. (2008) suggested that OspB plays a role in immune system evasion by 




previously presented by Bundoc and Barbour (1989), but little evidence was provided to 
support this earlier claim.  
While OspA and OspB are expressed by Borrelia burgdorferi within the Ixodes 
tick vector, down-regulation and reduced expression of these two proteins occurs once 
the blood meal commences and the bacterium enters the mammalian host (de Silva et al., 
1997; de Silva et al., 1996; Kenedy, Lenhart, & Akins, 2012; Neelakanta et al., 2007; 
Schwan et al., 1995). Outer surface protein C (OspC) is expressed for a short while 
during Borrelia migration from the mid-gut to the salivary glands and upon first entering 
the mammalian host (Carrasco et al., 2015; Grimm et al., 2004; Kenedy, Lenhart, & 
Akins, 2012; Neelakanta et al., 2007; Pal et al., 2004a; Stewart et al., 2006; Tilly et al., 
2006). The shift from OspA/OspB production to OspC production is related to the pH 
changes that occur in the mid-gut of the tick during the blood meal (Tilly et al., 2006).  
Pal et al. (2004b) found that OspC is present in greater numbers than OspA or 
OspB during migration of the bacteria to the salivary glands of the tick, but Grimm et al. 
(2004), Tilly et al. (2006), and Stewart et al. (2006) all found that OspC was not required 
for Borrelia motility or adherence to the tick salivary glands. It seems that OspC plays a 
vital role during early infection of the mammalian host (because OspC expression down-
regulates after 2 weeks post infection), but this role was unclear (Carrasco et al., 2015; 
Grimm et al., 2004; Stewart et al., 2006; Tilly et al., 2006). In a study conducted by 
Carrasco et al. (2015), OspC is important for evading phagocytosis by macrophages at 
the site of the infection. This phagocytic evasion allows the organism to colonize the 




According to Samuels (2011), one role of OspC is binding to mammalian 
plasminogen (an important protein for dissolving blood clots). Onder et al. (2012) 
suggested that the binding between plasminogen and OspC on the surface of B. 
burgdorferi provided a few advantages. First, plasminogen binding helped the bacteria 
cross over multiple cell membranes: from tick mid-gut to salivary glands; from tick 
salivary glands into mammalian skin; from skin at bite site to mammalian blood stream 
(Onder et al., 2012). Second, plasminogen helps to break down antibodies and deactivates 
parts of the complement system (Onder et al., 2012). Each of these factors provides 
support for the importance of OspC for B. burgdorferi infection of mammalian cells. 
OspC is not required for tick re-infection from the mammalian host (Tilly et al., 
2006). In a study with mice infected with an OspC mutant form of Borrelia burgdorferi, 
naïve ticks were infected with the OspC mutant form after feeding on infected mice (Tilly 
et al., 2006). Both Tilly et al. (2006) and Stewart et al. (2006) suggest that OspC plays a 
role in either evading the mammalian host’s innate immune system or recognition of the 
mammalian host tissue. Neither group provided adequate evidence to support either 
hypothesis, but Onder et al. (2012) provided evidence to support both.  
Stewart et al. (2006) suggested that genetic variations in OspC may allow for 
evasion of the innate immune system and subsequent dissemination from the initial site 
of infection, but the research did not support this conclusion. OspC gene expression 
down-regulates within two weeks post-infection, right at the time dissemination from the 
initial tick bite normally occurs (Grimm et al., 2004). This early research suggested that if 
OspC is important for dissemination in the host, down-regulation of the gene for OspC 




cycle. Recent research by Onder et al. (2012) show that OspC helps the bacteria get into 
the bloodstream for dissemination, but is not necessary for the actual spread of the 
infection. 
Samuels (2011) suggested that because OspC is considered a dominant 
immunogen, production shuts down to prevent antibody production. This shutdown 
would prevent adaptive and memory immune responses, but would not affect the innate 
immune system. Carrasco et al. (2015) suggest that OspC plays a role in evading innate 
immune system responses like macrophage phagocytosis. Onder et al. (2012) suggest that 
OspC serves as a plasminogen receptor that helps break down antibodies. The role of 
OspC in the immune process is still under investigation. While the functions of these 
outer surface proteins in the mammalian hosts are not completely understood, their 
interactions within the tick vector are important. 
The Vector 
The vector for Lyme disease is the Ixodes tick (Figure 1). Four primary species 
have been identified as a carrier for Borrelia burgdorferi: Ixodes scapularis in the eastern 
United States, Ixodes pacificus in the western United States, Ixodes ricinus in Europe, 
and Ixodes persulcatus in Europe and Asia (Borchers et al., 2015; Caimano et al., 2012; 
Mead, 2015; Rosa et al., 2005; Suss, Klaus, Gerstengarbe, & Werner, 2008). The tick 
becomes infected, usually during the larval stage of its life cycle, by feeding on an 
infected endemic host (Caimano et al., 2012; Mead, 2015; Subak, 2003). These hosts tend 
to be small mammals and birds (Caimano et al., 2012; Subak, 2003). In the United States, 
Peromyscus leucopus (white-footed mouse) is the primary reservoir (Caimano et al., 






Figure 1. Ixodes scapularis tick sizes (CDC, 2015) 
 
The Life Cycle 
Ixodes ticks are born uninfected with Borrelia burgdorferi because passage of the 
bacteria does not occur through transovarial routes (Borchers et al., 2015; Rosa et al., 
2005). As shown in Figure 2, Ixodes ticks lay eggs in May of the first year of their two 
year life cycle (CDC, 2015; Subak, 2003). Eggs hatch releasing larvae in the summer 
months (CDC, 2015; Subak, 2003). In order to continue to the next stage of development, 
larvae must feed and tend to feed on smaller mammals like Peromyscus leucopus 
(Caimano et al., 2012; Mead, 2015; Rosa et al., 2005; Subak, 2003). It is at this point that 
the tick becomes infected with Borrelia burgdorferi (Caimano et al., 2012; Mead, 2015; 
Rosa et al., 2005; Subak, 2003). The tick is infected with the Borrelia bacteria for life and 
can transmit the bacteria to any other organism it feeds on (Borchers et al., 2015; 
Caimano et al., 2012; Rosa et al., 2005; Subak, 2003). 
The larvae become dormant over the winter and molt into the nymph stage in the 
spring (CDC, 2015; Caimano et al., 2012; Subak, 2003). A second blood meal must be 
taken at this time in order for the final stage of development to occur (Caimano et al., 




for nymphal feeding (Caimano et al., 2012; Rosa et al., 2005; Subak, 2003). Nymphs 
develop into adults that are able to lay eggs and begin the cycle again (Caimano et al., 
2012; Rosa et al., 2005; Subak, 2003).  
 
Figure 2. Tick two-year life cycle (CDC, 2015) 
Larvae become infected with Borrelia during the blood meal and remain in the 
tick midgut until the tick enters the nymph stage (Rosa et al., 2005). At this point, 
Borrelia expresses both OspA and OspB (Rosa et al., 2005). The bacteria do not invade 
any other tissues within the tick until after becoming a nymph and the second blood meal 
occurs (Rosa et al., 2005). With the pH changes that occur during the second blood meal, 
OspA and OspB production is down-regulated and OspC production is up-regulated as 
the bacteria move from the midgut of the tick to the salivary glands (Caimano et al., 
2012; Kenedy, Lenhart, & Akins, 2012; Rosa et al., 2005). Once in the salivary glands, 
Borrelia can be transferred to the next organism bitten (Borchers et al., 2015; Caimano et 




Borrelia is not transferred immediately to the new host (Caimano et al., 2012; 
Rosa et al., 2005). Ticks must be attached more than 24 hours for the transfer to occur 
because during the first 24 hours of attachment, little blood is actually taken in by the tick 
(Borchers et al., 2015; Caimano et al., 2012; Dai et al., 2010; Hynote, Mervine, & 
Stricker, 2012; Rosa et al., 2005). After 48 hours of attachment, blood meal intake by the 
tick increases rapidly and poses the largest chance for transfer of Borrelia to the new host 
(Dai et al., 2010). While the minimum number of spirochetes required to cause infections 
in humans in not currently known, the infective dose of Borrelia in mice models suggest 
as few as 18 bacteria can lead to infection (Borchers et al., 2015).  
Incidence Rates 
Because Lyme disease is a vector-borne disease, each new case reported to the 
CDC is considered a new infection. In addition, Lyme disease is endemic to only 14 
states in the United States. These states are mostly located in the eastern United States 
and correspond to the habitat of the Ixodes scapularis tick. Incidence rates for Lyme 
disease for each state used in the study are shown in Table 2 (CDC, 2015).  
Table 2  
Incidence Rate by State of Residence of Study Participants for 2014 (CDC, 2015) 
State of residence Incidence rate (per 100,000 people) Lyme disease cases (count) 
Connecticut 47.8 2,360 
Massachusetts 54.1 5,304 
New Hampshire 46.9 724 
New Jersey 29.0 3,286 
New York 14.4 3,736 
Pennsylvania 50.6 7,487 





The lower incidence rate in New York is related to the fact that New York has a 
state population of 19.75 million people, 8.5 million that live in New York City alone 
(US Census Bureau, 2015). Living in a large urban setting reduces your risk for exposure 
to the Lyme disease tick and lowers your risk for developing Lyme disease. According to 
CDC data, New York (n = 3,736) had more reported cases than Connecticut (n = 2,360) 
in 2014, but due to the population differences between the two states, Connecticut has a 
higher incidence rate (CDC, 2015). The other states with low numbers of confirmed cases 
but high incidence rates follow the same pattern – the overall population size is lower in 
states like Vermont and New Hampshire (US Census Bureau, 2015). 
Risk Factors 
Behavioral and environmental risk factors for tick-borne diseases have been 
studied since the early 90’s. Risk factors associated with Lyme disease specifically have 
been studied in Pennsylvania, Maryland, New Jersey, California, Wisconsin, Rhode 
Island and Connecticut, all highly endemic states for Lyme disease and the normal habitat 
for the Ixodes tick that serves as the vector for Lyme disease. These studies examined the 
following risk factors: location of primary residence, activities associated with tick 
habitat contact, and pet or animal ownership. Occupational risk was also examined. 
In the one of the earliest studies, Glass et al. (1995) performed a case-control 
study (n = 47/492) in Baltimore County, Maryland for incident cases in 1989 and 1990. 
This study focused on environmental factors associated with tick habitat and interaction 
venues for tick/human interactions. Study results suggested that living close to a forest 
increased the risk for contact with a tick and the subsequent development of Lyme 




1995). As the distance between living space and forest increases, risk drops accordingly 
(Glass et al., 1995). In addition, living in a highly developed urban area provided a 
protective effect (Glass et al., 1995). Glass et al. (1995) were the only researchers to find 
this protective effect, although other studies did support distance from forested areas as a 
reduced risk for contracting Lyme disease. 
Ley, Olshen, and Reingold (1995) examined common outdoor activities that could 
provide an opportunity for a tick-human interaction. The case-control study took place in 
California with 101 cases and 107 controls (Ley, Olshen, &Reingold, 1995). During the 
period 1992-1997, California had only 581 confirmed Lyme disease cases so the case 
sample size for the study period of June 1991-December 1992 provided a large case 
population (CDC, 2015).  
Results of this study did not identify any activities that were significantly 
associated with contracting Lyme disease. Activities selected for examination included a 
variety of yard work activities, like gardening, clearing brush, and stacking wood, and 
leisure activities, like hiking, biking, camping, and fishing (Ley et al., 1995). The study 
did not examine distance of the home from a wooded area, but did examine whether a 
fenced in or natural yard was present (Ley et al., 1995).  
These results are in direct contrast with the studies by Glass et al. (1995), Orloski 
et al. (1998), and Belongia et al. (1999) discussed in this review. Ley et al. (1996) 
suggested that this contrast may be due to the fact that California is a very populous state 
with 29 million people living there in 1990 (US Census, 2001). A sample size of 101 
confirmed cases would not be representative of the entire state and significance levels 




surface area with many different climates present across the state. Tick habitat 
availability would vary significantly across the many distinct climate areas in California, 
further diluting the potential for significant differences in Lyme disease risk (Ley et al., 
1995).  
In an earlier study (n = 83) in California conducted by Lane et al. (1992), outdoor 
risk factors for Lyme disease were also examined. Of the variables examined as a 
potential risk factor for Lyme disease, only woodcutting (OR = 4.8; 95% CI 1.01-23.10) 
showed statistical significance (Lane et al., 1992). In addition, living in a “natural” area 
(with a home close to a wooded area) was considered an increased risk but the statistical 
measures were not provided for this risk, so the level of risk can’t be quantified from the 
reported data (Lane et al., 1992). Lane et al. (1992) were the only researchers to report a 
significant difference in risk between females and males (OR = 2.3; 95% CI 0.94-5.81) 
infected with Lyme disease. Sex data was collected in the studies conducted by Glass et 
al. (1995), Ley et al. (1996), Klein et al. (1996), Orloski et al. (1998), and Belongia et al. 
(1999) but were not analyzed as a potential risk factor for developing Lyme disease. 
Klein, Epps, and Hunt (1996) specifically studied environmental factors and 
activities in children. In this case-control study (n = 44/44), twenty four environmental 
factors and 45 activities were examined for increased risk for Lyme disease in the 
northeastern endemic states of Maryland, New Jersey, and Pennsylvania (Klein et al., 
1996). Based on the findings of this study, the only significant risk for Lyme disease in 
children is the presence of deer ticks in the home and yard (OR = 3.05; 95%CI 0.97-9.89) 




environmental factors or activities were surveyed so no comparisons can be drawn with 
the other studies examined in this literature review.  
Orloski et al. (1998) performed a case-control (n = 51) study that examined both 
behavioral and environmental factors for Lyme disease. Results showed the typical 
bimodal age distribution (<11 years and 40-60 years peaks), month of onset (May, June, 
or July), presence of erythema migrans (EM) rash (87%), and sex distribution (males in 
the younger age group; females in the older age group) as that reported by the Centers for 
Disease Control and Prevention (Orloski et al., 1998). In addition, living near wooded 
areas (OR = 15.0; 95CI) and clearing heavy brush (OR = 4.0; 95CI) on their properties 
produced the greatest risk for contracting Lyme disease. Lastly, rock walls present on the 
property also showed an increased risk for Lyme disease because rock walls provide a 
good habitat for small mammals, like the white-footed mouse, that serve as reservoir 
hosts for Borrelia burgdorferi (Orloski et al., 1998).  
In contrast to the study by Glass et al. (1995), Orloski et al. found that living in an 
urban environment did not produce a protective effect (Orloski et al., 1998). Outdoor 
activities like walking, hiking, or jogging in grassy or wooded areas, gardening or lawn 
mowing, and hunting or fishing did not increase the risk for developing Lyme disease 
(Orloski et al., 1998). Cat ownership also did not increase the risk, but dog ownership 
was not tested and no reason for the exclusion was given (Orloski et al., 1998).  
In a study by Belongia et al. (1999), dog ownership was identified as a risk factor 
for Lyme disease due to the fact that dog owners tend to actively check for and remove 
ticks from their pet dogs. Surprisingly, this study was one of the few conducted with dog 




found no correlation between cat ownership and increased risk for Lyme disease. Other 
factors identified to increase the risk of contracting Lyme disease include: living in a 
rural area on a property with more than two acres of land, living near a farm, clearing 
heavy brush from property or land near property, hiking or jogging on forest paths, and 
camping (Belongia et al., 1999). Surprisingly, and in direct contrast to the studies by 
Glass et al. (1995) and Orloski et al. (1998), living near a wooded area and/or having a 
rock wall or wood pile on the property produced no significant increase in the risk for 
developing Lyme disease (Belongia et al., 1999). In addition, occupational exposures 
were not identified as a significant risk factor (Belongia et al., 1999).  
Piacentino and Schwartz (2002) conducted a review of the extensive literature on 
occupational exposure risk of contracting Lyme disease. Workers identified as having a 
potential increased risk include: forestry workers and lumberjacks, farm workers, military 
personnel, veterinarians, and other workers who spend large amounts of time outdoors 
(Piacentino & Schwartz, 2002). Forty one articles were culled from the vast number of 
articles pertaining to occupational risk of Lyme disease. After careful examination of this 
literature, Piacentino and Schwartz concluded that there was no evidence to support an 
increased occupational risk of “symptomatic, clinically confirmed Lyme disease” in any 
of the categories of outdoor workers (Piacentino & Schwartz, 2002, p. 82).  
These result directly supported the study by Smith, Wileyto, Hopkins, Cherry, and 
Maher (2001) where no increased occupational risk of Lyme disease for outdoor workers 
was found. The authors conducted the largest case-control study (n = 294/449) to date 
that examined occupational, behavioral, and environmental risk factors for Lyme disease. 




reported by the CDC (2015), males did not make up more cases in the lower age range 
and females did not make up more cases in the 40-60 year age range (Smith, Wileyto, 
Hopkins, Cherry, & Maher, 2001).  
Similar to the studies by Glass et al. (1995) and Orloski et al. (1998), living in a 
rural setting increased the risk of developing Lyme disease three times over the risk 
associated with living in an urban setting (Smith et al., 2001). In fact, living in a single 
family home increased the risk for developing Lyme disease 2 ½ times over living in a 
multi-family dwelling (Smith et al., 2001). In addition, living within 100 feet of a wooded 
area increased the risk of developing Lyme disease 4-5 fold (Smith et al., 2001). This 
result is in line with the findings of Glass et al. (1995) and Orloski et al. (1998) but is in 
direct contrast to the findings of Belongia et al. (1999).  
Additional findings identified the following increased risk activities: gardening 
more than four hours per week (OR = 1.83; CI 1.21, 2.54); walking or jogging in the 
woods (OR = 1.48; CI 1.09, 2.00); and picnicking in non-traditional locations (OR = 
1.47; CI 1.02, 2.12) (Smith et al., 2001). There was no increased risk associated with 
camping, which was surprising considering most of the other studies found an increased 
risk for camping (Belongia et al., 1999; Glass et al., 1995; Orloski et al., 1998; Smith et 
al., 2001).  
A more recent study identified which examined risk factors for Lyme disease was 
conducted by Vazquez et al. (2008). The purpose of this case-control study (n = 
709/1,128) was to examine personal protective measures utilized by the sample 
population, but a few occupational, environmental, and activity variables were measured 




were not associated with increased Lyme disease risk (Vazquez et al., 2008). In addition, 
the only occupation with a positive association with increased risk for Lyme disease was 
farming (Vazquez et al., 2008). 
The most recent study identified on risk factors for Lyme disease was conducted 
by Finch et al. (2014). This study (N = 486 participants/ 105 properties) focused mainly 
on peridomestic methods of Lyme disease transmission, including pet ownership and 
shrub cover at the edge of a property. Finch et al. (2014) focused mainly on shrub cover, 
but surveyed land owners about pet ownership, occupational and recreational activities, 
and prevention methods. Results suggested that the density of shrub cover and time spent 
outdoors was correlated to an increased risk of Lyme disease. As with the study 
conducted by Vazquez et al. (2008), pet ownership did not increase the risk for Lyme 
disease (Finch et al., 2014). 
With the results from studies by Finch et al. (2014), Vazquez et al. (2008), 
Piacentino and Schwartz (2002), and Smith et al. (2001), occupational exposure to Ixodes 
ticks does not increase an individual’s risk of developing Lyme disease. Environmental 
factors, like living in a wooded area, may or may not increase the risk of developing 
Lyme disease (Belongia et al., 1999; Glass et al., 1995; Klein et al., 1996; Lane et al., 
1992; Ley et al., 1995; Orloski et al., 1998; Smith et al., 2001). Activities, like camping, 
hunting, hiking, or jogging in wooded areas, may or may not increase your risk of 
developing Lyme disease as well (Belongia et al., 1999; Glass et al., 1995; Klein et al., 
1996; Lane et al., 1992; Ley et al., 1995; Orloski et al., 1998; Smith et al., 2001). With 
the conflicting data provided by these studies, additional information on risk factors for 




Immune System Response 
In order to understand the sex differences found in the immune response to Lyme 
disease, one must first examine the immune system response to the bacterial pathogen in 
general. Borrelia burgdorferi enters the host through the tick bite. The tick provides some 
protection to the bacteria upon injection into the host because the tick also injects certain 
molecules that insure the tick can feed undetected. These molecules prevent immune 
system activation by preventing the activation of immune cells including neutrophils, B-
lymphocytes, T-lymphocytes and dendritic cells, as well as preventing the release of early 
cytokines and antimicrobial peptides (Radolf et al., 2012; Schuijt et al., 2008). One 
molecule used is Salp-15 (Schuijt et al., 2008). Salp-15 prevents CD4
+
 T-lymphocyte 
(helper T-cell) activation by binding to its cellular receptor (Schuijt et al., 2008). In 
addition, using the Salp-15 protein helps Borrelia to prevent the activation of the 
complement system and, if activated, allows evasion of the complement system proteins 
(Schuijt et al., 2008).  
Toll-like receptors (TLR2 and TLR1) on macrophages and dendritic cells 
circulating within the skin are activated by binding to lipoproteins (OspA) on the surface 
of Borrelia, causing the release of key cytokines to initiate the immune system response 
to the invading pathogen (Radolf et al., 2012; Shin et al., 2008). This response can be 
either a TH1-cell or a TH2-cell response. During a TH1-cell response, cytokines gamma 
interferon (IFN-γ), transforming growth factor – beta (TGF-β) and interleukin-2 (IL-2) is 
released (Romagnani, 2000). During a TH2-cell response, cytokines (IL-4, IL-5, IL-6, IL-
9, IL-10, IL-13) may be released, depending on the stimulus (Romagnani, 2000). Specific 




(TNF-α), transforming growth factor beta (TGF-β1), interleukins (IL-1, IL-6, IL-10, IL-
17) and interferons (IFN-α, IFN-γ) (Glickstein et al., 2003; Radolf et al., 2012; Sehgal & 
Khurana, 2015; Widhe et al., 2002). The functions of the various cytokines are shown in 
Table 3. 
Table 3  
Cytokine Functions (Owen, Punt, & Stranford, 2013) 
Cytokine Secreted by Effects 








Factor – beta (TGF-β1) 
Macrophages 
T-lymphocytes 
Inhibits T-cell and B-cell 
proliferation; Inhibits 
macrophages 
Interleukin -1 (IL-1) Macrophages Inflammation 









Interleukin – 17 (IL-17) TH-lymphocytes Inflammation; neutrophil 
recruitment 









Increases MHCI and 
MCHII expression 
 
Release of these cytokines initiate the inflammatory response, calls other immune 
cells to the site of infection, and activate B-lymphocyte differentiate and proliferation 
(Radolf et al., 2012; Widhe et al., 2002). While neutrophils are recruited early in the 








production of the EM rash in infected tissue (Glickstein et al., 2003; Radolf et al., 2012;). 
B-lymphocytes are not activated during the EM rash and the early localized portion of the 
infection cycle (Radolf et al., 2012).  
Activation of B-lymphocytes occurs once Borrelia leaves the initial infection site 
and enters the bloodstream where it can come in contact with B-lymphocytes in the 
spleen during normal transport through the body (Radolf et al., 2012). Antibody 
production occurs in a two-fold process – IgM antibodies are produced first, but don’t 
persist for very long (Radolf et al., 2012). IgG antibodies take longer to be produced, but 
last longer in tissues and circulation (Radolf et al., 2012). Antibodies are produced 
against many of the outer surface proteins (Osp), including OspA and OspC even though 
these proteins don’t seem to play a role outside of the tick host (Liang et al., 2004; Radolf 
et al., 2012). In addition, the lipoprotein VlsE is found on the surface of the organism but 
can demonstrate significant variation in structure, leading to the need for multiple 
antibodies against this specific protein to offer protection (Kenedy, Lenhart, & Akins, 
2012; Radolf et al., 2012). 
One of the primary identified differences between the male and female sex is the 
presence of the steroid hormone estrogen. While estrogen’s primary role in the body is 
during the reproductive cycle in women, estrogen does have an effect on the immune 
system (Baker et al., 2011; Bullard et al., 2012; Pennell et al., 2012). Several immune 
cells have membrane bound cell receptors that bind estrogen, which leads to the 
activation and amplification of a signal transduction cascade (Pennell et al., 2012). These 
immune cells include: B-lymphocytes, T-lymphocytes, dendritic cells, neutrophils, 




In addition, binding of estrogen by immune cells can initiate a cell-specific 
response. Binding of estrogen to B-lymphocytes increases proliferation and antibody 
production (Pennell et al., 2012). Binding of estrogen by TH-lymphocytes leads to 
increased production of IL-10, which also leads to increased proliferation of and antibody 
production in B-lymphocytes (Pennell et al., 2012). Estrogen inhibits IL-1 and IL-6, 
reducing the inflammatory response of effected tissue (Bullard et al., 2010).  
TNF-α and IL-1, along with IFN-γ, initiate the inflammatory response in vascular 
tissue, allowing more fluid and immune cells to enter into the site of the tick bite (Baker 
et al., 2003). This response occurs in both sexes, although IL-1 production is inhibited by 
estrogen in women (Bullard et al., 2010; Pennell et al., 2012). Estrogen increases the 
amount of IgM and IgG antibodies produced by women and can induce IgM and IgG 
production if administered to men (Oertelt-Prigione, 2012). Unfortunately, testosterone 
inhibits IgM and IgG production by reducing the amount of IL-6 produced (Oertelt-
Prigione, 2012). Lastly, estrogen tends to produce a TH2-lymphocyte response, which 
includes increased B-lymphocyte activation and release of IL-4, IL-5, and IL-9 cytokines 
(Pennell et al., 2012). Androgens in males produce a TH1-lymphocyte response, where 




 T-lymphocytes are activated 
(Pennell et al., 2012).  
Infection with Borrelia burgdorferi causes the release of the following cytokines 
in both male and female cases: tumor necrosis factor alpha (TNF-α), transforming growth 
factor beta (TGF-β1), interleukins (IL-1, IL-6, IL-10, IL-17) and interferon (IFN-α, IFN-
γ) (Glickstein et al., 2003; Radolf et al., 2012; Sehgal & Khurana, 2015; Widhe et al., 




inflammatory effect and a reduction in the proliferation and antibody production by B-
lymphocytes in females that would not be found in males (Pennell et al., 2012). In 
addition, estrogen causes an increase in the production of IL-10, a regulatory cytokine 
that helps to control inflammation, further reducing the inflammatory response (Pennell 
et al., 2012). IL-10 production is stimulated by testosterone in men (Giefing-Kroll et al., 
2015).  
Since the inflammatory response serves as an important factor to keep an 
infection localized and allow additional immune cells to enter the infection site, this 
reduction in the inflammatory response could lead to increased symptom frequency and 
severity in female cases. Reduced inflammation also allows the bacteria to spread from 
the site of infection to other locations, like the joints and nervous system. Lastly, 
androgens in males produce CD8
+
 T-lymphocyte activation, which helps to clear the 
infection at the initial infection site (Giefing-Kroll et al., 2015). While the focus of the 
current study was not based on estrogen levels, the effect of estrogen on the immune 
system’s response to an invading pathogen provides support for the reported sex 
differences. 
Sex Differences 
While sex differences in risk factors for Lyme disease was discussed by only 
Lane et al. (1992), sex differences for other diseases have been identified. Cardiovascular 
disease (CVD) sex differences have been documented and continue to be studied 
(DeVon, Ryan, Ochs, & Shapiro, 2008; Dey et al., 2009; Kure et al., 2016; Norris, 
Dasgupta, & Kirkland, 2007). CVD symptom presentation can be markedly different in 




suffering from CVD tend to present with the typical symptom of chest pain that radiates 
out to the left arm (DeVon et al., 2008; Dey et al., 2009; Norris et al., 2007). Women 
suffering from CVD tend to present with non-typical symptoms like pain in the back, 
neck, or jaw, shortness of breath, or indigestion (DeVon et al., 2008; Dey et al., 2009; 
Norris et al., 2007). This variation in symptom presentation often keeps women from 
seeking needed medical care early. In addition, non-typical symptom presentation 
increases the chances for misdiagnosis and administration of the wrong treatment when 
treatment delays can be life threatening (DeVon & Zerwic, 2002; Kure et al., 2016).  
One hypothesis for the sex differences in CVD hinges on estrogen. Estrogen, a 
female sex hormone, is believed to have cardio-protective effects because women 
develop less CVD prior to menopause than men of the same age, but the risk of 
developing CVD becomes equal between men and women after menopause (Baker et al., 
2003; Murphy et al., 2011). Estrogen not only controls the female menstrual cycle, but 
also plays a key role in regulating many other body mechanisms. One of those 
mechanisms is the inflammatory response (Murphy et al., 2011).  
Estrogen regulates several key cytokines responsible for the inflammatory 
response (Bullard et al., 2010). First, estrogen inhibits production of interleukin-1 (IL-1) 
by direct action and through promoting the production of interleukin-4 (IL-4) and 
interleukin-10 (IL-10), which also inhibit IL-1 production (Bullard et al., 2010). IL-1 is 
the cytokine responsible for the initiation of the inflammatory response (Bullard et al., 
2010). While estrogen levels remain in the normal physiological range, protection from 




2010). Once menopause occurs, this protective effect is reduced with reduced estrogen 
concentrations (Bullard et al., 2010).  
Parkinson’s disease is another condition that displays sex differences in symptom 
presentation. In a cohort study (n = 253) by Haaxma et al. (2006), women developed 
symptoms of Parkinson’s disease up to two years later than men. In addition, women 
suffered more frequently with dyskinesias at disease onset then men who tended to 
present with more bradykinesias/rigidity (Haaxma et al., 2006). Higher estrogen levels in 
women have been hypothesized to have protective value against Parkinson’s disease 
development (Currie, Harrison, Trugman, Bennett, & Wooten, 2004; Haaxma et al., 
2006; Liu et al., 2012). Unfortunately, not all research supports this theory (Lyons, 
Hubble, Troster, Pahwa, &Koller, 1998; Strijks, Kremer, &Horstink, 1999). In a study of 
630 Parkinson’s patients conducted by Lyons et al. (1998), the sex differences in 
symptom presentation was supported but estrogen as a protective factor against 
Parkinson’s disease was not.  
Autoimmune diseases affect only 8% of the entire population but almost 80% of 
those affected are women (Fairweather, Petri, Coronado, & Cooper, Jr., 2012; Ngo et al., 
2014; Quintero et al., 2012). Diseases such as RA (2-3:1 female to male ratio), SLE (9:1 
female to male ratio), MS (2-3:1 female to male ratio), scleroderma (up to 14:1 female to 
male ratio), and Sjogren’s syndrome (9:1 female to male ratio) are especially prominent 
in women (Fairweather et al., 2012; Ngo et al., 2014; Quintero et al., 2012; Whitacre, 
2001). All of these diseases display an inflammatory response of some type by the 
immune system that leads to the outward signs and symptoms of the disorder. These 




anti-inflammatory effects of estrogen, but inflammation that remains for extended periods 
of time leads to tissue damage as well (Casimir et al., 2010). Unfortunately, it is not only 
the anti-inflammatory response that does the damage in autoimmune disease; self-
antibodies cause long-term tissue destruction and damage (Whitacre, 2001).  
Estrogen regulates B-lymphocyte production and differentiation through IL-4 and 
IL-10 (Bullard et al., 2010). IL-4 increases the production of new B-lymphocytes that 
will ultimately produce IgG and IgE antibodies (Bullard et al., 2010). In addition, IL-10 
increase B-lymphocyte activation and stimulates antibody production (Bullard et al., 
2010). Lastly, estrogen promotes helper (CD4
+
) T-lymphocyte differentiation, increasing 
the body’s ability to activate B-lymphocytes (Bullard et al., 2010). This activity 
ultimately leads to the ability to produce large amounts of self-antibodies and 
autoimmune disease. Women tend to have a higher CD4
+
 T-lymphocytes numbers than 
men when in the healthy state, so increased activation and differentiation can lead to a 
disease state quickly (Whitacre, 2001).  
So far, all of the diseases examined here are chronic diseases and Lyme disease is 
caused by an infectious agent. How are sex differences between these two vastly different 
types of conditions connected? First, Lyme disease is commonly misdiagnosed as an 
autoimmune disease (Savely, 2010). Frequently, a patient is bitten by a tick in an area 
where the tick and/or bite is not easily seen – back of the body, hairline, armpits, and 
groin (Bennet, Stjernberg, & Berglund, 2007; Savely, 2010). The American College of 
Rheumatology estimates the number of tick bites that goes unnoticed to be between 10-




all. In a study conducted in the Netherlands, the number of cases of Lyme disease where 
the participant didn’t remember a tick bite was as high as 34% (Hofhuis et al., 2013).  
This misinformation often leads the physician to look at other illnesses with 
similar symptoms (Savely, 2010). Lyme disease may be misdiagnosed as any of the 
following disease: autoimmune diseases including but not limited to RA, MS, and SLE, 
along with non-autoimmune diseases like Parkinson’s disease and early onset Alzheimer 
disease (Savely, 2010). This misdiagnosis is based on symptoms that can mimic any or 
all of these conditions. 
Sex and Age Differences 
According to the CDC (2015), males in all age categories under age 70 suffer 
more frequently from confirmed Lyme disease than females of the corresponding age 
(Figure 3). 
 





The immune system undergoes extensive changes as a person ages (Giefing-Kroll 
et al., 2015). Innate immune cells, like macrophages and dendritic cells, lose the ability to 
effectively present foreign antigens to T-lymphocytes for activation (Giefing-Kroll et al., 
2015). In addition, thymus function declines with age so T-lymphocyte maturation is 
reduced leading to fewer T-lymphocytes available to fight infection (Giefing-Kroll et al., 
2015). Lastly, effective antibody production also declines with age (Giefing-Kroll et al., 
2015). Sex-differences of the immune system level off with declining production of 
estrogen by the ovaries as a woman ages (Giefing-Kroll et al., 2015).  
Aging has also been shown to have an effect on the cytokines and immune cells 
of innate immunity. Castle (2000) discusses the effects of aging on specific cytokines, all 
of which are induced by infection with Borrelia burgdorferi. Production of IL-6 increases 
with age-related changes to the immune system (Castle, 2000). Increased production of 
IL-6 has two effects: 1) IL-6 inhibits macrophage activity and 2) increased B-lymphocyte 
antibody production (Castle, 2000). Production of IL-10 also increases with age-related 
changes to the immune system. Increased IL-10 production also has two effects: 1) 
increased anti-inflammatory effects and 2) inhibition of the TH1-lymphocyte response 
(Castle, 2000). Lastly, TNF-α production increases with age leading to increased 
inflammatory responses in the individual (Castle, 2000). Even though immune system 
function changes with age and sex, the symptoms of Lyme disease produced by these 
changes may be an important tool in early diagnosis of the disease. 
Symptoms of Lyme Disease 
Lyme disease displays a wide array of symptoms based on the stage of the 




Stages of infection include: early localized Lyme disease, early disseminated Lyme 
disease, and late Lyme disease (Binder et al., 2012; Borchers et al., 2015; Donta, 2012; 
Girschick et al., 2009). In addition to these three stages, two separate conditions have 
been discussed in the literature – post-treatment Lyme disease syndromes and chronic 
Lyme disease (Aucott et al., 2012; Cairns & Goodwin, 2005; Cameron, 2010; Wormser 
et al., 2006). 
Early Localized Lyme Disease  
In this stage of infection, symptoms include mild flu-like symptoms, headache, 
fatigue, and malaise (Binder et al.., 2012; Borchers, 2015; Donta, 2012; Girschick et al., 
2009). During this stage, the characteristic “bull’s eye” erythema migrans (EM) rash will 
also appear (Binder, 2012; Borchers, 2015; Donta, 2012; Girschick et al., 2009; Miraflor 
et al, 2016). The EM rash begins at the site of the tick bite as a raised red rash with a 
clear central area (Moore, 2015; Muellegger, 2004). To differentiate between a true EM 
rash and an allergic response to the tick bite, the rash should be monitored over time 
(Muellegger, 2004; Tibbles & Edlow, 2007). The classic EM rash will start out as a small 
round to oval lesion, but will increase in size to at least 5 cm in diameter (Binder et al., 
2012; Borchers et al., 2015; Donta, 2012; Girschick et al., 2009; Tibbles & Edlow, 2007). 
An allergic response to the tick bite will decrease in diameter over time (Muellegger, 
2004).  
The EM rash appears in 70-80% of Lyme disease patients but takes on the 
characteristic “bull’s eye” appearance only 20% of the time (Aucott et al., 2012; Johnson 
& Stricker, 2004; Muellegger, 2004). Other, non-traditional appearances of the EM rash 




vesiculopustular lesions; and lesions with bruising, which typically occur on the calves 
(Aucott et al., 2012). 
One of the few reported sex differences with Lyme disease is related to the EM 
rash. In two separate studies, females were more likely to develop the EM rash than their 
male counterparts and of those females who developed the EM rash; the rash was more 
likely to appear in the non-typical form (Bennet et al., 2007; Strle et al., 2013). Strle et al. 
(2013) conducted a retrospective chart review of 15,539 patients over the age of 15 years 
diagnosed with an EM rash between 1990 and 2009. Results confirmed that 58% of the 
EM diagnoses were in women (Strle et al., 2013). This research was conducted in a single 
medical center in Slovenia, so confounding related to different diagnostic methods were 
minimized (Strle et al., 2013).  
Bennet et al. (2007) conducted a retrospective study in Sweden of 123,495 patient 
records for the presence and appearance of the EM rash. Results showed that 20% more 
women were diagnosed with EM rash than men during the years 1997-2003 (Bennet et 
al., 2007). Of those women diagnosed with the EM rash, 40% of them displayed the non-
typical presentation of the EM rash (Bennet et al., 2007).  
Bennet et al. (2007) also reported that a few other European studies had similar 
results for the higher prevalence of EM rash in women but after reviewing these 
additional studies, the results were not as reported. In the Bennet et al. study, German 
cases of EM rash in females were reported at 55%, but the actual study by Mehnert and 
Krause (2005) stated that 55% of reported Lyme disease cases in Germany were female. 
Mehnert and Krause did not report the percentage of EM rash cases in terms of females 




the number of cases of EM rash in females in Austria was 60%, but Stanek et al. reported 
that 60% of reported Lyme disease cases in Austria were females with no distinction in 
EM rash appearance (Stanek et al., 1987). 
Although evidentiary support was weak for the Bennet et al. (2007) study, study 
data did display sex differences in EM reporting and appearance. Unfortunately, all 
reported studies were conducted in Europe where the Borrelia strain varies significantly 
from the Borrelia strain found in the United States. Studies within the United States 
where Borrelia burgdorferi sensu stricto is the predominant strain must be conducted. 
An additional study was conducted by Schwarzwalder, Schneider, Lydecker, and 
Aucott (2010). This was a retrospective case series study of 125 patients from a Maryland 
clinic (Schwarzwalder et al., 2010). Early Lyme disease symptoms of EM rash and flu-
like symptoms were measured for sex differences (Aucott et al., 2013). No significant sex 
differences were found within the study population, but the authors contribute these 
results to the small sample size and the difficulty with confirming true early cases of 
Lyme disease via serology (Aucott et al., 2013).  
Early Disseminated Lyme Disease  
This stage of infection occurs when the bacteria leave the initial site of infection 
and spread to other body tissues. Typical symptoms that coincide with the spread of the 
bacteria include neurological symptoms like meningitis and facial palsies (Binder et al., 
2012; Borchers et al., 2015; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009; 
Muellegger, 2004; Wormser et al., 2006). Secondary EM rash lesions may appear at sites 
distant from the initial tick bite, but these lesions are more common in children than 




include various degrees of atrioventricular block (Alao & Decker, 2012). Heart 
complications tend to resolve with treatment (Alao & Decker, 2012). Finally, mild 
musculoskeletal symptoms may appear (Girschick et al., 2009). 
The hallmark of this stage of infection is the development of neurological 
symptoms, but meningitis and facial palsies can have other causes besides the Borrelia 
bacteria. Unfortunately, treatment is different for Borrelia burgdorferi infection than 
treatment given for facial palsies of other etiology. Determining the cause of the 
neurologic symptoms is paramount in providing appropriate treatment. 
Bremell and Hagberg (2011) conducted a study of 109 Swedish patients with 
some form of facial nerve palsy. The purpose was to identify clinical markers to increase 
the speed and accuracy for diagnosis of the causative agent of the palsy (Bremell & 
Hagberg, 2011). Bell’s palsy is generally treated with corticosteroids, while Lyme 
neuroborreliosis is treated with antibiotics (Bremell & Hagberg, 2011). Unfortunately, an 
inaccurate diagnosis would, at best, provide treatment that would not help the patient at 
all, and in the case of Lyme neuroborreliosis, would actually hurt the patient more 
(Bremell & Hagberg, 2011). Results of the study demonstrated that in confirmed 
neuroborreliosis cases, patients displayed a significantly higher number of mononuclear 
cells in extracted cerebrospinal fluid than patients without neuroborreliosis (Bremell & 
Hagberg, 2011). Unfortunately, even with early diagnosis and proper treatment, Lyme 
neuroborreliosis may persist. 
In a follow-up case control study conducted in Sweden five years after the initial 
study, recovery rate was only 73% in children (n = 84/84) diagnosed with and treated for 




symptom, partial facial palsy remained in 13% of subjects (Skogman et al., 2012). In 
addition, balance issues and persistent pain was found in 14% of subjects (Skogman et 
al., 2012). This impairment underscores the need for diagnosis in the earliest stage of 
infection to prevent these long term outcomes. 
Late Lyme Disease.  
If left untreated, Lyme disease can progress to late stage infection. This stage 
occurs months to years after the initial tick bite and is most commonly associated with 
arthritis in the large joints of the limbs (Binder et al., 2012; Borchers et al., 2015; Donta, 
2012; Girschick et al., 2009). Additionally, advanced neurological and cardiac symptoms 
can be found (Binder et al., 2012; Borchers et al., 2015; Donta, 2012; Girschick et al., 
2009). In the United States, arthritis is the most common late stage affliction (Alao & 
Decker, 2012; Bennet et al., 2007; Borchers et al., 2015). In Europe, acrodermatitis 
chronica atrophicans (ACA) can also manifest in late stage infections due to chronic skin 
infection by Borrelia burgdorferi (Alao & Decker, 2012).  
In a European study conducted by Strle et al. (2013), sex differences were present 
for arthritis symptoms. Within the patient sample (n = 60) diagnosed with Lyme arthritis, 
three quarters of the patients were male (Strle et al., 2013). This significant difference 
was supported even when the possibility of misdiagnosis was controlled for (Strle et al., 
2013). In the same study, males diagnosed with Lyme neuroborreliosis made up 60% of 
the study population (Strle et al., 2013). These findings have not been supported by other 




Posttreatment Lyme Disease Syndrome  
Controversy surrounds the existence of post-treatment Lyme disease syndrome. 
At its core, the controversy centers around the efficacy of current treatment guidelines for 
Lyme disease and whether longer courses of antibiotics are needed for complete 
eradication of the Borrelia burgdorferi from a patient. When diagnosed early and the 
treatment regimen is completed, most patients find relief from signs and symptoms of 
Lyme disease (Borchers et al., 2015; Deluca et al., 2013; Lantos, 2011; Moore, 2015). 
Unfortunately, in up to 10-15% of those patients who are not diagnosed early or complete 
a standard course of antibiotics, symptoms may persist after treatment is complete 
(Aucott, Crowder, & Kortte, 2013; Deluca et al., 2013). Persistent symptoms include 
musculoskeletal complaints including myalgia and arthralgia; headache; fatigue; and 
cognitive symptoms like difficulty concentrating and memory loss (Aucott, Crowder, & 
Kortte, 2013; Deluca et al., 2013; Lantos, 2011).  
Based on the clinical practice guidelines for Lyme disease created by the 
Infectious Disease Society of America (IDSA), post-treatment Lyme disease does not 
exist (Lantos et al., 2010; Wormser et al., 2006). According to the IDSA, the standard 
course of 21-days of antibiotics will kill the Borrelia bacteria and any persistent 
symptoms may be related to co-infection with another organism or just the normal aches 
and pains of daily life (Wormser et al., 2006). Unfortunately, this explanation does not 
take into the account the large number of patients who experience persistent symptoms 
after treatment is complete (Deluca et al., 2013).  
In order to address the IDSA’s claim that there is no scientific evidence to support 




(2013) designed a study to develop and support an operational definition for post-
treatment Lyme disease syndrome so that further studies can be standardized and data can 
be collected. The study included 71 cases (14 matched controls) that entered the study 
with a diagnosis of Lyme disease via the presence of the EM rash (Aucott et al., 2013). 
Subjects were followed for a period of up to two years post diagnosis (Aucott et al., 
2013). Based on results from this study, the following operational definition of post-
treatment Lyme disease is proposed by Aucott et al.: 
Inclusion criteria were as follows: 
 Documented Lyme disease with evidence of systemic disease 
 Treatment using doxycycline (FDA approved treatment regimen), resulting in 
the resolution of objective manifestation of disease 
 Onset of any of the following subjective symptoms within 6 months of the 
diagnosis of Lyme disease and persistence of continuous or relapsing 
symptoms for at least a 6 month period after completion of antibiotic therapy: 
o Endorsement of fatigue at a level higher than pre-infection 
o At least 3 areas of the body affected by musculoskeletal pain 
o Complaints of difficulty finding words, difficulty focusing or 
concentrating, or memory impact 
 A composite T-score < 45 (less than ½ standard deviation below normative 
mean) on SF-36 
Exclusion criteria were as follows: 
 Active co-infection 




 Previously diagnosed fibromyalgia or chronic fatigue syndrome 
 Undiagnosed or unexplained complaints of musculoskeletal pain or fatigue 
before diagnosis of Lyme disease (pg. e3). 
By establishing this operational definition, Aucott et al. (2013) looked to provide a 
framework for future research on posttreatment Lyme disease syndrome so that evidence 
either for or against this condition can be collected.  
Each stage of Lyme disease has clearly defined symptoms experienced by 
patients. These symptoms, along with severity of symptoms, will be used to determine 
what other factors may contribute to symptom presentation in Lyme disease sufferers. 
Theoretical Framework 
The theoretical framework of the study follows the CDC outbreak investigation 
model. In this model, the relationship between a variable under study and a disease like 
Lyme disease can be examined (Reingold, 1998). The typical descriptive epidemiology 
factors corresponding to person, place, and time are identified and relationships between 
potential exposures or risk factors and the disease in question are explored (Reingold, 
1998; Roher, 2013). While Lyme disease does not fall into the typical infectious disease 
category that would be examined as an outbreak, Lyme disease is a vector-borne disease 
and is well suited to the outbreak investigation model. In fact, the outbreak investigation 
model was initially used to identify the causative agent for Lyme disease after a 
significant number of cases of arthritis appeared in a group of children in the area of 
Lyme, Connecticut (Sternbach & Dibble, 1996). 
Lyme disease is currently the most frequently reported vector-borne illness in the 




by as high as 12 times, determining the factors that lead to this underreporting becomes 
paramount. Differences in symptom presentation and reporting based on 
sociodemographic factors like biological sex or age may hold the answers to identifying 
more cases earlier in the infection cycle, when treatment is most effective. This study will 





Chapter 3: Research Method 
Introduction 
This chapter contains a review the methodology associated with studying 
symptom presentation and severity for Lyme disease. I explain the research design along 
with the rationale for the selection of a case-control research design. In addition, I clearly 
describe the study population and the clinic and college where data collection occurs. 
Recruitment methods, informed consent methods, and sampling methods will be 
discussed. I provide information on instrument selection, validity, and reliability as well. 
Variables will be discussed in terms of research questions generated. In addition, I review 
statistical analysis methods. Lastly, I discuss the protections in place for the study 
subjects w along with how the final report of findings to subjects will occur.  
Research Design and Approach 
In this study I employed a case-control study design because this study examined 
factors associated with symptom presentation and severity in Lyme disease patients 
compared to unaffected control subjects. ROSS scales from the primary care clinic and 
college were reviewed to provide insight into variations in symptom presentation and 
severity. This data is retrospective and aligns well with the case-control study design.  
Case control study designs are often used to study rare diseases within the 
population because the number of subjects needed to reach statistical significance is 
smaller than the number of subjects needed for a cohort study design (Mann, 2003; 
Schulz & Grimes, 2002; Song & Chung, 2010). With 33,000 cases diagnosed in 2011 in 
the United States (population 310 million), Lyme disease would be considered a rare 




been studied by a case-control study design include, but are not limited to: certain types 
of cancer (breast, ovarian, esophageal, prostate, colon, and pancreatic); psychiatric 
disorders (schizophrenia and bipolar disorder); infectious diseases (neonatal tetanus and 
Nipah virus); and autoimmune disorders such as SLE (Schulz & Grimes, 2002; Song & 
Chung, 2010).  
A key advantage to the case control study design is the ability to examine multiple 
variables that may or may not be associated with a specific disease (Song & Chung, 
2010). In the case of Lyme disease, there are a wide variety of potential exposures to the 
Ixodes scapularis tick, the key vector in the spread of Lyme disease. In addition, Lyme 
disease shows a bivariate bimodal age distribution, with the largest number of cases 
occurring in males under 13 years old and females over the age of 40 (CDC, 2015). 
Variables including sociodemographic variables (age and sex), seasonal variables (month 
of diagnosis, month of exposure), symptoms present, and severity of symptoms were 
examined during this case-control study. 
Unfortunately, the case-control study design has a few disadvantages as well. The 
primary disadvantage for the case-control study design is the potential for bias (Pannucci 
et al., 2010; Song & Chung, 2010). The two main types of bias that must be considered 
when designing a case-control study are sampling bias and recall bias (Mann, 2003; 
Pannucci et al., 2010; Song & Chung, 2010). Sampling bias may be difficult to control 
for in a case-control study because the cases already represent a biased sample since they 
have the condition under study (Mann, 2003; Song & Chung, 2010). With a rare disease 
or condition, random sampling of a population is difficult since so few individuals may 




must be performed to reduce the impact of sampling bias (Mann, 2003; Pannucci et al., 
2010; Song & Chung, 2010). 
The best way to reduce sampling bias is to make sure that the controls are 
matched as closely as possible to the case population (Mann, 2003; Pannucci et al., 2010; 
Song & Chung, 2010; Zondervan, Cardon, & Kennedy, 2002). Matching must be done 
carefully because any variable selected to match the controls with the cases cannot be 
assessed as a variable for the study (Song & Chung, 2010; Zondervan et al., 2002). 
Because sex and age were two variables under investigation in this study, controls could 
not be matched to cases based on these criteria. In order to ensure that comparisons could 
be made between the case and control groups, frequency matching was used to provide 
consistency within and between the two groups (Song & Chung, 2010). For example, 
frequency matching makes sure that the percentage of males in the case group is the same 
as the percentage of males in the control group (Song & Chung, 2010). Thus, frequency 
matching was used for sex and age variables in this study. 
Matching was used among cases and controls on the basis of state of residence. 
Lyme disease is endemic to 14 states, primarily in the Northeastern United States (CDC, 
2015). These states include Pennsylvania, New York, New Jersey, Connecticut, 
Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, Rhode Island, 
Vermont, Virginia, and Wisconsin (CDC, 2015). Because the primary care clinic treats 
patients from all over the country, cases and controls were matched on state of residence 
to ensure that the potential exposure to the Ixodes tick is equal between the two groups. 
In addition, Lyme disease is a vector-borne disease that, if caught early, can be 




is therefore reported in incidence rates because each case reported to the National 
Notifiable Disease Surveillance System (NNDSS) represents a newly diagnosed 
infection. The nature of disease reporting between the states and the CDC may also lead 
to underreporting of the disease, over reporting of the disease, and/or false surveillance 
numbers due to misdiagnosis of the infection (CDC, 2015). States used in this study were 
all Lyme endemic states. The current study’s population (N = 591) came primarily from 
New York (39%) and Pennsylvania (42%), which is consistent with the high incidence 
rates reported for both states by the CDC (2015).  
The second type of bias, recall bias, occurs when cases recall exposures more 
frequently than controls. This often occurs because the cases spend more time trying to 
determine what exposure may have led to their disease state (Pannucci et al., 2010; 
Schulz & Courtright, 2002). One way to overcome this type of bias is to use information 
gathered prior to the beginning of the study (Mann, 2003; Pannucci et al., 2010). With the 
current study, access to patient records for prior symptoms and complaints was possible, 
and they were examined as part of the data collection process.  
In addition, the primary care site collects symptoms and severity of symptoms via 
the ROSS scale at every visit as part of the routine intake patient information. This 
symptom and severity information was part of the patients’ medical records and was the 
primary source of data for the cases in the current study. All controls filled out a ROSS 
scale describing symptoms experienced within the previous week, which also helps to 




Setting and Sample Population 
Research was conducted at a primary care clinic in New York State. The clinician 
for this study is a primary care physician who also treats acute and chronic Lyme disease 
patients. According to clinic records, more than 500 new Lyme disease patients are 
treated each year, along with an equal number of recurrent Lyme disease patients 
(Clinical partner, personal communication, April 2014). In addition to primary care, the 
clinician has been a renowned and published Lyme disease researcher since the early part 
of the 1990s (Lyme Project, n.d.). Study participants came from the primary care clinic’s 
patient population. 
Cases were defined as adult subjects (≥ 18 years of age) who met one of the 
following diagnostic criteria: (a) patient presents with a physician confirmed EM rash; (b) 
patient has a positive EIA and/or Western Blot laboratory result for IgG and IgM 
antibodies; or (c) patient has a score of 5 or higher on the Burrascano Diagnostic Criteria 
for Lyme Disease scale (Burrascano, 2005). These criteria meet both the Infectious 
Disease Society of America (IDSA) and the International Lyme and Associated Diseases 
Society (ILADS) diagnostic guidelines (Cameron, Johnson, & Maloney, 2014; Wormser 
et al., 2006). Lyme disease cases were selected and confirmed by the clinical partner, a 
Lyme disease specialist. Cases were randomly selected by the physician, based on the 
weekly appointment schedule during the study period. 
Because the primary care clinic could not provide enough controls for the study 
population, a secondary data collection site was added to the study. Controls were 
selected from adult patients (≥ 18 years of age) from the primary care clinic in New York 




disease. Participants may suffer from other diseases or conditions. All controls were 
Lyme disease free as determined by: (a) never having had a tick bite; (b) having no 
evidence of EM rash; or (c) no prior laboratory testing for or diagnosis of Lyme disease 
by a physician. Study controls were as likely as cases to develop Lyme disease. Controls 
were selected at a 1:2 case/control ratio to address the sampling bias introduced by 
nonrandom selection of participants. Unfortunately, because sex and age were two 
variables of interest in this study, matching of cases and controls along these lines could 
not occur. Matching based on state of residence was performed to insure that exposure to 
the Ixodes tick was the same between cases and controls. 
Sample size calculation is dependent on the types of statistical analyses planned to 
analyze the data. Each specific type of statistical analysis requires a slightly different 
number of participants in order to meet the minimal number for statistical significance 
(Cohen, 1992; Munro, 2005; Schlesselman, 1982). In order to satisfy all statistical 
analysis methods, the largest sample size was used. Based on the methods described in 
the statistical analysis section and tables provided by Cohen (1992) and a thorough power 
analysis performed using the Open Epi toolkit as described below, a minimum sample 
size of 120 cases and 240 controls was required (Dean & Sullivan, 2015). The actual 
sample size (N = 591) more than met this value with 203 cases and 388 controls included 
in the study. This value was above the minimum calculated value needed for statistical 
significance, met a 1:2 case to control ratio to address non-random sampling bias, and 





For all power analyses, the sample size of 120 cases and 240 controls were used. 
For the EM rash symptom, the CDC (2015) and Aucott et al. (2012a) suggested that the 
EM rash is found in 70% of the individuals who are diagnosed with Lyme disease. This 
value (70%) was used to represent the percent of exposure among cases. Because the EM 
rash can be confused with many different types of rashes, determining what to use for the 
percent of exposure among controls was a little more difficult. After careful 
consideration, bacterial induced skin rashes were used as the comparison since Lyme 
disease is caused by a bacterial infection. According to Ki and Rotstein (2008), 10% of 
the population suffers from a bacterial induced rash. This value (10%) was used to 
represent the percent of exposure among controls. 
Table 4 
Power for Unmatched Case-Control Studies – EM Rash 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 70 
Number of controls 240 
Percent of exposure among controls (%) 10 
Odds Ratio 21 
Power based on:  
Normal approximation 100% 




For the arthritis symptom, the CDC (2015) reports that 31% of individuals who 
are diagnosed with Lyme disease report arthritis as a symptom. Arthritis associated with 




symptoms of these two conditions (Savely, 2010). This value (31%) was used to 
represent the percent of exposures among cases. In addition, the CDC also reports that the 
annual incidence for RA is between 0.5-1.0%. One percent was used to represent the 
percent of exposure among controls for the power analysis. 
Table 5 
Power for Unmatched Case-Control Studies – Arthritis 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 31 
Number of controls 240 
Percent of exposure among controls (%) 1 
Odds Ratio 44 
Power based on:  
Normal approximation 100% 




For the Bell’s palsy symptom, the CDC (2015) reports the percentage of 
diagnosed Lyme disease patients that suffer from Bell’s palsy is 9%. This value (9%) was 
used to represent the percent of exposure in cases. According to Tiemstra and Khatkhate 
(2007), Bell’s palsy is found in 0.023% of the population. This value (0.023%) was used 





Power for Unmatched Case-Control Studies – Bell’s Palsy 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 9 
Number of controls 240 
Percent of exposure among controls (%) 0.023 
Odds Ratio 430 
Power based on:  
Normal approximation 97.73% 




For cardiac symptoms, the most prevalent cardiac symptom found in diagnosed 
Lyme disease patients is AV block, which is found in only 1% of the diagnosed Lyme 
disease patients (CDC, 2015). This value (1%) was used to represent the percent of 
exposure among cases. AV block in the general population is rare, but the incidence does 
increase somewhat with age (Sandesara & Olshansky, 2012). At age 20 years, the 
incidence is only 0.5-2 %. This value increases up to 5% at age 60 years. A power 






Power for Unmatched Case-Control Studies – AV Block Age 60 Years 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 1 
Number of controls 240 
Percent of exposure among controls (%) 5 
Odds Ratio 0.19 
Power based on:  
Normal approximation 47.19% 





Power for Unmatched Case-Control Studies – AV Block Age 20 Years 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 1 
Number of controls 240 
Percent of exposure among controls (%) 0.5 
Odds Ratio 2 
Power based on:  
Normal approximation 10.25% 
Normal approximation with continuity correction 12.42% 
 
According to this power analysis, the sample size was inadequate to find this rare 
condition. A sample size analysis was performed to identify the correct sample size to 
use. Based on this analysis, the potential to identify a significant difference between the 
cases and controls will be difficult. The sample size at 20 years is unrealistic based on the 
available population of cases at the primary care clinic where the study will take place 




value is based on having this large number of patients above 60 years of age, which is 
also not possible at the primary care clinic (Table10). 
Table 9 
Sample Size for Unmatched Case-Control Study – AV Block Age 20 Years 
 Input data 
Two-sided confidence level(1-alpha) 95 
Power(% chance of detecting) 80 
Ratio of Controls to Cases 2 
Hypothetical proportion of controls with 
exposure 
2 
Hypothetical proportion of cases with 
exposure: 
0.99 
Least extreme Odds Ratio to be detected: 0.49 
 Kelsey Fleiss Fleiss with 
CC 
Sample Size - Cases 1889 1770 1916 
Sample Size - 
Controls 
3777 3540 3831 
Total sample size: 5666 5310 5747 
 
Table 10 
Sample Size for Unmatched Case-Control Study – AV Block Age 60 Years 
 Input data 
Two-sided confidence level(1-alpha) 95 
Power(% chance of detecting) 80 
Ratio of Controls to Cases 2 
Hypothetical proportion of controls with 
exposure 
5 
Hypothetical proportion of cases with 
exposure: 
0.99 
Least extreme Odds Ratio to be detected: 0.19 
 Kelsey Fleiss Fleiss with CC 
Sample Size - Cases 259 228 264 
Sample Size - 
Controls 
517 456 528 





Lastly, mild cognitive impairment was considered. This group of symptoms is 
difficult to identify the percentage to use for cases because these symptoms are often only 
seen in those patients diagnosed with post-treatment Lyme disease disorder and/or 
chronic Lyme disease. Because the existence of these conditions is still controversial, 
finding a study that provided the incidence or prevalence of these symptoms was 
impossible. While the symptoms are listed as present, incidence rates were not calculated 
for the sample population or the sample populations were too small to generalize to the 
broader Lyme positive cases. In literature available from the International Lyme and 
Associated Diseases Society (ILADS), neurological symptoms, like memory or 
concentration issues, are found in 15-40% of Lyme patients (Caliendo et al., 1995). 
Unfortunately, this study was one of the most recently published articles on cognitive 
impairment in Lyme disease.  
In order to determine a percentage to use for controls, mild cognitive impairment 
was used as the search criteria and included similar symptoms to those found in Lyme 
disease patients (memory issues, attention issues, confusion, etc.). Because Alzheimer’s 
disease and dementia are accepted diagnoses, there were many more articles available 
with these symptoms. Unfortunately, these symptoms in the general population are often 
only found in older individuals (60 years +). In a study conducted by Iverson et al. 
(2011), mild cognitive impairment was found in 8.2% of the population within the 20-54 
year age group. According to the CDC (as published in the MMWR for May 2013), mild 
cognitive impairment was found in 12% of the population between the ages of 60-74 
years. Katz (2012) determined that mild cognitive impairment in the population over 70 




Multiple power analyses were performed to cover the range of ages discussed 
here. Because the clinician for this study, a respected Lyme disease specialist, treats 
many post-treatment Lyme disease and chronic Lyme disease cases at the primary care 
clinic, the odds of examining the records of a patient experiencing mild cognitive 
impairment was increased. Using the 40% value for the percentage of exposure in cases 
and the 8.2% value for the percentage of exposure in controls, a power analysis was 
conducted (Table 11). In addition, multiple power analyses were conducted to find the 
lowest percent of exposure in cases acceptable with the available sample size. Table 12 
shows the minimum of 19% exposure in cases power analysis. Below 19% exposure in 
cases, additional patients must be added. 
Table 11 
Power for unmatched case-control studies – MCI symptoms 20-54 years age group 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 40 
Number of controls 240 
Percent of exposure among controls (%) 8.2 
Odds Ratio 7.5 
Power based on:  
Normal approximation 100% 








Power for unmatched case-control studies – MCI symptoms 20-54 years age group 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 19 
Number of controls 240 
Percent of exposure among controls (%) 8.2 
Odds Ratio 2.6 
Power based on:  
Normal approximation 82.48% 




Because this study will include ages over 54, an additional power analysis was 
conducted that used the 40% for exposure in cases and 12% for exposure in controls 
(Table 13). In addition, another power analysis was done to test the lower end of required 
percentage for exposure in cases. As shown in Table 14, a minimum of 24% exposure in 
cases will be required at this sample size to reach the 80% power minimum. While this 
value is slightly higher than the 19% required for the lower age group, this value should 
be achievable within the primary care clinic patient population. 
Table 13 
Power for unmatched case-control studies – MCI symptoms 60+ years age group 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 40 
Number of controls 240 
Percent of exposure among controls (%) 12 
Odds Ratio 4.9 
Power based on:  
Normal approximation 99.99% 





Power for unmatched case-control studies – MCI symptoms 60+ years age group 
 Input data 
Two-sided confidence interval (%) 95 
Number of cases 120 
Percent of exposure among cases (%) 24 
Number of controls 240 
Percent of exposure among controls (%) 12 
Odds Ratio 2.3 
Power based on:  
Normal approximation 81.49% 




Based on this power analysis, the sample size was adequate to find a significant 
difference for the three major symptoms associated with Lyme disease in the United 
States (EM rash, arthritis, and Bell’s palsy). For the rare symptom of AV cardiac block, 
the sample size selected for this study was inadequate to find a significant difference 
between cases and controls. Because AV cardiac block is rare, the expectation of finding 
cases with this symptom was small. Mild cognitive impairment (MCI) is found in the 
later stages of infection, post –treatment, and chronic Lyme disease, but is rare in the 
general population at ages below 60 years. Because the clinician treats patients in the 
later stages of infection, the potential for identifying these symptoms at the required 
percent exposure in cases was high. Significant differences between cases and controls 
may be found at the suggested sample size. 
Level of significance (α) will be set at 0.05 following a review of the relevant 
literature and based on the statistical work of Cohen (1992). Probability (p) values will 




acceptance of the alternate (HA) hypothesis. With a p-value > 0.05, the null hypothesis 
was accepted. According to Cohen (1992), the effect size is the impact the independent 
variable has on the dependent variable. Based on the statistical method chosen for 
analysis, the effect size varied from 0.30 to 0.50 for a medium to large effect (Cohen, 
1992). In addition, Cohen suggests setting the power of the study at 0.80 (Munro, 2005; 
Cohen, 1992).  
Research Instrument 
Data was collected using a modified Burrascano Symptom Checklist (ROSS 
Scale) that is based on the Wahler Physical Symptoms Inventory (PSI), which has been 
demonstrated previously to have a high level of internal consistency on test-retest scores 
over several different subgroups (Wahler, 1968). The PSI collects data on the frequency 
of general symptoms associated with most any illness, but does not address severity of 
symptoms. A modified version of the PSI was created by Burrascano (2008) to address 
the specific symptoms associated with Lyme disease and the severity of those symptoms. 
A modified version of the Burrascano Symptoms Checklist (ROSS Scale) was created to 
address the needs of this study. The modified Burrascano Symptoms Checklist (Ross 
Scale) that was used in this study can be obtained by request. 
In addition to symptoms present, symptom severity, and symptom frequency, 
demographic data (age, sex, state of residence) and the seasonality of infection/time since 
tick exposure (month of diagnosis and/or month of tick bite were collected from the 




Data Collection and Analysis 
Research questions one through five were answered through a thorough review of 
patient medical records and the ROSS Scale. Symptoms at the initial patient visit (related 
to Lyme disease diagnosis for cases and at first visit for controls) were collected and 
transcribed onto the modified Burrascano Symptom Checklist (ROSS Scale) (Burrascano, 
2008).  
All forms were numbered upon return (by the primary care clinic staff for cases) 
which ensured that each form was linked to a specific record in the Microsoft Access 
database where the ROSS scale results were stored and managed. The ROSS scales were 
NOT linked to a specific person by the numbering system, as there was no personal 
information on the ROSS scale that could identify an individual.   
Analysis of data allowed for either the null hypothesis to be accepted or rejected 
so that the alternate hypothesis can be accepted. Independent variables included 
biological sex, age, time since tick exposure, month of diagnosis and/or tick exposure. 
Dependent variables included symptoms, symptom severity, and symptom frequency. 
Computation of Variables 
The independent variables for this study included age, sex, and time since 
exposure to the Ixodes tick. State of residence was collected to match cases and controls. 
Analysis was not performed using this variable because the primary care clinic was found 
within the Lyme disease endemic region identified by the CDC. Finding cases or controls 
from a non-endemic Lyme disease state for comparison was more difficult with the 





The age variable was defined based on the CDC’s surveillance groupings and 
included the following breakdown: < 20 years; 20-24 years; 25-29 years; 30-34 years; 35-
39 years; 40-44 years; 45-49 years; 50-54 years; 55-59 years; 60-64 years; 65-69 years; 
70-74 years; >75 years (CDC, 2015). Age categories may have been combined into 10 
year intervals only if there are more than six categories with less than five subjects. Age 
category combination was not required. Biological sex included male and female 
categories.  
Seasonality of infection variables included month of tick exposure and month of 
diagnosis. Based on CDC data (2015), most Lyme disease diagnoses occur during the 
months of June, July, and August. In addition, the winter months (December through 
March) contain the fewest reported Lyme disease diagnoses (CDC, 2015). Months with 
less than five diagnoses may have been combined into seasons (Spring, Summer, Fall, 
Winter) for statistical analysis. Combining months into seasons was not required at the 
time of analysis. 
Independent variables were compared to the dependent variables of symptom 
presentation, symptom severity, and symptom frequency. Symptom presentation was 
examined for absence or presence of the described symptom using the modified 
Burrascano Symptom Checklist (ROSS Scale) instrument and calculated using the 
symptom index scoring system described below. 
Symptom Index 
Symptoms from the modified Burrascano Symptoms Checklist (ROSS Scale) 
were grouped together into six categories for analysis purposes. Grouping of symptoms 




fatigue syndrome (Hickie et al., 2006), which are as difficult to diagnose as the later 
stages of Lyme disease. The six categories matched the major groups of reported 
symptoms in the NNDSS database and include: 1) musculoskeletal; 2) neurological; 3) 
cognitive; 4) cardiac; 5) general; and 6) cutaneous. The general category included the 
following symptoms: fever, sore throat, persistent swollen glands, unexplained weight 
loss or gain, nausea, diarrhea, and pain in the genital area. The musculoskeletal category 
included symptoms related to joint pain, stiffness, and swelling along with muscle 
stiffness, twitches, and aches/pain. The neurological category included facial paralysis 
(Bell’s palsy) and other symptoms associated with cranial neuropathy, as well as 
meningitis not related to known bacterial or viral agents. The cognitive category included 
symptoms associated with memory, concentration, and speech difficulties. The cardiac 
category included chest pain, heart palpitations, or evidence of heart block. Lastly, the 
cutaneous category included the EM rash and other unexplained skin manifestations.  
The frequency scale measured how often a patient experienced particular 
symptoms within the week prior to their appointment at the primary care clinic. The one 
week time frame was used to minimize recall bias on the part of the participant. 
Categories on the frequency scale included: never, 1-2 days, 3-4 days, 5-6 days, and 
everyday/7 days. The severity scale measured how the symptom affected the daily life of 
the participant. Categories on the severity scale included: not affected (0), slight/barely 
noticeable (1), minor problem but noticeable (2), moderate problem that interferes with 
some daily activities (3), major problem that interferes with most daily activities (4), and 




An overall score (12 points) was calculated for the symptom index. Each category 
was worth 2 points of the total score – 1 point for severity and 1 point for frequency. 
Symptom scores in each category were averaged to reach this 2 point total.  
This overall score was used to make comparisons between the Lyme positive case group 
and the Lyme negative control group, controlling for covariates like age, sex, and time 
since exposure to the Ixodes tick. Additional analysis made comparisons based on each 
symptom category that contributed to the total score. For example, if the symptom index 
score of the case group was based entirely on musculoskeletal and cutaneous symptoms, 
these category scores were compared between the case and controls by multivariate 
analysis methods. 
Comparisons between cases and controls were conducted using the two way table 
and calculating the odds ratio for each symptom category reported. Since both cases’ and 
controls’ ROSS Scales provided information, these comparisons were easily made for 
each symptom category reported. This information provided insight into the symptoms 
that could be used for early diagnosis of Lyme disease. 
In addition, univariate and bivariate statistical analyses were used. Univariate 
analysis allowed for descriptive statistics to be generated. Bivariate methods allowed 
comparisons to be made between two different variables to determine what, if any, 
relationship existed between these variables. The Chi-square test (if the data is normally 
distributed), the Kruskal-Wallis test, the odds ratio, and the odds ratio with the Mantel-
Haenszel method (for age-adjusted comparison) were used to analyze the data and 





In addition to the described univariate and bivariate statistical analyses, 
multivariate regression analysis was conducted on certain independent and dependent 
variable combinations. The independent variables age and sex were included in the 
analysis regardless of their association with the dependent variables after bivariate 
analysis based on evidence from previous literature (Katz, 2006). Independent or 
dependent variables were excluded from the multivariate regression analysis if there was 
a lot of missing data associated with that specific variable. 
RQ1: Is the presentation of symptoms in Lyme disease-positive patients 
associated with the sociodemographic variables age and sex as assessed by patient 
medical record and ROSS Scale survey review? 
H01 Lyme disease symptom presentation is not associated with the 
sociodemographic variables age and sex as assessed by patient reported 
symptoms recorded in patient medical records or on the ROSS Scale survey. 
Ha1 Lyme disease symptom presentation is associated with the 
sociodemographic variables age and sex as assessed by patient reported 
symptoms recorded in patient medical records or on the ROSS Scale survey. 
RQ2: Is the severity of symptoms in Lyme disease positive patients associated 
with the sociodemographic variables age and sex as assessed by patient medical 
record and ROSS Scale survey review? 
H02: Lyme disease symptom severity is not associated with the 
sociodemographic variables age and sex as assessed by patient reported 




Ha2: Lyme disease symptom severity is associated with the sociodemographic 
variables age and sex as assessed by patient reported symptoms recorded in 
patient medical records or on the ROSS Scale survey. 
RQ3: Is the presentation of symptoms associated with the diagnosis of Lyme 
disease as assessed by patient medical record and ROSS Scale survey review? 
H03: Lyme disease symptom presentation is not associated with the diagnosis 
of Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
Ha3: Lyme disease symptom presentation is associated with the diagnosis of 
Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
RQ4: Is the severity of symptoms associated with the diagnosis of Lyme disease 
as assessed by patient medical record and ROSS Scale survey review? 
H04: Lyme disease symptom severity is not associated with the diagnosis of 
Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
Ha4: Lyme disease symptom severity is associated with the diagnosis of Lyme 
disease as assessed by patient reported symptoms recorded in patient medical 
records or on the ROSS Scale survey. 
RQ5: Is Lyme disease symptom presentation and severity associated with 
seasonality of infection variables as assessed by medical record and the ROSS 




H05: Lyme disease symptom presentation and severity are not associated with 
the seasonality of infection variables as assessed by patient medical record 
and the ROSS Scale survey review. 
Ha5: Lyme disease symptom presentation and severity are associated with the 
seasonality of infection variables as assessed by patient medical record and 
the ROSS Scale survey review. 
Statistical Analysis 
Statistical analysis was performed with SPSS (version 21). Statistical tests 
included the Chi-square test (if the data are normally distributed) or the Kruskal-Wallis 
test (if the data are not normally distributed), which allowed for comparisons between the 
control group and the study population for specific symptoms and independent variable 
comparisons (Munro, 2005). A Chi-Square test was performed for age distribution 
categories and symptom presentation. This test was performed because the sample size is 
well over 60 participants and there were more than five participants in each age category 
(Munro, 2005). An ANOVA (with the Tukey Post Hoc test) was performed comparing 
age and symptom frequency and severity scores, because both of these categories had 
more than two groups (Munro, 2005). Lastly, an odds ratio was calculated both with and 
without the Mantel-Haenszel method (Munro, 2005). 
In addition to the described univariate and bivariate statistical analyses, regression 
analysis was conducted on certain independent and dependent variable combinations. The 
independent variables age and sex were included in the analysis regardless of their 
association with the dependent variables after bivariate analysis based on evidence from 




the multivariate regression analysis if there was a lot of missing data associated with that 
specific variable. 
Since the goal of this research was to identify additional potential factors to use 
for the earliest possible diagnosis of Lyme disease, an analysis based on the use of the 
information from this study for diagnosis was performed. Once associations between 
symptoms and/or symptom severity and the independent variables were determined, the 
sensitivity, specificity, positive predictive value, and the negative predictive values were 
calculated for the groups of symptoms. These values describe the ability of the test to 
identify correctly those individuals who have a disease. An ROC plot was generated to 
graphically show the data provided to help determine if the variables under investigation 
could be used to diagnose Lyme disease. 
Protection of Human Participants 
Participation in this study was completely voluntary. Study participants received a 
thorough explanation of the purpose of the study and the role the participant would play 
in the study. Each participant received an informed consent form prior to inclusion in the 
study. Participants were given an explanation of the study, a description of how to fill out 
the ROSS Scale, allowed to ask additional questions, and were told that returning the 
completed ROSS Scale was evidence of their consent to be included in the study. 
Participant privacy has been maintained throughout the course of the study by 
coding each participant record to avoid the use of participant names or other identifying 
information. Coded records have been kept on a password protected computer and in a 
locked filing cabinet. In addition, the study was approved by the Walden University 




College Institutional Review Board (approval number 2015-000559) prior to data 
collection and again after the addition of the secondary data collection site. 
Dissemination of Findings 
Because the primary care clinic’s participant population comes from all over the 
United States, study participants will receive information about the study results through 
a report mailed directly to their home. Researcher contact information will be provided to 
each study participant in case a participant has any questions about the study or the 
results. In addition, updates on publication or presentation of results will be provided to 
both the study clinician and study participants through post card updates. 
In addition, a presentation of study results was given at the college that served as 
a secondary data collection site. The presentation was advertised through normal 
channels on the college campus, including the daily e-newsletter, announcements at 
meetings, and on the college website. Participants interested in the study results, as well 
as the general public, was encouraged to attend. Approximately, 120 individuals attended 
the presentation. 
Summary 
This study examined the factors associated with symptom presentation and 
severity in Lyme disease through a case-control methodology. Data was collected at a 
primary care clinic through an examination of patient records and ROSS Scale analysis. 
Data was collected at the secondary college site and analyzed through ROSS Scale 
analysis. The symptom index score was used to aid in the analysis portion of the study. 










Chapter 4: Results 
Introduction 
Lyme disease is currently one of the most frequently reported vector-borne 
diseases (Binder, Telschow, & Meyer-Hermann, 2012; Borchers et al., 2015; Mead, 
2015). According to the CDC (2015), Lyme disease is likely underreported by a factor of 
12, leaving approximately 300,000 cases untreated. Successful treatment of Lyme disease 
requires early diagnosis and treatment. Delayed treatment may lead to long-term 
functional disability (Aucott et al., 2013; Johnson et al., 2011). The purpose of this study 
was to identify potential differences in the way Lyme disease symptoms are presented 
based on sex and/or age differences in order to help identify Lyme disease cases that 
might go undiscovered or misdiagnosed. In addition, a comparison was also made 
between symptom presentation and seasonality of infection to determine if symptoms 
vary based on month of tick exposure. 
In this chapter, I will reiterate the research questions and hypotheses, describe the 
process of data collection and the addition of a secondary data collection site, discuss the 
modifications to the data collection procedures, describe the final make-up of the sample 
population, present the results obtained from data collection, and provide the statistical 
analysis methods used and results. 
Data Collection Process 
Data was collected at two collection sites, a primary care clinic that specializes in 
Lyme disease treatment and a small, 4-year liberal-arts college campus. The secondary 




controls for the study population. At both data collection sites, cases and controls were 
determined as follows. 
Cases (n = 203) were defined as adult subjects (≥ 18 years of age) who met one of 
the following diagnostic criteria: (a) patient presents with a physician confirmed EM 
rash; (b) patient has a positive EIA and/or Western Blot laboratory result for IgG and 
IgM antibodies; or (c) a score of 5 or higher on the Burrascano Diagnostic Criteria for 
Lyme Disease scale (Burrascano, 2005). These criteria meet both the Infectious Disease 
Society of America (IDSA) and the International Lyme and Associated Diseases Society 
(ILADS) diagnostic guidelines (Cameron, Johnson, & Maloney, 2014; Wormser et al., 
2006). Lyme disease cases were selected and confirmed by the clinical partner, a Lyme 
disease specialist. Cases were randomly selected by the physician, based on the weekly 
appointment schedule during the study period.  
Controls (n = 388) were selected from adult subjects (≥ 18 years of age) who did 
not suffer from Lyme disease at the primary care clinic, family members of Lyme disease 
patients at the primary care clinic, and employees and students at a small, 4-year liberal 
arts college. Participants who suffered from illnesses other than Lyme disease were not 
excluded from the study. All controls were Lyme disease free at the time of selections as 
determined by: (a) never having had a tick bite; (b) having no evidence of EM rash; or (c) 
no prior laboratory testing for or diagnosis of Lyme disease by a physician. Controls were 
selected at an approximate 1:2 case/control ratio to address the sampling bias introduced 
by non-random selection of participants.  
Because sex and age were two variables of interest in this study, matching 




of residence was done to insure that exposure to the Ixodes scapularis tick was the same 
between cases and controls. Participants were only included if they lived in one of the 14 
states endemic for Lyme disease and the habitat for the Ixodes scapularis tick. These 
states included: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, 
New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, 
Virginia, and Wisconsin. In addition, both cases and controls had to be available from a 
particular state to be considered for inclusion in the study. 
At both data collection sites, the ROSS scale, an abbreviated and modified version 
of the Burrascano Symptom Scale, was used (Burrascano, 2008). The ROSS scale was 
administered to every participant at patient registration, as is standard procedure for 
intake at the primary care clinic. The ROSS scale became a permanent part of each 
patient’s record and was used by the physician and staff to track symptom frequency and 
severity visit to visit. Each ROSS scale was scanned into the patient’s record, de-
identified, numbered and placed into a folder for entry as a participant into the study. 
These de-identified ROSS scales were collected once per week from the clinic over a 
period of four months. 
At the secondary site, the ROSS scale was administered to several different 
populations including faculty, professional staff, hourly staff, and students. Information 
was distributed to the entire campus community about the study through daily 
newsletters, social media, and mass emails. This distribution of information was designed 
to increase interest in participation in the study. Data was then collected at large group 
meetings. The ROSS scale was passed out to all individuals in attendance. Informed 




Any questions from the group were answered as clearly as possible and directions 
were given on how to fill out the ROSS scale, highlighting key questions that required a 
response. Sex, date of birth, and state of residence questions were specifically discussed 
as important variables within the study. After completing this discussion, an envelope 
was left with the person in charge of the group for immediate return of the ROSS scale by 
participants. Instructions were also provided for on-campus mail return, scanning and 
email return, and/or drop box return of the ROSS scale, if the participants preferred to 
take the ROSS scale with them to fill out in private. Returning the completed form by any 
of the methods available was considered consent to participate in the study. The response 
rate at the college site was 84% and included primarily controls (Table 15). Response rate 
at the primary care clinic was 93%, and included both cases and controls (Table 15).  
Table 15 
























2 0 291 0 84 5 288 
*Number of participant responses includes all participants collected prior to the application of exclusion criteria. 
 
The college ROSS scales were numbered upon return, which ensured that each 




scale results were stored and managed. The ROSS scales were NOT linked to a specific 
person by the numbering system, as there was no personal information on the ROSS scale 
that could identify a specific individual. Data collected from the primary care clinic used 
the same numbering system. The numbering system served a secondary purpose at the 
primary care clinic. In order to distribute information about the completed study to all 
participants, the primary care office staff used the numbers to identify which patients 
were included in the study. This identifying list was only available to the primary care 
office staff.  
Exclusion Criteria 
Completed forms were reviewed with the primary care physician to verify 
inclusion as a case or control for this study from a clinical standpoint. Because controls 
must NOT be Lyme disease positive, any indicators from the symptom checklist for a 
potential undiagnosed Lyme disease patient were reviewed carefully for appropriate 
case/control placement or exclusion from the study. No undiagnosed Lyme diseases cases 
were identified through this review. Forms containing ROSS scale data that was 
incomplete for the major study variables were excluded from the study. The ROSS scale 
does collect additional data that is not included in the current study, so if this additional 
data was incomplete, the ROSS Scale was not excluded. 
Data collected was entered into Microsoft Access for storage and management. 
All records were double-checked for accuracy and completeness of required information. 
After review for accuracy in data entry, data records were reviewed to verify inclusion in 




total of 591 participants were included in the final study analysis. Participants were 
removed for the following reasons. 
Age under 18 years. Because the primary care site treats very few patients under 
the age of 18 years, the office staff did not pay special attention to the age requirement 
for the study and provided eleven ROSS scales for patients who were 17 years old. 
Participants must be 18 years of age for inclusion in the study, so these participants were 
excluded. 
No date of birth listed. One of the major study variables is age. Without a 
birthdate listed, there was no way to determine how old the participant was so 
participants without a date of birth were excluded from the study. In addition, a few of 
the respondents listed the date the ROSS scale was completed as the date of birth. For the 
same reason, these respondents were excluded from the study. 
State of Residence. State of residence was used to match cases and controls to 
address the non-random nature of participant selection. In addition, all participants 
needed to come from one of the 14 Lyme endemic states for inclusion in the study. The 
Lyme endemic states correspond to the habitat of the Ixodes tick, the vector for Lyme 
disease in the United States. Three participants were removed for not listing a state of 
residence at all. Seventeen additional participants were removed for not living in a Lyme 
endemic state because exposure to the Ixodes tick would not be possible thus eliminating 
the potential for developing Lyme disease. These participants lived in California, 
Georgia, Michigan, Tennessee, Texas, and Wyoming. Parts of northern California have a 
high incidence of Lyme diseases (even though the state as a whole has a low incidence of 




al., 2015; Deluca et al., 2013). Ixodes pacificus is the tick vector in the western states and 
Ixodes scapularis is the tick vector in the eastern United States (Borchers et al., 2015; 
Deluca et al., 2013). While this variation in vector species may not have an effect on the 
study outcome, keeping the exposure possibilities as similar as possible within the study 
population was important.  
An additional study participant was removed because the participant was from the 
United Kingdom. This participant was removed for two reasons: (a) there were no 
controls available from the same country for comparison; and (b) the causative agent and 
vector for Lyme disease is different in Europe than the causative agent in the United 
States (Borchers et al., 2015; Caimano et al., 2012). In Europe, the primary tick vector is 
Ixodes ricinis, which is different from the primary vector in the United States (Borchers 
et al., 2015; Caimano et al., 2012). In addition, the causative agent in Europe can be one 
of three bacteria, Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii (Borchers et 
al., 2015; Caimano et al., 2012). Each of these agents produces distinctly different 
symptom outcomes (Borchers et al., 2015; Deluca et al., 2013). European cases of Lyme 
disease tend to produce more neurological symptoms; American cases of Lyme disease 
tend to produce more musculoskeletal symptoms, which have been linked to the species 
of Borrelia that causes the infection (Borchers et al., 2015; Mead, 2015; Stanek et al., 
2011).  
Lastly, additional participants were excluded from the study that lived in 
Maryland, Rhode Island, and Wisconsin. Even though all three of these states are 
considered Lyme endemic states, all participants were controls. There were no reported 





The study population consisted of cases (n = 203) and controls (n = 388) that were 
similar in composition. Cases consisted of both females (n = 130) and males (n = 73) 
ranging in age from 18 years to 75+ years (Table 16). Controls consisted of both females 
(n = 268) and males (n = 120) also ranging in age from 18 years to 75+ years (Table 16). 
According to the CDC (2015), males in all age categories under age 70 suffer more 
frequently from confirmed Lyme disease (Figure 4). This age difference was not 
supported when recruiting case participants into this study (Figure 5). As shown in Figure 
5 and Table 16, female cases outnumber male cases by almost 2:1. Most of the female 
cases were between the ages of 40-65 years. This discrepancy with the CDC’s confirmed 
cases data may be due to the primary care clinic’s much larger population of female cases 
over male cases to recruit.  
Table 16: 
Age Distribution of Study Lyme Disease Cases 








<20 6 6 133 38 
25 2 6 37 16 
30 6 8 10 6 
35 9 2 4 10 
40 12 5 7 6 
45 17 11 10 14 
50 18 5 10 9 
55 24 7 11 8 
60 10 6 12 4 
65 11 9 10 6 
70 7 2 10 7 
75 5 4 5 2 
80 2 1 4 2 
85 0 1 3 1 






    
 
 Figure 4. Frequency distribution of Lyme disease cases by gender – General population 
            
 




States of residence for both cases and controls included Connecticut, 
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, and Vermont 
(Table 17). All of these states are considered Lyme-endemic states by the CDC (2015).  
Table 17 







Male - Case Male - 
Control 
Total (%) 
CT  16 9 17 6 48 (8) 
MA  2 1 0 1 4 (0.7) 
NH  2 2 0 0 4 (0.7) 
NJ  9 19 6 12 46 (8) 
NY  89 64 46 34 233 (39) 
PA 8 168 3 66 247 (42) 
VT  4 3 1 1 9 (2) 
Total 130 268 73 120 591 (100) 
 
In order to ensure that the sample population was as uniform as possible, 
matching based on state of residence and frequency matching was performed. State of 
residence matching (as shown in Table 17) required at least one case and one control 
from a state in order for the study participant to remain in the study. Frequency matching 
based on sex was performed so that the sample population did not contain a single sex in 
cases or controls. Females made up 64% of the case population and 69% of the control 
population. Males made up 36% of the case population and 31% of the control 
population. In addition, a case-control ration of 1:2 was used to reduce sampling bias.  
Lastly, random sampling was utilized as much as possible given the fact that cases 
needed to be Lyme disease positive for inclusion. At the primary care site, cases were 




selected based on the daily appointment schedule (for non-Lyme disease patients) or 
because the control was at the primary care site with a patient. At the secondary site, 
ROSS scales were distributed at a variety of meetings on campus to anyone who was in 
attendance at the meeting. This method for selection of meetings and campus groups 
allowed for some random sampling of the population.  
While educational level was not a variable under study, the secondary site was a 
college campus so matching based on educational level became an important 
consideration as advanced educational level can change socioeconomic status and effect, 
specifically, access to health care (Heck & Parker, 2002; Saydah, Imperatore, & Beckles, 
2013). Because all but five of the cases came from the primary care site, a comparison of 
cases between collection sites was not necessary. Comparisons between controls 
collected at each site were performed.  
Overall, 51% of the study population had at least a high school diploma and 44% 
of the population had completed at least a baccalaureate degree (Table 18). According to 
the United States Census Bureau (2014), 30% of the population of the United States over 
the age of 18 years old has at least a high school diploma. In addition, 29% of the 
population of the United States over the age of 18 years old has at least a baccalaureate 
degree. Site 1 females with a college degree made up 5% of the control population and 
site 2 females with a college degree made up 4% of the control population. Site 1 males 
with a college degree made up 5% of the control population and site 2 males with a 
college degree made up 0.5% of the control population. Site 1 females with a graduate 




made up 3% of the control population. Lastly, males with a graduate degree at both sites 
made up 4% of the population.  
Table 18 

































Unassigned 2  0 2  0 3 0 1 0 8 (2) 
College 
Graduate 












11  0 2  0 4 0 2  0 19 (3) 
Total 126 4 75 190 71 2 42 78 588* 
(100) 
*Three participants did not list educational level on the ROSS Scale. 
The age variable was defined based on the CDC’s surveillance groupings and 
included the following breakdown: < 20 years; 20-24 years; 25-29 years; 30-34 years; 35-
39 years; 40-44 years; 45-49 years; 50-54 years; 55-59 years; 60-64 years; 65-69 years; 
70-74 years; >75 years (CDC, 2015). Age categories were not combined into 10 year 
intervals because there were not more than six categories with less than five participants.  
Table 19 shows an age range distribution for cases and controls collected from the 
primary care site and the secondary college site. Ages within the case and the control 
populations were well matched in all age categories with the exception of the <20 years 
and the 20-24 years age categories. Many more controls over cases are present in both of 
these age categories. This inconsistency between age categories should not 




experiencing symptoms of Lyme disease more frequently than cases or at a more severe 
level if the symptoms under study can truly be used as an indicator of the presence of 
Borrelia burgdorferi.  
Table 19 





























<20 4 2 1 132 5 1 0 38 183 
(33) 
25 2 0 1 36 6 0 1 15 61 
(10) 
30 5 1 4 6 8 0 2 4 30 (5) 
35 9 0 1 3 2 0 2 8 25 (4) 
40 12 0 6 1 4 1 2 1 27 (5) 
45 17 0 7 3 11 0 4 1 43 (7) 
50 17 1 8 2 5 0 8 4 45 (8) 
55 24 0 6 5 7 0 6 2 50 (9) 
60 10 0 9 3 6 0 4 0 32 (5) 
65 11 0 8 2 9 0 4 2 36 (6) 
70 12 0 8 2 2 0 4 3 31 (5) 
75 2 0 4 1 4 0 2 0 13 (2) 
80 0 0 4 0 1 0 2 0 7 (1) 
85 0 0 3 0 1 0 1 0 5 (1) 
90 1 0 2 0 0 0 0 0 3 (1) 
Grand 
Total 
126 4 72 196 71 2 42 78 591 
(100) 
 
A power analysis was conducted to determine an adequate sample size to find 
statistically relevant results (see chapter 3 for the full analysis discussion). Based on this 
power analysis, the sample size of cases (n = 203) and controls (n = 388) was adequate to 
find a significant difference for the three major symptoms associated with Lyme disease 
in the United States (EM rash, arthritis, and Bell’s palsy). For the rare symptom of AV 
cardiac block, the sample size selected for this study was inadequate to find a significant 




of finding cases with this symptom was small. Mild cognitive impairment (MCI) is found 
in the later stages of infection, post–treatment, and chronic Lyme disease (Caliendo et al., 
1995), but is rare in the general population at ages below 60 years (Iverson et al., 2011; 
Katz, 2012; CDC, 2015). Because the primary care clinic treats patients in the later stages 
of infection, the potential for identifying these symptoms at the required percent exposure 
in cases was high. 
Level of significance (α) for the statistical analysis was set at 0.05 following a 
review of the relevant literature and based on the statistical work of Cohen (1992). 
Probability (p) values followed that a p-value ≤ 0.05 resulted in rejection of the null (H0) 
hypothesis and acceptance of the alternate (Ha) hypothesis. With a p-value > 0.05, the 
null hypothesis was accepted, because a large p-value suggests that the null hypothesis is 
more likely to be true given the specific set of test parameters (Munro, 2005)  
According to Cohen (1992), the effect size is the impact the independent variable 
has on the dependent variable. Based on the statistical method chosen for analysis, the 
effect size varied from 0.30 to 0.50 for a medium to large effect (Cohen, 1992). In 
addition, Cohen suggests setting the power of the study at 0.80 (Munro, 2005). 
Symptom Index 
Symptoms were grouped together into six categories for analysis purposes. The 
six categories matched the major groups of reported symptoms to the NNDSS database 
and included: 1) musculoskeletal; 2) neurological; 3) cognitive; 4) cardiac; 5) general; 
and 6) cutaneous. The general category included the following symptoms: fatigue, fever, 
chills, headaches, sore throat, persistent swollen glands, dizziness, lightheadedness, 




symptoms: painful joints, stiff neck, back pain, stiff joints, and sore muscles. The 
neurological category included facial paralysis (Bell’s palsy), blurred vision, eye pain, ear 
ringing, jaw pain, testicular/pelvic pain, and tingling/burning/numbness. The cognitive 
category included the following symptoms: disturbed sleep, poor concentration, memory 
loss, irritability, crying, and sadness/depression. The cardiac category included chest pain 
and heart palpitations. Lastly, the cutaneous category included the presence of the EM 
rash.  
The frequency scale measured how often a patient experienced the listed 
symptoms within the week prior to filling out the ROSS scale. The one week time frame 
was used to minimize recall bias on the part of the participant. Categories on the 
frequency scale included: never, 1-2 days, 3-4 days, 5-6 days, and everyday/7 days 
(Table 20). The severity scale measured how each specific symptom affected the daily 
life of the participant (Table 20). Categories on the severity scale included: not affected 
(0), slight/barely noticeable (1), minor problem but noticeable (2), moderate problem that 
interferes with some daily activities (3), major problem that interferes with most daily 





 Frequency and Severity Symptom Score Breakdown 
Frequency Frequency Score Severity Severity Score 
Never 0.2 Not Affected (0) 0.17 
1-2 Days 0.4 Slight/Barely 
Noticeable (1) 
0.34 
3-4 Days 0.6 Minor Problem but 
Noticeable (2) 
0.51 
4-5 Days 0.8 Moderate Problem that 
Interferes with Some 
Daily Activities (3) 
0.68 
Every Day/7 Days 1.0 Major Problem that 
Interferes with Most 
Daily Activities (4) 
0.85 
  Disabling Problem (5) 1.00 
 
An overall score (12 points) was calculated for the symptom index. Each of the 
six symptom categories was worth 2 points of the total score – 1 point for severity and 1 
point for frequency. Symptom scores in each category were assigned a value (which is a 
fraction of 1 point based on the level of frequency and severity shown in Table 20), 
totaled, and averaged to reach this 2 point total.  
To illustrate a symptom index calculation in Table 21, a female case reported a 
list of symptoms experienced the week prior to filling out the ROSS scale. For frequency 
scores, there were five potential responses (never, 1-2 days, 3-4 days, 5-6 days, and 
everyday/7 days). Each of these responses was assigned a numerical value in 0.2 
increments as shown in Table 20. For severity scores, there were six potential responses 
ranging from zero (no effect on daily life) to five (severely disrupts daily activities). Each 
of these responses was also assigned a numerical value that was 1/6
th
 of the 1 point 




symptoms, and then averaged to determine the frequency and severity score for that set of 
symptoms. 
Table 21  








Musculoskeletal Back Pain Everyday 1 4 0.85 
Neurological Blurred Vision 1-2 Days 0.4 0 0.17 
General Chills 3-4 Days 0.6 1 0.34 
Cognitive Disturbed Sleep Everyday 1 4 0.85 
General Dizziness 1-2 Days 0.4 1 0.34 
General Fatigue/Tiredness 3-4 Days 0.6 4 0.85 
General Headaches Everyday 1 4 0.85 
Cognitive Irritability Everyday 1 4 0.85 
General Lightheadedness 1-2 Days 0.4 1 0.34 
Cognitive Memory Loss 5-6 Days 0.8 4 0.85 
General Nausea 1-2 Days 0.4 1 0.34 
General Night Sweats 3-4 Days 0.6 1 0.34 
Musculoskeletal Painful Joints Everyday 1 5 1 
Cognitive Poor Concentration 5-6 Days 0.8 4 0.85 
Cognitive Sadness/Depression 3-4 Days 0.6 0 0.17 
Musculoskeletal Sore Muscles Everyday 1 5 1 
 
Using the data displayed in Table 21, the female case reported the following five 
musculoskeletal symptoms: back pain, painful joints, stiff joints, stiff neck, and sore 
muscles. Based on the scale in Table 20, a frequency of everyday is awarded a 1.0 score. 
Since all of the symptoms were experienced every day, the average score for the five 
symptoms is 1.0 (the third column in Figure 6).  
To calculate the severity score for the musculoskeletal symptoms, the severity 
score shown in Table 20 was used. Three of the symptoms were considered (by the 




score of 1.0. Two of the symptoms were considered major problems that interfere with 
most daily activities (score of 4 on the severity scale) and were assigned a severity score 
of 0.85 for each. To calculate the final severity score, the average of the five scores ([1.0 
+ 1.0 + 1.0 + 0.85 + 0.85]/5) resulted in a severity score of 0.94 (the fourth column in 
Figure 6).  
Lastly, each symptom category score was added together to compose the final 
symptom index score (the last column in Figure 6). An example symptom index score is 
shown in Figure 6 below. 
General Musculoskeletal Cognitive Neurological Cardiac Cutaneous Symptom 
Index 
Freq Sev Freq Sev Freq Sev Freq Sev Freq Sev Freq Sev 
0.44 0.34 1.00 0.94 0.40 0.34 0.47 0.34 0.00 0.00 0.50 0.50 5.27 
 
Figure 6. Symptom index score card showing total symptom index score and frequency 
and severity scores for each symptom category. 
Results 
Symptom Frequency 
Overall symptom frequency scores were calculated by adding the calculated 
frequency scores for each of the six symptom categories together. From Figure 6 above, 
frequency scores for general (0.44), musculoskeletal (1.00), cognitive (0.40), 
neurological (0.47), cardiac (0.00), and cutaneous (0.50) symptoms were combined to 
represent the overall symptom frequency score. A comparison was made of the overall 
symptom frequency score based on sex of the participant. Results are shown in Table 22 




were combined into the categories listed in Table 22 for analysis to increase the number 
of participants in each category. 
Table 22 
Frequency Score for Participants 
Frequency 
Score 
Female Case Female Control Male Case Male Control 
0.00 – 0.99 5 120 13 49 
1.00 – 1.99 5 79 47 44 
2.00 – 2.99 55 55 13 23 
3.00 – 3.99 44 10 0 4 
4.00 – 4.99 20 4 0 0 
5.00 – 5.99 1 0 0 0 
6.00 0 0 0 0 
 
Both male and female controls displayed an overall frequency score on the lower 
end of the scale (less than 3.00) with only 14 female controls scoring above 3.00. 
Noteworthy is the fact that male cases also had frequency scores below 3.00, while 
female cases were clustered primarily between 2.00 and 5.00. Figure 7 shows the 
distribution of score by cases and controls.  
 





Univariate statistical analysis of frequency scores between cases and controls 
(Table 24), as well as between male and female cases (Table 23), support this 
arrangement as statistically significant [χ
2
 (15, N = 588) = 290.42, p < 0.05; χ
2
 (5, n = 
203) = 122.04, p < 0.05]. 
Table 23 
Frequency Scores in Cases by Sex 
 
Table 24 
Frequency Scores by Cases/Controls 
 
 
Raw data is shown below for breakdown by age of the overall frequency scores 
for cases (Table 25) and controls (Table 26). Most of the overall frequency scores for 
cases were between 1.00 and 5.00, while most of the overall frequency scores for controls 
were below 3.00.  
In order to compare case and control overall frequency scores and the age 
category variable, the Kruskal-Wallis test was conducted. Initially, an ANOVA was 
conducted because both the age category and the frequency scores had multiple levels 




 5 .000 
Likelihood Ratio 144.646 5 .000 
N of Valid Cases 203   




 15 .000 
Likelihood Ratio 289.682 15 .000 




within the groups. Unfortunately, the Levene’s Test of Equality of Error Variances was 
0.011, which is not larger than the p-value of 0.05. This test looks for homogeneity 
within the samples (Munro, 2005). This low score suggested that the test sample is not 
normally distributed. The Kruskal-Wallis test is a non-parametric test that does not 
require the sample population to be normally distributed across the age groupings. 
Based on the Kruskal Wallis test comparison (Table 27), whether a participant 
was a case or a control was correlated to both the age group category, [χ
2 
(1, N = 591) = 
84.80, p = 0.00] and the symptom frequency score, [χ
2 
(1, N = 591) = 118.43, p = 0.00] 
as shown in Table 28. 
Table 25 
Overall Frequency Scores of CASES by Age Groups 
Freq 























0.00-0.99 3 0 2 2 1 1 4 2 1 1 1 1 0 
1.00-1.99 4 2 4 4 4 3 6 4 5 3 8 2 3 
2.00-2.99 1 1 1 7 3 8 6 11 8 7 5 4 6 
3.00-3.99 1 3 1 0 2 5 6 3 14 1 5 3 0 
4.00-4.99 0 0 0 1 2 0 3 4 4 1 3 1 0 
5.00-5.99 0 0 0 0 0 0 0 0 1 0 0 0 0 





Table 26  
Overall Frequency Scores of CONTROLS by Age Group 























0.00 - 0.99 64 5 43 6 7 1 8 6 7 6 5 6 3 
1.00 - 1.99 41 3 28 5 7 4 3 8 8 3 3 9 1 
2.00 - 2.99 24 4 16 4 1 3 2 7 4 4 5 3 1 
3.00 - 3.99 0 0 0 0 0 1 3 0 1 2 2 2 3 
4.00 - 4.99 1 0 2 0 1 0 1 0 0 0 0 0 0 
5.00 - 5.99 0 0 0 0 0 0 0 0 0 0 1 0 0 
6.00 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
 
Table 27      Table 28 
Kruskal-Wallis Comparison    Overall Frequency Score by 








Case 203 397.73 
Control 388 242.77 
Total 591  
Age 
Category 
Case 203 384.53 
Control 388 249.68 
Total 591  
 
RQ1: Is the presentation of symptoms in Lyme disease-positive patients associated with 
the sociodemographic variables age and sex as assessed by patient medical record and 
ROSS Scale survey review? 
H01: Lyme disease symptom presentation is not associated with the 
sociodemographic variables age and sex as assessed by patient reported symptoms 















Ha1: Lyme disease symptom presentation is associated with the sociodemographic 
variables age and sex as assessed by patient reported symptoms recorded in 
patient medical records or on the ROSS Scale survey. 
Based on the statistical evidence presented, the null hypothesis can be rejected and the 
alternate hypothesis for research question one can be accepted – Lyme disease symptom 
presentation is associated with the sociodemographic variables age and sex as assessed by 
patient reported symptoms recorded in patient medical records. 
Symptom Severity 
A comparison was made between the overall severity score and the sex of the 
participants. Results are presented in Table 29 and Figure 8. As with the frequency 
scores, overall severity scores for male cases and controls and female controls are less 
than 3.00. Female cases’ overall severity scores ranged from 1.00 – 5.00.  
Table 29 
Overall Severity Scores by Participant 
Severity 
Score Female Case 
Female 
Control Male Case Male Control 
0.00 – 0.99 12 141 29 63 
1.00 – 1.99 34 95 32 42 
2.00 – 2.99 46 24 11 12 
3.00 – 3.99 28 6 1 3 
4.00 – 4.99 10 2 0 0 
5.00 – 5.99 0 0 0 0 






Figure 8. A comparison of the overall severity score between cases/controls based on 
sex. 
After Chi-Square analysis, results (Table 30) indicate that there is a correlation 
between sex of the participant and the overall symptom severity score [χ
2
 (4, N = 591) = 
20.94, p = 0.00]. In addition, statistical analysis (Table 31) suggests that there is a 
significant difference between cases and controls based on overall symptom severity 
score [χ
2
 (4, N = 591) = 106.39, p = 0.00]. Lastly, the comparison (Table 32) between 
overall symptom severity scores and participant age also suggests a significant 
correlation [χ
2
 (48, N = 591) = 106.81, p = 0.00].  
Table 30 
Overall Severity Scores by Sex 




 4 .000 
Likelihood Ratio 26.455 4 .000 
Linear-by-Linear 
Association 
17.523 1 .000 





Overall Severity Scores Between Cases and Controls 




 4 .000 
Likelihood Ratio 106.483 4 .000 
Linear-by-Linear 
Association 
103.092 1 .000 
N of Valid Cases 591   
 
Table 32 
Overall Severity Scores by Age Categories 




 48 .000 
Likelihood Ratio 111.154 48 .000 
Linear-by-Linear 
Association 
32.938 1 .000 
N of Valid Cases 591   
 
RQ2: Is the severity of symptoms in Lyme disease positive patients associated with the 
sociodemographic variables age and sex as assessed by patient medical record and ROSS 
Scale survey review? 
H02: Lyme disease symptom severity is not associated with the 
sociodemographic variables age and sex as assessed by patient reported 
symptoms recorded in patient medical records or on the ROSS Scale survey. 
Ha2: Lyme disease symptom severity is associated with the sociodemographic 
variables age and sex as assessed by patient reported symptoms recorded in 




Based on the statistical evidence presented, the null hypothesis can be rejected and the 
alternate hypothesis for research question two can be accepted – Lyme disease symptom 
severity is associated with the sociodemographic variables age and sex as assessed by 
patient reported symptoms recorded in patient medical records. 
In order to discuss how the presentation and severity of symptoms are associated 
with the diagnosis of Lyme disease (RQ3 and RQ4), the specific categories of symptoms 
were examined individually first for an effect on accurate diagnosis. The overall 
symptom score was then examined for an effect on accurate diagnosis of Lyme disease. 
Symptom categories of Musculoskeletal, Neurological, Cognitive and Cutaneous were 
examined because the study population size was adequate in power to identify a 
statistically relevant correlation if one was present. General symptoms were reviewed 
because these symptoms are common indicators of many other diseases and conditions, 
as well as indicators for Lyme disease. Cardiac symptoms, due to their rare occurrence in 
both the general and Lyme disease populations, required a much larger sample population 
than was feasible for this study (CDC, 2015; Sandesara & Olshansky, 2012). Analysis 
based on the cardiac symptom category was not performed individually, but the cardiac 
category symptom scores were included in the total symptom index score calculations 
and the overall effect calculations. 
General Symptoms 
The general symptoms category contains a variety of symptoms that can be an 
indicator of many different diseases, including Lyme disease. General symptoms 
examined included fatigue, fever, chills, headaches, sore throat, persistent swollen glands, 




disease presents as fever, chills, fatigue, headache, and the erythema migrans rash 
(discussed separately next). 
Based on Chi-square analysis of the general symptom category (Tables 35 & 36), 
significant differences were found between cases and controls [χ
2
freq (4, N = 591) = 
105.468, p = 0.00; χ
2
sev (4, N = 591) = 71.243, p = 0.00] (Tables 33 & 34), but not based 
on sex [χ
2
freq (4, N = 591) = 5.403, p > 0.05; χ
2
sev (4, N = 591) = 6.496, p > 0.05]. In 
addition, analysis was performed comparing frequency and severity with the age variable. 
ANOVA analysis (Table 37) showed a significance based on both frequency score (p = 
0.000) and severity score (p = 0.019) when compared to age. The Tukey post-hoc 
analysis showed the significance was between the < 20 years category and the 40-44 
years, 45-49 years, and the 60-64 years categories for frequency, but showed no real 
significance between age groups based on general symptom severity scores (Tables 38 & 
39). 
Table 33 
General Symptom Frequency vs Case/Control    




 4 .000 
Likelihood Ratio 115.894 4 .000 
Linear-by-Linear 
Association 
96.333 1 .000 






General Symptom Severity vs Case/Control 




 4 .000 
Likelihood Ratio 76.269 4 .000 
Linear-by-Linear 
Association 
64.690 1 .000 
N of Valid Cases 591   
 
Table 35 
General Symptom Frequency by Sex 




 4 .248 
Likelihood Ratio 5.412 4 .248 
Linear-by-Linear 
Association 
1.629 1 .202 
N of Valid Cases 591   
 
Table 36 
General Symptom Severity by Sex 




 4 .165 
Likelihood Ratio 6.496 4 .165 
Linear-by-Linear 
Association 
2.083 1 .149 






General Symptom Frequency Comparison via ANOVA by Age 







66.327 12 5.527 4.142 .000 
Within Groups 771.337 578 1.334   
Total 837.665 590    
 
Table 38 
General Symptom Tukey Post-Hoc Analysis by Age 
(I) Age 
Category 
(J) Age Category Mean Difference 
(I-J) 
Std. Error Sig. 
<20 Years 
20-24 Years -.06910 .15264 1.000 
25-29 Years -.58249 .23887 .418 
30-34 Years -.36821 .23887 .946 
35-39 Years -.76381 .24642 .097 
40-45 Years -.77297
*
 .20291 .010 
45-49 Years -.83646
*
 .19762 .002 
50-54 Years -.57441 .18595 .099 
55-59 Years -.55294 .23540 .482 
60-64 Years -.89202
*
 .21556 .003 
65-69 Years -.24148 .22901 .998 
70-74 Years -.78418 .29648 .286 
>75 Years -.44757 .28903 .944 
 
Table 39 
General Symptom Severity Comparison via ANOVA by Age 
 Sum of 
Squares 
df Mean Square F Sig. 
Between 
Groups 
32.533 12 2.711 2.044 .019 
Within Groups 766.566 578 1.326   




Erythema Migrans Rash 
According to the CDC (2015), the erythema migrans (EM) rash “occurs in 
approximately 60 to 80 percent of infected persons” (para. 1). This ratio was also 
supported by other studies (Aucott, Seifert, & Rebman, 2012a). Based on this percentage, 
the EM rash is currently used as a diagnostic tool for Lyme disease. The presence of the 
EM rash with a known tick exposure can be used to diagnose Lyme disease without any 
further laboratory testing (Aucott, Crowder, Yedlin, &Kortte, 2012; CDC, 2015).  
This 60-80% of cases ratio was not supported by the current study. According to 
the data collected (Table 40), only 28% of participants experienced the EM rash. Of the 
28% of participants who experience the EM rash, female cases constituted 61% of the 
cases that experienced the rash. 
Table 40 




Male Female Total 













Yes 22 34 56 28 38 61 
No 50 94 144 72 34 67 
Total 72 128 200 100 72 128 






Figure 9. Comparison of cases and controls who displayed the EM rash by sex of 
participant. 
Based on Chi-Square analysis of EM rash in males and females (Table 41), the 
relationship was not significant [χ
2 
(1, n = 200) = 0.546, p > 0.05]. When comparing the 
presence of EM rash between cases and controls (Table 42), the relationship was 
significant [χ
2
 (1, N = 588) = 120.076, p < 0.05]. This relationship supports using the EM 
rash as a diagnostic tool, but does not show a statistically relevant difference based on sex 
of the patient. 
Table 41 
EM Rash by Sex  
 Value df Asymp. Sig. 
(2-sided) 
Exact Sig.  
(2-sided) 









.193 1 .660   
Likelihood Ratio .362 1 .548   
Fisher's Exact Test    .623 .328 






EM Rash in Cases vs. Controls 
 Value df Asymp. Sig. 
(2-sided) 











116.848 1 .000   
Likelihood Ratio 132.662 1 .000   
Fisher's Exact Test    .000 .000 
N of Valid Cases 588     
 
Analysis was also conducted based on the age of the participants. As shown in 
Table 43, presence of the EM rash in women was present primarily in cases over the age 
of 35, with the largest number of female cases with EM rash falling in the 50-54 year age 
category. 
Table 43 
EM Rash Comparison by Sex and Age Categories 
Age Categories 
Female - Case Male - Case 
Total 
No Yes No Yes 
<20 4 1 3 1 9 
>75 3 1 1 1 6 
20-24 3 0 5 0 8 
25-29 5 0 6 2 13 
30-34 9 0 2 2 13 
35-39 8 4 3 1 16 
40-44 11 4 9 1 25 
45-49 15 2 5 2 24 
50-54 17 9 6 0 32 
55-59 7 2 2 2 13 
60-64 8 4 5 5 22 
65-69 3 4 1 2 10 
70-74 1 3 2 3 9 





A comparison was made between the age categories (as listed in the Table 43 
above) and the presence of the EM rash. The results (Table 44) suggest a statistical 
significance between age and presence of the EM rash [χ
2
 (12, = 200) = 21.43, p < 0.05], 
although the level of significance is relatively small (p = 0.044). Kruskal Wallis testing 
(because the data was not normally distributed) was unable to support this level of 
significance (p = 0.05), suggesting age and presence of the EM rash were not related. 
Table 44 
Age vs Presence of EM Rash 






 12 .044 
Likelihood Ratio 22.405 12 .033 
N of Valid Cases 200   
 
Musculoskeletal Symptoms 
Because Lyme disease caused by Borrelia burgerferi tends to produce 
musculoskeletal symptoms in the United States, these symptoms were examined next for 
diagnostic use (Stanek et al., 2011). The musculoskeletal symptoms category included 
painful joints, stiff joints, stiff neck, back pain, and sore muscles. Analysis was conducted 
using sex, age, and case/control comparisons. Population sample size (N = 591) for the 
musculoskeletal category was slightly different than that used for the EM rash analysis. 
Three participants were unsure about the presence of the EM rash, so these participants 




for the other symptom categories, so these participants were included in the rest of the 
symptom analyses.  
Breakdown of musculoskeletal symptoms frequency scores are shown in Table 45 
and Figure 10. Of note, male (Mcase) cases experienced musculoskeletal symptoms 
across the entire range of frequency categories with the score evenly distributed across 
the scores. Female cases (Fcase) were also distributed across all frequency levels, but the 
largest concentration of scores was located in the highest musculoskeletal symptom 
frequency score. Additionally, both male (Mcontrol) and female (Fcontrol) controls 
experienced musculoskeletal symptoms across all score categories with the highest 
concentration of scores at the lowest end of the scale. 
Table 45 
Musculoskeletal Symptom Frequency Score by Sex and Case/Control  
Frequency 
Score 
Female Case Female Control Male Case Male Control 
0.00-0.20 7 140 10 53 
0.21-0.40 12 53 17 23 
0.41-0.60 24 33 17 28 
0.61-0.80 27 15 16 9 







Figure 10. Comparison of musculoskeletal frequency scores by case/control and sex of 
participant. 
Initial descriptive statistics demonstrated that all participants (N = 591) could be 
included in the analysis. Upon Chi-Square analysis, relationships between the frequency 
score for musculoskeletal symptoms compared to sex (Table 46), age (Table 47), and 
case or control (Table 48) displayed a significant correlation [χ
2
 (4, N = 591) = 19.85, p = 
0.01; χ
2
 (48, N  591) = 120.34, p = 0.00; χ
2
 (4, N = 591) = 148.74, p = 0.00]. 
Table 46 
Musculoskeletal Frequency Score vs Sex  






 4 .001 
Likelihood Ratio 20.645 4 .000 
Linear-by-Linear 
Association 
1.671 1 .196 






Musculoskeletal Frequency Scores vs. Age 




 48 .000 
Likelihood Ratio 123.063 48 .000 
Linear-by-Linear 
Association 
49.507 1 .000 
N of Valid Cases 591   
 
Table 48 
Musculoskeletal Frequency Score vs Case/Control 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 148.736
a
 4 .000 
Likelihood Ratio 159.936 4 .000 
Linear-by-Linear 
Association 
145.614 1 .000 
N of Valid Cases 591   
 
After performing Levene’s Test of Equality of Error Variances, the significance 
value was 0.059, which is higher than the alpha value of 0.05. Because the test statistic 
was higher than the accepted level of significance, the values being tested were normally 
distributed and a one way analysis of variance (ANOVA) was performed (Munro, 2005). 
When comparing the musculoskeletal frequency score with case/controls or male/female, 
differences found were significant, F (1, 1) = 74.51, p = 0.00; F(1,1) = 8.33, p = 0.00 
respectively. In addition, comparison of the musculoskeletal frequency scores with 




8.03, p = 0.01. Further post hoc analysis was not performed on these variables because 
there were only two categories for each variable. 
When examining the musculoskeletal frequency score with the age variable by 
ANOVA, initial results implied a lack of significance between age as a whole and the 
musculoskeletal frequency score. Post hoc analysis, via the Tukey post hoc test, 
comparing frequency scores of each age group with each other age group did show some 
areas of significance (highlighted in yellow). The <20 years age group was significantly 
different from most of the other age groups with the exception of the 20-24 years, 25-29 
years and the >75 years age groups (Table 49). The 20-24 years age group was only 
significantly different from the 40-44 years and the 50-54 years age groups. The other 
age groups were not significantly different from each other, with the exception of those 






Tukey Post Hoc Test Comparing Musculoskeletal Frequency Score with Age Categories 
(Partial Table) 
 
Musculoskeletal symptom severity scores were also calculated. Scores were 
broken down by sex and case or control status (Table 50). Female (Fcase) cases had a 
more even distribution of scores across all severity levels with the highest scores in the 
top severity level. Male (Mcase) cases had lower severity scores overall. Female 
(Fcontrol) and male (Mcontrol) controls had the highest number of individuals 
experience little to no discomfort associated with their musculoskeletal symptoms (as 
expected), but also had participants experience symptoms across the entire range of 
scores in higher numbers than expected. 
 





















20-24 Years -.3041 .17107 .860 -.8734 .2652 
25-29 Years -.6836 .26771 .342 -1.5745 .2073 
30-34 Years -1.0407
*
 .26771 .007 -1.9316 -.1499 
35-39 Years -1.1479
*
 .27618 .003 -2.0670 -.2288 
40-45 Years -1.3384
*
 .22741 .000 -2.0951 -.5816 
45-49 Years -1.0590
*
 .22148 .000 -1.7960 -.3220 
50-54 Years -1.6196
*
 .20840 .000 -2.3131 -.9261 
55-59 Years -1.1824
*
 .26383 .001 -2.0603 -.3044 
60-64 Years -1.0646
*
 .24159 .001 -1.8685 -.2606 
65-69 Years -.8898
*
 .25667 .032 -1.7439 -.0357 
70-74 Years -1.2655
*
 .33228 .010 -2.3713 -.1598 





Musculoskeletal Severity Score for Male/Female Cases and Controls 
 
Severity Score Female Case Female Control Male Case Male Control 
0.00-0.20 15 158 15 63 
0.21-0.40 29 48 24 27 
0.41-0.60 24 32 20 18 
0.61-0.80 23 16 5 11 
0.81-1.00 39 14 9 1 
 
Musculoskeletal symptoms severity scores were also statistically analyzed. 
Comparisons were made between these severity scores for cases/controls (Table 51), 
males/females (Table 52), and with the various age categories (Table 53). Pearson Chi-
Square analysis suggested a significant relationship between musculoskeletal severity and 
being a case or control [χ
2
 (4, N = 591) = 116.54, p = 0.00]; being a male or female [χ
2
 
(4, N = 591) = 14.55, p = 0.01]; and with age [χ
2
 (48, N = 591) = 128.36, p = 0.00]. 
Table 51 
Musculoskeletal Severity Score vs Case/Control 




 4 .000 
Likelihood Ratio 122.993 4 .000 
Linear-by-Linear 
Association 
107.236 1 .000 





Musculoskeletal Severity Score vs Sex 




 4 .006 
Likelihood Ratio 15.454 4 .004 
Linear-by-Linear 
Association 
2.452 1 .117 
N of Valid Cases 591   
 
Table 53 
Musculoskeletal Severity Score vs Age Category 




 48 .000 
Likelihood Ratio 129.435 48 .000 
Linear-by-Linear 
Association 
24.788 1 .000 
N of Valid Cases 591   
 
Neurological Symptoms 
Neurological symptoms are the hallmark of the second stage of Lyme disease 
infection (early disseminated Lyme disease) where the B. burgdorferi bacteria leave the 
initial site of infection and spreads to other areas of the body, including the nervous 
system. Neurological symptom data collected included: facial numbness (Bell’s palsy); 
blurred vision, eye pain, ear ringing, and jaw pain (cranial nerve involvement), 
testicular/pelvic pain, and tingling/burning/numbness. Variables compared with symptom 
frequency and severity scores included case/control, sex, and age. All participants (N = 




Neurological symptom frequency scores (Table 54 and Figure 11) vary in their 
distribution between cases and controls. Both male (Mcase) and female (Fcase) cases 
display a more even distribution across the scale of scores available. Conversely, male 
(Mcontrol) and female (Fcontrol) controls’ scores are heavily skewed to one side of the 
scale of available scores with a sharp decrease in the number of controls that experience 
these symptoms more than once per week. 
Table 54 
Neurological Symptom Frequency Scores by Sex and Case/Control 
Frequency 
Score 
Female Case Female Control Male Case Male Control 
0.00-0.20 14 182 14 76 
0.21-0.40 26 45 14 23 
0.41-0.60 30 19 16 12 
0.61-0.80 29 14 16 6 
0.81-1.00 31 8 13 3 
 
 
Figure 11. Comparison of the neurological symptom frequency score between 




Comparison was first performed based on the neurological symptom category 
frequency score. As shown in Table 55, Chi-Square analysis comparing frequency scores 
of cases and controls supported a significant difference between cases and controls based 
on neurological symptom frequency scores [χ
2
 (4, N = 591) = 184.76, p = 0.00]. In 
addition, Chi-Square analysis based on age (Table 56) supported a significant difference 
based on age of participant [χ
2
 (48, N = 591) = 155.81, p = 0.00]. 
Table 55 
Neurological Symptom Frequency Score by Case/Control 
 
Value df 




 4 .000 





N of Valid Cases 591   
 
Table 56 
Neurological Symptom Frequency Score by Age Category 
 
Value df 




 48 .000 





N of Valid Cases 591   
 
Not surprisingly, Chi-Square analysis based on sex (Table 57) did not support a 
significant difference between the frequency a neurological symptom was experienced 
and the sex of the participant [χ
2




cases displayed a broad distribution of frequency scores, so the lack of significance 
between the sexes based on the data collected was not unexpected. 
Table 57 
Neurological Symptom Frequency Score by Sex 
 
Value df 




 4 .886 





N of Valid Cases 591   
  
Next, neurological symptom severity scores were examined. Comparisons were 
made between neurological symptom severity scores and case/control, sex, and age 
categories. Aggregate data can be found in Table 58 and Figure 12 below. As with the 
neurological symptom frequency scores, the neurological symptom severity scores 
displayed a similar distribution. Male (Mcase) and female (Fcase) cases experienced 
neurological symptoms with varying degrees of severity across all possible score 
categories. In comparison, male (Mcontrol) and female (Fcontrols) controls experienced 
neurological symptoms mainly on the less severe end of the severity scale, if at all. 
Table 58 
Neurological Symptom Severity Scores by Sex and Case/Control 
Severity Score Female Case Female Control Male Case Male Control 
0.00-0.20 22 201 20 88 
0.21-0.40 36 34 21 16 
0.41-0.60 33 21 16 8 
0.61-0.80 25 9 10 6 






Figure 12. Comparison of neurological symptom severity score between cases and 
controls by sex of participant. 
Statistical analysis was performed. Chi-Square analysis supported a significant 
difference between the neurological symptom severity scores of cases and controls [χ
2
 (4, 
N = 591) = 165.51, p = 0.00], as well as neurological symptom severity scores found 
between age categories [χ
2
 (48, N = 591) = 163.85, p = 0.00]. Results for these analyses 
are found in Tables 59 and 60 below. 
Table 59 
Neurological Symptom Severity Score by Case/Control 
 
Value df 




 4 .000 











Neurological Symptom Severity Score by Age Category 
 
Value df 




 48 .000 





N of Valid Cases 591   
 
As with the neurological symptom frequency score, the neurological symptom 
severity score comparison based on sex of the participant (Table 61) did not support a 
significant difference between the severity levels of neurological symptoms experienced 
by males and females [χ
2
 (4, N = 591) = 0.445, p = 0.98]. This finding was not surprising 
based on the distribution of neurological symptom severity scores reported. 
Table 61 
Neurological Symptom Severity Score by Sex 
 
Value df 




 4 .979 





N of Valid Cases 591   
 
Cognitive Symptoms 
The last area for individual examination was cognitive symptoms frequency and 
severity scores. These scores were compared with case/control status, male/female sex, 




Cognitive symptoms included in this category were: disturbed sleep, poor concentration, 
memory loss, irritability, crying, and sadness/depression.  
Cognitive symptom frequency scores were examined first for significant 
differences across all variable categories. Aggregate data for cognitive symptom 
frequency scores based on sex and case/control status are shown in Table 62 and Figure 
13. Both male (Mcase) and female (Fcase) cases experienced cognitive symptoms across 
a broad range of frequencies in an almost even distribution across categories. Male 
(Mcontrol) and female (Fcontrol) controls experienced cognitive symptoms infrequently 
(Table 62 & Figure 13). 
Table 62 
Cognitive Symptom Frequency Scores by Sex and Case/Control 
Frequency 
Score 
Female Case Female Control Male Case Male Control 
0.00-0.20 14 182 14 76 
0.21-0.40 26 45 14 23 
0.41-0.60 30 19 16 12 
0.61-0.80 29 14 16 6 






Figure 13. Comparison of cognitive frequency scores between cases and controls based 
on sex of the participants. 
Chi-Square analysis of cognitive symptom frequency scores in cases and controls 
(Table 63) confirmed a significant difference [χ
2
 (4, N = 591) = 141.71, p = 0.00] 
between how often an individual with Lyme disease experiences cognitive issues and 
how frequently an individual who does not have Lyme disease experiences these same 
symptoms. In addition, a significant difference was found between the different age 
categories (Table 64) based on cognitive symptom frequency score [χ
2
 (48, N = 591) = 
148.61, p = 0.00]. 
Table 63 
Cognitive Symptom Frequency Score by Case/Control 
 
Value df 




 4 .000 











Cognitive Symptom Frequency Score by Age Category 
 
Value df 




 48 .000 





N of Valid Cases 591   
  
As with neurological symptom frequency, cognitive symptoms (Table 65) 
occurred no more frequently in male or female participants [χ
2
 (4, N = 591) = 5.22, p = 
0.27]. This outcome was slightly less expected than the outcome observed for the 
neurological symptom frequency because the cognitive frequency raw data shows an 
upward trend in scores for females while the male cognitive frequency scores remain 
fairly steady across all frequency categories (Figure 13). 
Table 65 
Cognitive Symptom Frequency by Sex  
 
Value df 




 4 .266 





N of Valid Cases 591   
 
Severity scores for the cognitive symptom category followed a similar pattern to 
the cognitive symptom frequency scores with a significant difference shown in the 
severity of cognitive symptoms experienced between cases and controls [χ
2




= 105.23, p = 0.00] (Table 66) and between the various age categories [χ
2
 (48, N = 591) = 
83.61, p = 0.01] (Table 67). Significant differences in the severity of cognitive symptoms 
between males and females were absent [χ
2
 (4, N = 591) = 5.66, p = 0.23] (Table 68). 
Table 66 
Cognitive Symptom Severity by Case/Control 
 
Value df 




 4 .000 





N of Valid Cases 591   
 
Table 67 








 48 .001 










Cognitive Symptom Severity by Sex 
  
For each symptom category analyzed, differences between cases and controls and 
between age categories were supported. Because these categories were developed to help 
diagnose Lyme disease, variations between cases and controls would be important to 
identify. Interestingly, there were no significant differences between male and female 
symptom presentation in these four categories, but from a diagnostic stand point, 
determining that there is no difference between male and female symptom presentation is 
also an important finding. 
RQ3: Is the presentation of symptoms associated with the diagnosis of Lyme disease as 
assessed by patient medical record and ROSS Scale survey review? 
H03: Lyme disease symptom presentation is not associated with the diagnosis 
of Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
Ha3: Lyme disease symptom presentation is associated with the diagnosis of 
Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
 
Value df 




 4 .226 









RQ4: Is the severity of symptoms associated with the diagnosis of Lyme disease as 
assessed by patient medical record and ROSS Scale survey review? 
H04: Lyme disease symptom severity is not associated with the diagnosis of 
Lyme disease as assessed by patient reported symptoms recorded in patient 
medical records or on the ROSS Scale survey. 
Ha4: Lyme disease symptom severity is associated with the diagnosis of Lyme 
disease as assessed by patient reported symptoms recorded in patient medical 
records or on the ROSS Scale survey. 
Based on the reported statistical analyses and the resultant significant differences 
between cases and controls for musculoskeletal, neurological, cognitive, and cutaneous 
symptoms in both the frequency of experienced symptoms and the severity of those 
symptoms, the null hypothesis can be rejected and the alternative hypothesis can be 
accepted for both RQ3 and RQ4. Musculoskeletal, neurological, cognitive, and cutaneous 
symptom frequency and severity can be used to help diagnose Lyme disease. 
Odds Ratio 
Odds ratios were calculated (using the OpenEpi calculator) for the 
musculoskeletal, neurological, cognitive and cutaneous symptom categories (Dean, 
Sullivan, & Soe, 2015). These odds ratios were based on the symptom frequency score 
only for the specific symptom category, since this score represents the presence of the 
symptom. All participants were included in the calculations with the exception of the 
odds ratio calculation for the cutaneous symptom category. This group had three 




participants were excluded from the odds ratio calculation. The odds ratios were 
calculated as shown in Figure 14. 
 
Figure 14. Odds ratio calculation chart. 
According to the odds ratio calculation, the likelihood of an individual 
experiencing musculoskeletal symptoms with Lyme disease is 11 (95% CI: 6.34, 18.49) 
times higher than experiencing those symptoms in the absence of Lyme disease. Because 
the confidence interval is greater than and does not contain 1.0, there is a significant 
difference between the cases and controls based on the presence of musculoskeletal 
symptoms (Table 69). This result supports the statistical analysis discussed previously. 
Table 69 
















CMLE Odds Ratio* 10.79 6.434, 18.93¹  Mid-P Exact 
 
   
6.258, 19.67¹  Fisher Exact 
 
 
Odds Ratio 10.83 6.342, 18.49¹  Taylor series 
 
Etiologic fraction in 
pop.(EFp|OR) 
83.16% 75.32, 91.01 
  
 
Etiologic fraction in 
exposed(EFe|OR) 





Next, the odds ratio was calculated for the presence of neurological symptoms in 




neurological symptoms with Lyme disease is 12 (95% CI: 7.90, 19.48) times more likely 
than experiencing neurological symptoms in the absence of Lyme disease. Because the 
95% confidence interval is larger than and does not include 1.0, the results for 
neurological symptom odds ratio analysis are significant between cases and controls in 
this study. The odds ratio results (Table 70) support the statistical relevance determined 
by the statistical analysis discussed previously. 
Table 70 
















CMLE Odds Ratio* 12.34 7.937, 19.66¹  
Mid-P 
Exact  
   








Etiologic fraction in pop.(EFp|OR) 79.26% 71.97, 86.54 
  
 




  *Conditional maximum likelihood estimate of Odds Ratio 
  
(P)indicates a one-tail P-value for Protective or negative association; otherwise one-tailed exact P-values are for a 
positive association.   
° ¹ 95% confidence limits testing exclusion of 0 or 1, as indicated 
  
P-values < 0.05 and confidence limits excluding null values (0,1, or [n]) are highlighted. 
  
 
The odds ratio was then calculated for the presence of cognitive symptoms in 
study participants. Based on this calculation, the likelihood of an individual experiencing 
cognitive symptoms with Lyme disease is 10 (95% CI: 5.24, 17.30) times more likely 
than experiencing cognitive symptoms in the absence of Lyme disease. Because the 95% 
confidence interval is larger than and does not include 1.0, the results for cognitive 




odds ratio results (Table 71) support the statistical relevance determined by the statistical 
analysis discussed previously. 
Table 71 
















CMLE Odds Ratio* 9.486 5.347, 17.92¹  
Mid-P 
Exact  
   








Etiologic fraction in pop.(EFp|OR) 83.76% 74.99, 92.53 
  
 




  *Conditional maximum likelihood estimate of Odds Ratio 
  
(P)indicates a one-tail P-value for Protective or negative association; otherwise one-tailed exact P-values are for a 
positive association.   
° ¹ 95% confidence limits testing exclusion of 0 or 1, as indicated 
  
P-values < 0.05 and confidence limits excluding null values (0,1, or [n]) are highlighted. 
  
 
Lastly, the odds ratio was calculated for the presence of cutaneous symptoms in 
study participants. Based on this calculation, the likelihood of an individual experiencing 
cutaneous symptoms with Lyme disease is 144 (95% CI: 19.72, 1048.73) times more 
likely than experiencing cutaneous symptoms in the absence of Lyme disease. Because 
the 95% confidence interval is larger than and does not include 1.0, the results for 
cutaneous symptom odds ratio analysis are significant between cases and controls in this 
study. The odds ratio results (Table 72) support the statistical relevance determined by 
the statistical analysis discussed previously. This result also supports the common use of 





















CMLE Odds Ratio* 142.9 27.55, 2931¹  
Mid-P 
Exact  
   








Etiologic fraction in pop.(EFp|OR) 26.91% 20.76, 33.05 
  
 




  *Conditional maximum likelihood estimate of Odds Ratio 
  (P)indicates a one-tail P-value for Protective or negative association; otherwise one-tailed exact P-values are for a 
positive association.   
° ¹ 95% confidence limits testing exclusion of 0 or 1, as indicated 
  P-values < 0.05 and confidence limits excluding null values (0,1, or [n]) are highlighted. 
  
 
Symptom Index Score 
The symptom index score was evaluated as a diagnostic tool for Lyme disease. As 
stated previously, an overall symptom index score can be achieved based on a maximum 
score of two for each of the six symptom categories. The symptom index score was first 
evaluated by multiple linear regression based on the age and sex variables. All 
participants (N = 591) were included in this analysis. Symptom index scores were 
calculated as shown in Figure 6.  
The multiple regression analysis was performed to determine if the 
sociodemographic factors sex and age could be used to predict the presence of Lyme 
disease based on the symptom index score. Based on the linear model, sociodemographic 
factors are significantly related to the symptom index score [F (2, 588) = 34.98, p = 0.00] 
and account for approximately 10% of the variance (R
2
 = 0.106) between the symptom 




correlation; for each incremental increase in age group, there is a small increase in 
symptom index score. 
When looking at each individual factor’s effect, age is the only factor that 
displayed any significant results (p = 0.00) when holding the sex variable constant (Table 
73). When holding the age variable constant, sex (p > 0.05) is not a significant 
contributor to the symptom index score. Based on the multiple regression model, for each 
increase in age category, the symptom index score increase by a factor of 0.2. In addition, 
the symptom index scores for females are 0.18 points higher than those found in male 
participants but these variations do not reach the level of significance. 
Table 73 



















(Constant) 2.379 .291  8.177 .000 1.808 2.951 
Sex -.178 .193 -.036 -.922 .357 -.557 .201 
Age Category .200 .024 .327 8.356 .000 .153 .247 
a. Dependent Variable: Symptom Index 
 
Next, the symptom index score was evaluated by construction a receiver operating 
characteristic (ROC) curve to determine whether the symptom index score can be a valid 
method for diagnosing Lyme disease. The resultant ROC curve for symptom index scores 






Figure 15. ROC curve comparing the symptom index scores of participants with case vs 
control status. 
The area under the curve (AUC) can be used to show the validity of a diagnostic 
test (Kumar & Indrayan, 2011). With an AUC value equal to 1 showing a perfect 
diagnostic test, AUC values should be as close to 1 as possible. The AUC for the ROC 
curve shown in Figure 15 is 0.88, as shown in Table 74. This result supports using the 
symptom index score as a diagnostic tool for Lyme disease. 
Table 74 
Area Under the Curve 








Asymptotic 95% Confidence Interval 
Lower Bound Upper Bound 
.878 .015 .000 .850 .907 
The test result variable(s): Symptom Index has at least one tie between the positive actual state group and the 
negative actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
From the ROC curve, the optimal diagnostic cut-off value can be determined 




Because these two values are inversely proportional to each other, increasing sensitivity 
leads to a decrease in specificity (Kumar & Indrayan, 2011). If you increase sensitivity to 
correctly identify all cases of Lyme disease (true positives), you lose the ability to 
correctly identify all those individuals who don’t have Lyme disease (specificity) at the 
same time (true negatives). Using any symptom index score above zero for diagnosis 
provides 99.5% sensitivity but 28% specificity (Table 75). Anyone who has Lyme 
disease will be diagnosed with Lyme disease, but there will be a large number of Lyme 
disease negative individuals who are also diagnosed as positive for Lyme disease. Using 
the ROC curve, a symptom index score of 3.7 points as a cut-off point will provide an 
82% sensitivity and a 78% specificity, providing some balance to the diagnostic test and 
a more informed approach to disease diagnosis (Table 76). 
Table 75 
High Sensitivity/Low Specificity Using Symptom Index Score > 0.00  
Parameter Estimate Lower - Upper 95% CIs 
 
Sensitivity 99.51% (97.26, 99.91¹ ) 
Specificity 27.58% (23.37, 32.23¹ ) 
Positive Predictive Value 41.82% (37.5, 46.27¹ ) 
Negative Predictive Value 99.07% (94.94, 99.84¹ ) 






Moderate Sensitivity/Specificity Using Symptom Index Score > 3.69 
Parameter Estimate Lower - Upper 95% CIs 
 
Sensitivity 81.77% (75.89, 86.48¹ ) 
Specificity 77.84% (73.44, 81.68¹ ) 
Positive Predictive Value 65.87% (59.82, 71.45¹ ) 
Negative Predictive Value 89.09% (85.32, 91.98¹ ) 
Diagnostic Accuracy 79.19% (75.73, 82.27¹ ) 
 
Based on the ROC analysis and the multiple linear regression analysis, the 
symptom index score can be used as another tool in the arsenal for diagnosing Lyme 
disease.  
Seasonality of Infection 
Seasonality of infection variables included month of tick exposure and month of 
diagnosis. Based on CDC data (2015), most Lyme disease diagnoses occur during the 
months of June, July, and August. In addition, the winter months (December through 
March) contain the fewest reported Lyme disease diagnoses (CDC, 2015).  
As shown in Figure 16, the distribution of reported month of exposure to the 
Ixodes scapularis tick or the month of symptom onset (for those cases that did not recall a 
tick bite) differs from the distribution of cases by month reported to the Centers for 
Disease Control and Prevention shown in Figure 17 (CDC, 2015). The greatest number of 
cases in this study occurred in May (n = 34) and June (n = 29) with May showing the 
most cases in the study. According to CDC data, July is the month with the greatest 
number of cases overall (CDC, 2015). In addition, study participants reported January 




February have the lowest number of reported cases (CDC, 2015). The study distribution 
directly contradicts CDC data showing the summer months as the most likely months for 





















Figure 16: Total Number of Cases per Month
 
Figure 16. Total number of Lyme disease cases per month within the study population. 
 
 
Figure 17. Confirmed cases of Lyme disease by month of disease onset – United States, 
2001-2010 (CDC, 2015).  
A few cases (n = 21) were removed from this analysis due to missing data for 
either tick bite exposure or month of initial symptom appearance. Either of these dates 




with the Borrelia burgdorferi bacteria (CDC, 2015). If bitten by an Ixodes scapularis tick 
that is in the nymphal stage, a person may not necessarily notice the bite, but would 
experience the same symptoms at disease onset. When both dates were present, date of 
tick bite exposure was used in the analysis. 
Statistical analysis was conducted using SPSS (ver. 21). Descriptive statistics for 
the symptom index scores used for analysis are shown in Table 77. A comparison was 
made between the symptom index score for all cases and the month of diagnosis of Lyme 
disease. The Chi-square results are shown in Table 78. Results show a p-value of 0.371, 
which is greater than the accepted p-value of 0.05. Month of diagnosis is not related to 
the symptom index score. 
Table 77 






Month of Diagnosis vs Symptom Index Score 
 




174 .84 9.20 4.4171 1.93778 
Valid N (listwise) 174     
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 1643.505
a
 1617 .317 
Likelihood Ratio 759.037 1617 1.000 
Linear-by-Linear Association .003 1 .958 




RQ5: Is Lyme disease symptom presentation and severity associated with seasonality of 
infection variables as assessed by medical record and the ROSS Scale survey review? 
H05: Lyme disease symptom presentation and severity are not associated with 
the seasonality of infection variables as assessed by patient medical record 
and the ROSS Scale survey review. 
Ha5: Lyme disease symptom presentation and severity are associated with the 
seasonality of infection variables as assessed by patient medical record and 
the ROSS Scale survey review. 
Because the symptom index score encompasses both symptom presentation and severity 
of symptoms, neither of these characteristics are associated with the seasonality of 
infection of Lyme disease. The null hypothesis is accepted. 
Summary 
Based on the analysis and results presented, Lyme disease symptom presentation 
and severity was affected by the sociodemographic variables age and sex. Assessing 
frequency and severity scores independently provided significant differences between 
cases and controls based on age and sex. Unfortunately, these differences between the 
sexes were not maintained when examining most symptom categories individually.  
In addition, Lyme disease symptom presentation and severity can be used as a 
diagnostic tool (in the form of the total symptom index score), although differences 
between the sexes cannot be used reliably. Musculoskeletal symptoms appeared to show 
a distinct difference based on both age and sex, but the other symptom categories did not 




Lastly, seasonality of Lyme disease infection was not associated with symptom 
presentation or severity of reported symptoms. There was no correlation between the 
month of tick exposure and the severity and frequency of Lyme disease symptoms.  
Overall, the study proposed that the differences in symptom presentation based on 
age and sex could lead to a decrease in the rate of misdiagnosis and under-diagnosis of 
Lyme disease in the general population. The finding that there were few differences 
between males and females in their experience of Lyme disease symptoms is important. 
Many hard to diagnose autoimmune diseases can be mistaken for Lyme disease and are 
found more prominently in one sex over the other. Removing sex from the diagnosis can 
help narrow the diagnostic search for root cause of disease. The following chapter will 





Chapter 5: Discussion, Conclusions and Recommendations 
Introduction 
Although Lyme disease is currently the most frequently reported vector-borne 
illness in the United States, recent evidence from the CDC suggests that the estimates of 
Lyme disease prevalence from the National Notifiable Disease Surveillance System 
(NNDSS) may be inaccurate and actual prevalence levels may be much higher (Binder et 
al., 2012; Borchers et al., 2015; CDC, 2015; Mead., 2015). Lyme disease typically 
presents with many symptoms that can be mistaken for a wide variety of other diseases, 
which can complicate the diagnosis. Unfortunately, the only way to ensure complete 
recovery after treatment with no long term functional disabilities is to receive treatment 
while still in the early localized stage of infection (Aucott et al., 2013; Miraflor et al., 
2016). 
The purpose of this study was to determine the predictive value of symptom 
frequency and severity to diagnose Lyme disease at an earlier stage of infection, and the 
possible confounding effects of sex, age, and seasonality of infection. The results of this 
study suggest that novel diagnostic symptom patterns can significantly predict a 
diagnosis of Lyme disease at an earlier stage of infection, which may lead to dramatic 
improvements in health outcomes for afflicted patients.  
Females over 30 years of age experienced musculoskeletal symptoms more 
frequently and with greater severity than their male counterparts. In addition, the 
presence of the musculoskeletal, neurological, cognitive, and cutaneous symptoms 
observed in this study served as a useful diagnostic tool because musculoskeletal 




neurological symptoms appear 12 times more frequently in Lyme disease cases than in 
controls; cognitive symptoms appear 10 times more frequently in Lyme disease cases 
than in controls; and cutaneous symptoms appear 144 times more frequently in Lyme 
disease cases than in controls. Based on the receiver operator characteristic (ROC) 
analysis, the symptom index score, generated to measure symptom frequency and 
severity, can be used as a diagnostic tool. Unfortunately, no significant relationship was 
found between seasonality of infection and the symptom index score measured in this 
study, so the month of diagnosis was not related to the frequency or severity of 
participant symptoms. The implications of the study findings in terms of advancing 
knowledge in Lyme disease research will be discussed further in this chapter. 
Interpretation of the Findings 
Symptom Frequency and Severity 
Symptom frequency and severity scores were compared between cases and 
controls, males and females, and between different age groups. Significant differences 
were found between cases and controls, based on sex of participants, and between certain 
age groups based on symptom frequency and severity scores. Lyme disease cases of both 
sexes experienced selected symptoms more frequently and with greater severity than 
controls. In addition, significant differences were seen based on the age of the participant. 
The specific symptom categories that contribute most to the identified difference will be 
discussed in this chapter.  
Sex differences. The identified differences between male and female symptom 
frequency and severity scores provided some interesting results. One of the primary 




estrogen. While estrogen’s primary role in the body is during the reproductive cycle in 
women, estrogen does have an effect on the immune system (Baker et al., 2011; Bullard 
et al., 2012; Pennell et al., 2012). Molecular research suggests a possible sex basis with 
estrogen regulation of the immune system response to Borrelia burgdorferi, and is an 
area for future research. The focus of the current study was not based on estrogen levels, 
but the effect of estrogen on the immune system’s response to an invading pathogen 
provides support for the reported sex differences found in this study. 
Few studies have been conducted in the United States that discuss sex and age 
differences in relation to Lyme disease infection. Wormser and Shapiro (2009) found that 
females were more likely to suffer from the chronic stages of infection than other stages, 
although the authors do not feel this difference is related to an inherent difference 
between males and females. Wormser and Shapiro attributed this increase in females with 
chronic Lyme disease to misdiagnosis of Lyme disease in the earlier stages of infection. 
According to the most recent available surveillance data analyzed by the CDC, 53.1% of 
reported cases of Lyme disease were male (Bacon et al., 2008). Based on the 2001-2010 
surveillance data, more males suffered from confirmed Lyme disease than females across 
all age groups (up to age 70 years) in the United States (CDC, 2015). Data collected in 
the current study does not support this trend. 
European studies have found sex and age differences in Lyme disease incidence. 
In a German study conducted by Wilkings and Stark (2014), 55.3% of the Lyme disease 
cases in the study were female (N = 18,894). In addition, women aged 25 – 69 years old 
had an increased rate of diagnosed Lyme disease (Wilkings & Stark, 2014). The data 




and Celec (2014) in Slovakia, Strle et al. (2013) in Slovenia, and Bennet, Stjernberg, and 
Berglund (2007) in Sweden that showed a higher incidence of Lyme disease in females 
over males. The current study supports the European data, but contradicts the few studies 
conducted in the United States. The lack of current studies on sex differences in Lyme 
disease in the United States shows an important area for continued research in the future. 
Erythema migrans rash. The hallmark sign of early stage Lyme disease is the 
presence of the EM rash (Binder et al, 2012; Donta, 2012; Miraflor et al., 2016). 
According to Aucott et al. (2012), the EM rash appears in 70 – 80% of Lyme disease 
cases, but takes on the classic bull’s eye appearance only 20% of the time. In a study 
conducted by Stonehouse, Studdiford, and Henry (2010), the classic bull’s eye 
appearance may actually occur in as few as 9% of cases sampled. The CDC (2015) 
reported that 60 – 80% of Lyme disease cases report the EM rash. Miraflor et al. (2016) 
reported that 50 – 80% of Lyme disease cases display the EM rash. 
One of the few reported sex differences with Lyme disease is related to the EM 
rash. In two separate studies, females were more likely to develop the EM rash than their 
male counterparts and of those females who developed the EM rash; the rash was more 
likely to appear in the nontypical form (Bennet et al., 2007; Strle et al., 2013). The 
studies conducted by Aucott et al. (2012), Stonehouse, Studdiford, and Henry (2010) and 
the CDC (2015) did not report sex differences in EM rash presentation.  
The EM rash percentage (50-80%) reported by the CDC (2015), Miraflor et al. 
(2016), and Aucott et al. (2012) was not supported by the current study. According to the 
data collected, only 28% of case study participants experienced the EM rash, as opposed 




experienced the EM rash, female cases constituted 61% of the cases that experienced the 
rash. The EM rash percentage found in the current study supported recent research 
conducted by Strle et al. (2013), which determined that the EM rash was found more 
frequently in female cases (58%) than male cases (42%). 
In the same study by Strle et al. (2013), women who displayed the EM rash were 
15 years younger than those who did not display the rash. The results from the current 
study may or may not support the results presented by Strle et al. (2013). As shown in 
Table 35, presence of the EM rash in women was present primarily in cases over the age 
of 35, with the largest number of female cases with EM rash falling in the 50-54 year age 
category. This result closely matched the data reported by Strle et al. (2013). 
Unfortunately, other cutaneous symptoms were not measured in the current study so 
additional comparison to Strle et al. (2013) cannot be made. 
In a study conducted by Dandache and Nadelman (2008), the EM rash presence 
shows a bimodal distribution. Caucasian males in age ranges 514 years and 45-54 years 
reported the most cases of EM rash (Dandache & Nadelman, 2008). In addition, 
Dandache and Nadelman (2008) were the first to discuss race in data reporting. The 
current study did not support the reported sex and bimodal age distribution reported by 
Dandache and Nadelman (2008). In the current study, females were more likely to have 
the EM rash. Of the males who had the EM rash in the current study, most were above 
age 55 years. In addition, the current study did not collect data on race or on participants 
under 18 years of age. 
Musculoskeletal symptoms. Musculoskeletal symptoms tested in the current 




Musculoskeletal symptoms are more common during the late stages of B. burgdorferi 
infection, especially in the United States and with the species of Borrelia endemic to this 
area of the world (Feder et al., 2006). In the current study, musculoskeletal symptoms 
occurred more frequently and with greater severity in females over males; in cases more 
often than controls; and between the ages of 30 and 75 years than in other age groups 
below 30 years and over 75 years. Unfortunately, few other studies have been conducted 
examining the variables of age and sex with regard to symptom frequency and severity. 
In a European study conducted by Strle et al. (2013), sex differences were present 
for arthritis symptoms. Within the patient sample (n = 60) diagnosed with Lyme arthritis, 
three quarters of the patients were male (Strle et al., 2013). This significant difference 
was supported even when the possibility of misdiagnosis was controlled for (Strle et al., 
2013). In a study conducted in Germany, male participants made up 52% of the subjects 
positive for Lyme arthritis (Wilking & Stark, 2014). These findings have not been 
supported by other published research in the United States or Europe to date and have not 
been supported by the current study either.  
In the current study, 46% of female cases experienced musculoskeletal symptoms 
every day, while only 18% of males experienced musculoskeletal symptoms every day. 
In a study conducted in Slovakia, 56% of women with Lyme disease had musculoskeletal 
symptoms (Bochnickova, Szilagyiova, & Celec, 2014). In addition, 30% of female cases 
from the current study classified the musculoskeletal symptoms as being completely 
disabling, as opposed to only 12% of the male cases ranking the musculoskeletal 
symptoms with the same severity. These results are directly contradictory to most of the 




species of bacteria causing the infection. In the United States, Borrelia burgdorferi is the 
primary causative agent of Lyme disease and typically presents with musculoskeletal 
symptoms (O’Connell, 2014). In Europe, Borrelia garinii and Borrelia afzelii tend to 
present with neurological symptoms (O’Connell, 2014).  
Neurological symptoms. Neurological symptoms included in the current study 
included: facial paralysis (Bell’s palsy), blurred vision, eye pain, ear ringing, jaw pain, 
testicular/pelvic pain, and tingling/burning/numbness. Neurological symptoms occur 
during the early disseminated stage of Lyme disease (Binder et al., 2012; Donta, 2012). 
Neurological presentation of Lyme disease is often described as neuroborreliosis 
(Koedel, Fingerie, & Pfister, 2015). 
Strle et al. (2013) found that males diagnosed with Lyme neuroborreliosis made 
up 60% of the study population. Unfortunately, Strle et al. only provided the age range of 
participants (15-79 years) but did not provide specific data on age distribution by sex for 
neuroborreliosis cases. Bochnickova, Szilagyiova, and Celec (2014) found that males 
with Lyme neuroborreliosis made up 44% of the study population and morbidity occurred 
between the ages 35-54 years. This morbidity was not differentiated based on sex, so 
direct correlation to the current study cannot be completed. In addition, Wilking and 
Stark (2014) discovered that 57% of the Lyme neuroborreliosis cases were male and 
showed a bimodal distribution. The first mode occurred in males between ages 5-9 years; 
the second mode occurred in males between ages 50-69 years. The current study did not 
support these results.  
While the current study found a significant difference in neurological symptom 




participant, there was no significant difference between neurological symptoms 
experienced by the males and females in the study. The age range for cases experiencing 
neurological symptoms from the current study were primarily in the 35-65 years age 
range, which is consistent with previously published findings (Bochnickova, Szilagyiova, 
& Celec, 2014; Bremell & Hagberg, 2011; Strle et al. 2013; Wilking & Stark, 2014). 
Unfortunately, the neurological symptom results of the current study do not 
support the reported results from these four European studies. All studies reported male 
cases experiencing neurological symptoms more frequently than female cases 
(Bochnickova, Szilagyiova, & Celec, 2014; Bremell & Hagberg, 2011; Strle et al. 2013; 
Wilking & Stark, 2014). The current study shows male and female cases experiencing 
neurological symptoms equally across the range of frequency and severity scores. 
This discrepancy may be related to the fact that all four studies were conducted in 
Europe where the causative agent for Lyme disease is different than the causative agent 
present in the United States. There is strong evidence that the different species of 
Borrelia produce distinctly different symptoms (O’Connell, 2014; Rizzoli et al., 2011). 
Borrelia burgdorferi sensu stricto causes musculoskeletal symptoms; Borrelia afzeli 
causes cutaneous symptoms; and Borrelia garinii causes neurological symptoms 
(Bochnickova, Szilagyiova, & Celec, 2014). The current study did not identify the 
bacterial species that caused Lyme disease in the cases. Because B. afzeli and B. garinii 
are found only in Europe, the assumption was made that all cases were caused by 
Borrelia burgdorferi, the causative agent for Lyme disease in the United States.  
Cognitive Symptoms. Cognitive symptoms included in this category were: 




sadness/depression. Aucott et al. (2013) conducted a study that examined Post-treatment 
Lyme disease syndrome (PTLDS) and the functional disability related to long term Lyme 
disease symptoms. This study by Aucott et al. was the only study that examined cognitive 
symptoms as outlined above. While the Aucott et al. study provided demographic 
information on the study participants, the study did not make comparisons based on age 
or sex. The study had 63 participants (35 males/28 females) whose ages ranged from 20-
75 years (Aucott et al., 2013). In addition, 43 out of the 63 study participants were 
college graduates, which is similar to the education level found within the current study 
case population. Lastly, Aucott et al. found that one-third of the study participants 
experienced cognitive symptoms at the end of the study. 
In the current study, cognitive symptoms were found more frequently and with 
greater severity in cases over controls and upon comparison between age groups. No 
significant difference was found based on sex. Cognitive symptoms associated with 
Lyme disease have not been studied extensively, partially due to the controversy over 
whether PTLDS and chronic Lyme disease exist. Cognitive symptoms are not typically 
found in the early stages of infection, but do show up in the later stages (Aucott, Seifter, 
& Rebman, 2012). In the current study, comparisons were not made based on length of 
time from diagnosis, so participants may have been in the later stages of infection where 
cognitive symptoms would occur. 
General symptoms. Analysis of general symptom frequency and severity results 
are complicated. All of the symptoms are not cause specific and can occur in relation to 
many different infections. General symptoms included in the current study were fatigue, 




nausea, diarrhea, and night sweats. For example, fever and chills are generated in 
response to a bacterial or viral infection, so the presence of these two symptoms in both 
the case and control groups was not surprising (Mayo Clinic, 2015). Dizziness, 
lightheadedness and headache also have a wide variety of causes including infection, 
inner ear problems, eye problems, and blood pressure issues (Mayo Clinic, 2015).  
Each symptom could have multiple causes. Cases and controls were only selected 
based on Lyme disease status. No one was excluded based on the presence of another 
illness, so the presence of the general category symptoms in both groups was expected. 
Comparisons of frequency and severity scores between cases and controls and males and 
females based on the whole group of symptoms did reach the level of statistical 
significance. Because many of the symptoms found in the general symptom category are 
also present during the early localized stage of Lyme disease, further exploration of this 
group of symptoms in diagnosis is warranted.  
Age differences. The immune system undergoes extensive changes as a person 
ages (Giefing-Kroll et al., 2015). Innate immune cells, like macrophages and dendritic 
cells, lose the ability to effectively present foreign antigens to T-lymphocytes for 
activation (Giefing-Kroll et al., 2015). In addition, thymus function declines with age so 
T-lymphocyte maturation is reduced leading to fewer T-lymphocytes available to fight 
infection (Giefing-Kroll et al., 2015). Lastly, effective antibody production also declines 
with age (Giefing-Kroll et al., 2015). Sex-differences of the immune system level off 
with declining production of estrogen by the ovaries as a woman ages (Giefing-Kroll et 




Lyme cases displayed a significant difference from controls with regards to both 
symptom frequency and severity. Symptom frequency and severity scores for cases 
increased progressively as the case ages increased, with the highest frequency and 
severity scores falling in the 35-60 age range. Females made up 2/3 of both the case and 
control populations and most were under 60 years of age. Sixty-four percent of female 
cases and 69% of female controls had not completed menopause yet. Estrogen effects 
were equal between both groups, so differences in symptom frequency and severity 
related to age were based on Lyme disease differences.  
In a study conducted by Nelson et al. (2015), Lyme disease incidence supported 
the CDC bimodal distribution of cases based on age. Males aged 5-9 years and 
males/females aged 60-64 had the highest incidence rate of Lyme disease (Nelson et al., 
2015). In addition, physician diagnosed Lyme disease showed an increased incidence in 
females aged 15-44 years (Nelson et al., 2015). The study by Nelson et al. did not 
examine specific symptoms associated with Lyme disease, but the study does support the 
increased incidence of Lyme disease found in the current study population. 
Unfortunately, few studies have been conducted on symptom frequency and severity of 
Lyme disease symptoms based on age and sex. Reported differences in specific symptom 
presentation have been discussed previously in this chapter.  
Seasonality of infection. In the current study, no differences in symptom 
presentation based on sex and age were found related to month of tick exposure or month 
of diagnosis. Lyme disease transmission to a susceptible host is dependent on the tick life 
cycle and availability of host-tick interactions (Moore et al., 2014). Cases in the current 




typical for tick questing and feeding behaviors (Moore et al., 2014). Month of diagnosis 
varied among cases dependent mainly on whether the EM rash was present or the tick 
was discovered. Based on the current study data, the largest number of cases occurred in 
May (n = 34) and June (n = 29).  
In addition, a large number of cases were diagnosed in January (n = 21). This 
winter diagnosis may be because the EM rash was not present and/or no tick was 
discovered. According to Moore et al. (2014), temperature and moisture levels can affect 
the length of time tick questing and feeding behaviors continue. With a warm or moist 
fall, ticks are able to seek blood meals later in the season leading to later cases of Lyme 
disease (Moore et al., 2014). In addition, warmer weather in fall or spring encourages 
humans to spend more time outdoors, allowing for the opportunity for the human-tick 
interaction to occur (Moore et al., 2014). No matter what month tick exposure or 
diagnosis occurred, there was no significant difference in the way symptoms presented in 
cases. 
Theoretical Framework 
The CDC outbreak investigation model was used as a basis for the current study. 
Ultimately, this model is designed to determine the causative agent involved in a disease 
outbreak and prevent the continued spread of the disease. Lyme disease surveillance has 
been limited, resulting in the under-reporting of Lyme disease cases (Hinkley et al., 
2014). According to Hinkley et al (2014), the number of actual cases of Lyme disease in 
the United States in 2008 was between 288,000 and 440,000 people based on clinical 




Results from the current study can be used to reduce the number of under-reported (and 
untreated) cases of Lyme disease in the United States. 
Lyme disease symptoms frequency and severity are associated with both sex and 
age as supported by the statistically significant differences found between cases and 
controls, males and females (for certain symptoms categories), and various age groups. 
The differences in symptom frequency and severity can be used to aid in the early 
diagnosis of Lyme disease. In addition, the Lyme disease symptom frequency and 
severity symptom index score can be used as a diagnostic tool. Odds ratio calculations 
were performed based on the symptom index score. The musculoskeletal (OR = 11), 
neurological (OR = 12), cognitive (OR = 10) and cutaneous (OR = 144) symptoms all 
displayed significant variation between cases and controls. Clinical symptom observation 
would fall under the “physician-based surveillance” method (Ertel, Nelson, & Carter, 
2012, pg. 246).  
Ertel, Nelson, and Carter (2012) examined the importance of physician-based 
surveillance methods compared to laboratory-based surveillance methods alone or in 
combination with physician-based surveillance. A combination method of laboratory 
diagnosis with physician surveillance provided the most complete and accurate 
surveillance information for case reporting in the earliest stages of infection (Ertel, 
Nelson, & Carter, 2012). The calculated odds ratios and the observed differences between 
Lyme disease cases and controls in symptom frequency and severity found in the current 





Limitations of the Study 
One of the main limitations for this study was sampling bias. Cases needed to be 
Lyme disease positive. This fact reduces the ability to have a true random sample 
population. The sampling bias was addressed in several ways. At the primary care site, 
cases were selected at random based on the daily appointment schedule. During the study 
period, cases who came in for an appointment (whether the appointment was Lyme 
disease related or not) were enrolled in the study. In addition, controls were selected 
based on the daily appointment schedule (for non-Lyme disease patients) or because the 
control was at the primary care site with a patient. At the secondary site, ROSS scales 
were distributed at a variety of meetings on campus to anyone who was in attendance at 
the meeting. This method for selection of meetings and campus groups allowed for some 
random sampling of the population. 
Matching was also utilized to reduce sampling bias (Mann, 2003; Zondervan, 
Cardon, & Kennedy, 2002). First, matching was performed based on state of residence 
for participants. All participants came from one of the 14 Lyme endemic states for 
inclusion in the study. The endemic states include Pennsylvania, New York, New Jersey, 
Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, 
Rhode Island, Vermont, Virginia, and Wisconsin (CDC, 2015). The Lyme endemic states 
correspond to the habitat of the Ixodes tick, the vector for Lyme disease in the United 
States. States of residence for both cases and controls included Connecticut, 
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, and Vermont. 
State of residence matching required at least one case and one control from a state in 




In addition, no cases or controls were enrolled in the study from Wisconsin or 
Minnesota. During data collection, a new species of bacteria was linked to Lyme disease 
– Borrelia mayonii. Currently, this species of Borrelia has only been identified in 
Wisconsin and Minnesota. At the time of the bacteria’s discovery, there were no cases or 
controls that resided in either Wisconsin or Minnesota, so complications associated with 
the new species of Borrelia were not introduced into the current study. 
The second type of matching performed was frequency matching. Frequency 
matching based on sex was performed so that the sample population did not contain a 
single sex in cases or controls (Schlesselman, 1982). Females made up 64% of the case 
population and 69% of the control population. Males made up 36% of the case population 
and 31% of the control population. In addition, a case (n = 203) to control (n = 388) ratio 
of approximately 1:2 was used to reduce sampling bias. 
Matching on education level was performed. While educational level was not a 
variable under study, the secondary site was a college campus. Matching on educational 
level became an important consideration as advanced educational level can change 
socioeconomic status and effect, specifically, access to health care. Because all but five 
of the cases came from the primary care site, a matching of cases between collection sites 
based on educational level was not necessary. Matching between controls based on 
educational level was explored. While the population was not matched person for person, 
participants with at least a college degree were matched by percentage of the total 
population at both sites. In addition, all cases and controls had at least a high school 
education. With all three types of matching performed to minimize sampling bias, 




An additional limitation of this study was recall bias. Recall bias occurs when 
cases recall exposures more frequently than controls (Hassan, 2005; Pannucci et al., 
2010; Schulz & Courtright, 2002). This differential recall between cases and controls can 
be intentional or unintentional (Hassan, 2005). This recall difference often occurs 
because the cases spend more time trying to determine what exposure may have led to 
their disease state (Pannucci et al., 2010; Schulz & Courtright, 2002). In addition, the 
amount of time between an occurrence and the remembrance of an occurrence can 
contribute to the problem (Hassan, 2005; Pannucci et al., 2010). The longer the time 
frame, the more likely recalled data may be distorted (Hassan, 2005).  
To reduce recall bias, all participants were asked to fill out a ROSS scale. The 
ROSS scale collects symptoms for the week prior to the date the form is filled out, so the 
amount of time between symptom occurrence and recall is minimized. The ROSS scale is 
completed at each visit to the primary care clinic, so symptoms in cases were verified by 
comparison to the previous visit’s ROSS scale. 
An additional way to address recall bias is to use an instrument with a high degree 
of validity (Hassan, 2005). Data for this study was collected using a modified Burrascano 
Symptom Checklist that is based on the Wahler Physical Symptoms Inventory (PSI), 
which has demonstrated previously to have a high level of internal consistency on test-
retest scores over several different subgroups (Wahler, 1968). The PSI collects data on 
the frequency of general symptoms associated with most any illness, but does not 
specifically address severity of symptoms. A modified version of the PSI was created by 
Burrascano (2008) to address the specific symptoms associated with Lyme disease and 




Checklist (ROSS scale) was created by my clinical partner to address the needs of his 
practice. The only modification in both the Burrascano Symptom Checklist and the PSI 
was to reduce the number of symptoms surveyed. Symptoms surveyed were specific to 
Lyme disease; all other symptoms were removed. 
One additional limitation of note was the fact that most cases (n = 198) came from 
a single clinical practice. The clinical practice treats a large number of Lyme disease 
patients each year, some of whom are in the later stages of infection. Because this clinical 
practice specializes in Lyme disease and treats patients in the later stages of infection, 
reported symptom frequency and severity may reflect long term infection. All cases were 
not necessarily in the same stage of infection. 
The use of the EM rash as a diagnostic tool for identifying cases is also a 
limitation. Based on the CDC criteria for reporting cases to the NNDSS, presence of the 
EM rash is a positive indicator of Lyme disease and no further testing is required (CDC, 
2015). In addition, both the IDSA and ILADS accept the presence of the EM rash as a 
positive indicator of Lyme disease and don’t require further testing to confirm the 
diagnosis (Cameron, Johnson, & Maloney, 2014; Wormer et al., 2006). The current study 
only identified the EM rash in 28% of cases and other studies found the EM rash didn’t 
follow the classic bull’s eye pattern (Aucott et al., 2012; Bennet et al., 2007; Stonehouse, 
Studdiford, & Henry, 2012; Strle et al., 2013). If the presence of the EM rash is 
considered a gold standard for diagnosis and not all cases of Lyme disease experience the 
EM rash, other avenues to early diagnosis must be explored. 
The final study limitation also leads into areas for further research. All data 




records, control data could not be independently verified. Unfortunately, the study 
required participant self-reporting of symptoms and severity. All cases and controls 
received the same forms, were allowed take as much time as needed to fill the forms out, 
and were assured of the completely anonymous nature of the form as no personal 
identifiers were included on the form.   
Future Research 
Symptoms, by definition, are subjective since they are experienced only by the 
person describing them. The severity of a symptom is also subjective; what one person 
experiences as debilitating pain may be considered minor by another. This difference in 
symptom reporting and severity may be related to sex. In a review of the literature 
conducted by Barsky, Peekna, and Borus (2001), women consistently reported “more 
intense, more numerous, and more frequent bodily symptoms than men” (pg. 266). 
Kroenke and Spitzer (1998) found that symptom reporting was significantly higher in 
women than in men, regardless of the symptom type surveyed.  
Some of the symptoms in the current study were included in the Barsky, Peekna, 
and Borus (2001) and the Kroenke and Spitzer (1998) studies. These symptoms included 
headache, nausea, fatigue, palpitations, joint pain, and back pain (Barsky, Peekna, & 
Borus, 2001; Kroenke & Spitzer, 1998). Joint and back pain was assessed as part of the 
musculoskeletal category of symptoms when analyzing study data and displayed a 
significant difference between males and females in the current study. Headache, nausea, 
and fatigue were included in the general category of symptoms and were only included in 
the total symptom index score. Palpitations were included in the cardiac category of 




In cases where a specific disease was experienced, these sex differences in 
symptom reporting disappeared (Barsky, Peekna, & Borus, 2001; Davis, 1981; Eskelinen, 
Ikonen, & Lipponen, 1994; Katz & Criswell, 1996; Macintyre, 1993; Marshall & Funch, 
1986). Katz and Criswell (1996) studied rheumatoid arthritis, an autoimmune disease. 
Eskelinen, Ikonen, and Lipponen (1994) studied acute appendicitis, caused by a bacterial 
infection, and Macintyre (1993) studied the common cold, caused by a virus. Lastly, 
Marshall and Funch (1986) studied colorectal cancer. Since the current study was based 
on a specific disease (Lyme disease), the sex differences in reporting may also be 
minimal.  
Many of the research studies cited are older studies; the current focus of sex 
differences in symptom reporting has shifted to specific diseases and variations in 
reporting based on age group. Macintyre, Hunt, and Sweeting (1996) suggested that 
gender differences in symptom reporting vary over the course of a person’s lifetime. Both 
sex and age based differences in Lyme disease symptom reporting across a period of time 
would make an interesting area to explore next.  
An additional area for future research focuses on the biological differences related 
to the immune system response to an infection. Pennell et al. (2012) discussed the 
differences in immune system responses based on genes contained on the X-chromosome 
and the presence of miRNA. While genetic influences were not a part of the current 
study, sex based differences in symptom presentation, frequency and severity could be 
related to the physical differences in how the immune system reacts to the Borrelia 
bacteria. The X-chromosome contains miRNA; the Y-chromosome does not (Pennell et 




regulate the immune system response (Pennell et al., 2012). Genetic mapping of miRNAs 
from case X-chromosomes may present some insight into the symptom presentation 
differences found in the current study. 
Positive Social Change Implications 
The suggested implications of this research for positive social change include 
increased knowledge of the sex differences found in Lyme disease; prevention of delays 
in diagnosis and treatment for patients with Lyme disease; decreased expenses associated 
with late Lyme disease due to increased diagnosis in the early stage of infection; and 
early access to needed health care services. 
Based on the results of the current study, presence of the EM rash and the 
musculoskeletal symptoms examined in this study displayed a significant difference 
based on both sex and age variables. The EM rash did not occur as frequently overall as 
reported in previous studies; the EM rash only appeared in 28% of cases in the current 
study (Binder et al., 2012; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009; 
Miraflor et al., 2016; Wormser et al., 2006). Of the 28% of cases that reported the EM 
rash, 56% were women over the age of 35 years. Musculoskeletal symptoms were present 
with greater frequency and severity in female cases over male cases.  
In addition, this significant difference extended to case/control differences. 
Significant differences between cases and controls were also found for the overall 
symptom index scores, as well as the specific symptoms in the neurological and cognitive 
categories. Because all of the symptoms of Lyme disease can be associated with another 




in Lyme disease cases will help with the earlier diagnosis of the disease (Henry et al., 
2012).   
Based on a recent online survey conducted by Lymedisease.org, only 7% of the 
6,000 study participants were diagnosed within the first month after the initiation of 
symptoms (Lymedisease.org, 2015). Most research suggests that earlier treatment 
provides the patient’s best chance for a full recovery (Cameron, 2007; Donta, 2012; 
Johnson & Stricker, 2004). Once treatment is initiated, 80-90% of patients significantly 
improve (CDC, 2015). Delaying treatment can be costly, both in patient health costs and 
in reduced quality of life (Johnson et al., 2011). Zhang et al. (2006) determined that the 
annual health care costs associated with late Lyme disease treatment ($16,199 per person) 
can be 12 times higher than those costs associated with early Lyme disease treatment 
($1,310 per person). 
During the early stage of infection, treatment with beta-lactam antibiotics is 
highly successful at killing the bacteria and stopping the progression of the infection 
(Binder et al., 2012; Cameron, 2007; Donta, 2012; Franz & Krause, 2003; Girschick et 
al., 2009; Johnson & Stricker, 2004; Muellegger, 2004; Wormser et al., 2006). Late phase 
infections may require longer term or intravenous treatments with antibiotics (Binder et 
al., 2012; Cameron, 2007; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009; 
Johnson & Stricker, 2004; Muellegger, 2004; Wormser et al., 2006). Unfortunately, 
antibiotic treatment for late phase infections does not always result in a complete 
recovery with no symptoms (Johnson et al., 2011). It is in these instances that post-




Because late phase manifestations can be incapacitating, adults could be burdened 
with “functional impacts” of Lyme disease (Aucott et al., 2013, p 2). Functional impacts 
occur when a patient experiences symptoms, and/or increased severity of symptoms, that 
prevent them from completing daily activities (Aucott et al., 2013). These functional 
impacts may include loss of job, loss of productivity, lapse of insurance coverage, and 
disability (Johnson et al., 2011). In fact, loss of productivity makes up more than half the 
costs of late Lyme disease infection (Johnson et al., 2011). Early, accurate diagnosis of 
Lyme disease can prevent all of these impacts by stopping the spread of the infection 
before the serious complications of late Lyme disease occur. 
Early, accurate diagnosis of Lyme disease is so important to recovery that the 
federal government is working on legislation to improve the possibility for early 
detection. In the House of Representatives, HR 4701 – “Vector-Borne Disease Research 
Accountability and Transparency Act of 2014” passed in September 2014. This act 
establishes an advisory committee to examine all aspects of Lyme disease including 
research, diagnosis and treatment and includes all stages of Lyme disease, including the 
heavily disputed chronic Lyme disease stage (Lyme Disease Association, 2016). In the 
U.S. Senate, The Lyme and Tick-Borne Disease Prevention, Education, and Research Act 
of 2015 was proposed in July 2015. This act provides more federal government action in 
the development of education and prevention programs, along with enhanced research 
support for diagnosis and treatment options for Lyme disease patients (Lyme Disease 
Association, 2016). Vital to creation of federal legislation are research findings to provide 




used to provide additional insights into sex and age differences in symptom presentation 
of Lyme disease.  
In addition, 18 states have proposals under consideration to become laws (Lyme 
Disease Association, 2016). Currently, eleven of those states have some type of law in 
place to allow extended treatments for Lyme disease patients and to protect physicians 
from medical hearing and licensing issues related to extended Lyme disease treatments. 
Proposals that require insurance companies to pay for extended treatments are also being 
considered. Each of these instances provide Lyme disease patients the opportunity for 
access to the necessary treatments for complete recovery once the infection has moved 
beyond the early stages of infection. 
Methodological Implications 
The current study followed a quantitative quasi-experimental methodology. A 
case/control prospective study was conducted to determine whether frequency and 
severity of Lyme disease symptoms were different in males and females or based on the 
age of the individual. In addition, the current study sought to determine if Lyme disease 
symptom frequency and severity could be used as a diagnostic tool through calculation of 
a symptom index score. 
This method was well suited for data collection and analysis to answer the 
research questions posed. A few changes to the study design would improve the outcome 
slightly. Additional locations for control enrollment would help boost the sample size of 
the population. Surprisingly, case enrollment was easy. The minimum number of cases 
required to reach statistical significance was quickly reached. Unfortunately, control 




controls to reach the 1:2 case to control ratio needed to reduce the sampling bias present 
in the study. 
The ROSS scale has been used by the primary care clinic physician for many 
years and is a modification of a validated instrument. Despite this fact, the ROSS scale 
has not been validated on its own. Comparing reported results within the study population 
(N = 591), participant answers displayed consistent reporting across the entire study 
population, which provides some support for the validity of the instrument. In addition, 
evidence of consistency from patient medical records is present. Patients at the primary 
care clinic fill out the ROSS scale at each visit, so consistency is present from form to 
form.  
Lastly, race/ethnicity information was not collected in the current study, but a 
recently published study conducted by Nelson et al. (2016) suggested that Lyme disease 
among the Hispanic population in Lyme endemic states is increasing. Lyme disease 
displayed the same bimodal age distribution in the Hispanic population that is reported 
overall for Lyme disease (Nelson et al., 2016). This bimodal distribution was slightly 
skewed to older age groups (Nelson et al., 2016). In addition, Hispanic males were 
reported to have Lyme disease more frequently than Hispanic females (Nelson et al., 
2016). One interesting finding from the Nelson et al. study was that Hispanic males and 
females are often diagnosed at a later stage of infection than their Caucasian counterparts. 
Lack of access to health care was the proposed cause.   
In an earlier study conducted in Connecticut, Caucasians made up 82% of the 
reported cases of Lyme disease and Hispanics made up only 1% of the sample population 




primarily Caucasian disease with 94% of all reported cases for 1992-2006, with Blacks, 
Asians/Pacific Islanders, and American Natives/Alaskan Natives making up the other 6% 
(CDC, 2008). In the case of African Americans, inability to recognize the EM rash may 
lead to misdiagnosis in the early stage of infection (Borchers et al., 2015). No ethnicity 
data was available at all and data for the time period 2006-2015 was not available. More 
studies on race/ethnicity variations in Lyme disease are required.  
Recommendations 
Diagnosis of Lyme disease continues to be a controversial topic. The efficacy of 
the two-tiered testing method recommended by the CDC is consistently called into 
question (Donta, 2012; Moore, 2015; Stricker & Johnson, 2011). Typically, the issue is 
related to when the two-tiered testing is performed. The first step in the two-tiered testing 
process is an enzyme immunoassay (EIA), which looks for IgM and IgG antibodies to 
Borrelia (Borchers et al., 2015). The second test is the Western Blot (Moore, 2015). 
Unfortunately, antibody production takes some time after exposure to an antigen – IgM 
antibodies develop first but can take up to two weeks to be found in measureable 
quantities (Borchers et al., 2015). IgG antibodies develop later in the infection and are not 
found in measureable quantities until 4-6 weeks after the initial infection (Borchers et al., 
2015). In addition to this delay in production, the EIA and Western Blot tests cannot 
distinguish between old and new infections (Borchers et al., 2015). Lastly, the cost of the 
two-tiered testing method has increased in recent years. According to Hinkley et al 
(2014), the cost of two-tiered testing for Lyme disease in 2008 was $492 million. As the 




In addition to the problems associated with the two-tiered testing methods, a 
second imperfect diagnostic method is the presence of the EM rash (Binder et al., 2012; 
CDC, 2015; Donta, 2012; Franz & Krause, 2003; Girschick et al., 2009; Miraflor et al., 
2016; Wormser et al., 2006). The current study, as well as other studies, showed that the 
EM rash does not occur in all cases of Lyme disease (Aucott et al., 2012; Bennet et al., 
2007; Miraflor et al., 2016; Stonehouse, Studdiford & Henry, 2010; Strle et al., 2013). If 
the EM rash is present, it may have a non-typical appearance (Aucott et al., 2012).  
Lastly, PCR and bacterial culturing from infected tissues are alternative testing 
methods that can be used to confirm diagnosis (Borchers et al., 2015). Both methods are 
expensive, time-consuming, and not always successful (Borchers et al., 2015). Waiting 
for results from both PCR and bacterial culturing would delay treatment as well 
(Borchers et al., 2015).  
With these issues in mind, finding alternative methods for diagnosis is important. 
The symptom index scoring (SIS) system is based on symptom frequency and severity as 
experienced by the patient. The SIS system can be used at the initial visit independent of 
when the tick exposure happened or whether enough time has elapsed for antibodies to be 
produced. The SIS system’s only requirement is computer access and the computational 
Excel spreadsheet developed as part of the current research study. While the SIS system 
is not a standalone diagnostic tool, it can be used during any stage of infection and will 
help to identify possible Lyme disease cases.  
Conclusions 
Lyme disease is a vector-borne disease that is caused by the bacteria Borrelia 




pacificus ticks in the United States. Lyme disease is endemic to 14 states, primarily 
located in the northeastern section of the United States. As the habitat for the tick vector 
expands, the incidence of Lyme disease will increase in new states along the border for 
the current endemic region. 
Based on the results of the current research study, Lyme disease symptom 
frequency and severity display significant differences based on biological sex and age. In 
addition, odds ratio variations support these differences. The likelihood of an individual 
experiencing musculoskeletal symptoms with Lyme disease is 11 (95% CI: 6.34, 18.49) 
times higher than experiencing those symptoms in the absence of Lyme disease. The 
likelihood of an individual experiencing neurological symptoms with Lyme disease is 12 
(95% CI: 7.90, 19.48) times more likely than experiencing neurological symptoms in the 
absence of Lyme disease. The likelihood of an individual experiencing cognitive 
symptoms with Lyme disease is 10 (95% CI: 5.24, 17.30) times more likely than 
experiencing cognitive symptoms in the absence of Lyme disease. The likelihood of an 
individual experiencing cutaneous symptoms with Lyme disease is 144 (95% CI: 19.72, 
1048.73) times more likely than experiencing cutaneous symptoms in the absence of 
Lyme disease. Each of these symptoms can then be used to help diagnose Lyme disease 
at an early stage of infection, where treatment will be the most successful. 
The symptom index scoring (SIS) system can provide assistance in the diagnosis 
of Lyme disease at any stage of infection. A minimal calculated score of 3.7 or higher in 
the SIS system is suggestive of Lyme disease infection. The SIS system has 82% 




be another weapon in the arsenal for early Lyme disease diagnosis. The earlier the 
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Appendix A: ROSS Scale 
Sex:     Date of Birth:   State of Residence:   
Male                 
Female  
 
Menopause:       Occupation: 
 Completed 
 Experiencing symptoms now         
 Have not experienced symptoms yet 
 Not applicable      
 
Marital Status:   Education Level:  Number of Children Under 18: 
Married          High School Graduate   0 
Single          College Graduate   1-2 
Divorced   Graduate School    3-4 
Widowed   Technical School   5+ 
 
ANSWER THE NEXT QUESTIONS IF YOU ARE A LYME AND ASSOCIATED DISEASES PATIENT 
 
History of Tick Bite:   Date of Tick Bite (Month/Year)  Bull’s Eye Rash 
Present:         
Yes                     Yes 
No          No 
 
Lyme Test Positive:   Which Test (if Applicable): 
 Yes             ELISA 
No      Western Blot 
     Other:        
 
Date of Initial Diagnosis (MM/YY): Diagnosis Based on: 
      Clinical Symptoms 
      EM Rash 
Date of Initial Symptoms(MM/YY):  ELISA and Western Blot 
      Other:       





Please put an X in the box that BEST describes the frequency of each symptom as you 
experienced it – DURING THE PAST WEEK. 
Symptom Never 1-2 days 3-4 days 5-6 days Everyday 
      
Fatigue/Tiredness           
Fever           
Chills           
Facial Numbness           
Disturbed Sleep           
      
Poor Concentration           
Memory Loss           
Irritability           
Crying           
Sadness/Depression           
      
Headaches           
Blurred Vision           
Eye Pain           
Ear Ringing/Buzzing           
Jaw Pain           
      
Sore Throat           
Swollen Glands           
Dizziness           
Lightheadedness           
Stiff Neck           
      
Back Pain           
Chest Pain           
Palpitations           
Nausea           
Diarrhea           
      
Testicular/Pelvic Pain           
Tingling/Numbness/Burning           
Painful Joints           
Stiff Joints           
Sore Muscles           
      
Night Sweats      
Other      




Please put an X in the box that BEST describes the severity of each symptom as you  
experienced it – DURING THE PAST WEEK. Scale: 0 – Not affected; 1 – slightly noticeable; 2 – 
Minor problem but noticeable; 3 – Moderate problem that interferes with some daily 
activities; 4 – Major problem that interferes with most daily activities; 5 – Disabling 
Symptom 0 1 2 3 4 5 
       
Fatigue/Tiredness           
Fever           
Chills           
Facial Numbness           
Disturbed Sleep           
       
Poor Concentration           
Memory Loss           
Irritability           
Crying           
Sadness/Depression           
       
Headaches           
Blurred Vision           
Eye Pain           
Ear Ringing/Buzzing           
Jaw Pain           
       
Sore Throat           
Swollen Glands           
Dizziness           
Lightheadedness           
Stiff Neck           
       
Back Pain           
Chest Pain           
Palpitations           
Nausea           
Diarrhea           
       
Testicular/Pelvic Pain           
Tingling/Numbness/Burning           
Painful Joints           
Stiff Joints           
Sore Muscles           
       
Night Sweats       
Other       




Appendix B: Permissions 
Permission to modify the Burrascano Symptom Checklist to align with the ROSS 
Scale 
Hi Dr. Burrascano, 
  
My name is Vicki Stanavitch and I am an Assistant Professor at Keystone College, but I am 
writing to you today in my other role as a PhD Candidate at Walden University. I am working 
with Dr. Daniel Cameron as my clinical supervisor and he gave me this email address.  
  
I am proposing a Lyme disease study to look at whether there are differences in symptom 
presentation and severity based on sex or age. I would like to use your Symptom Checklist with a 
slight modification as the measurement instrument. I am looking for either your permission or 
your confirmation that the checklist is in the public domain. I need this for my IRB application.  
  
You will be given full credit in all publications or presentations for the instrument whether it is in 
the public domain or not.  
 
The modification that will be made will be two-fold. 
  
1. A few of the symptoms listed have been eliminated to allow for data collection and analysis to 
be simplified.  
  
2. The severity and frequency scale will be quantified in the following way: 
  
a. frequency will be measured as never, 1-2 days, 3-4 days, 5-6 days, and/or everyday 
  
b. severity will be measured as not affected, slight/barely noticeable, minor problem but 
noticeable, moderate problem that interferes with some daily activities, or major problem that 
interferes with most daily activities. 
  
Both of these changes will help in the quantitative analysis of the data collected. 
  
I hope that you will either give me permission to use your checklist or confirm that it is part of 
the public domain. 
  




Vicki A. Stanavitch  
Assistant Professor of Biology, Chemistry and Public Health 
Faculty Coordinator for Undergraduate Research 
Keystone College 
One College Green 














Vicki A. Stanavitch 
Inbox 





You forwarded this message on 9/24/2014 8:33 PM. 
Good morning 
Thank you for your e-mail. Your work sounds exciting! I would be happy to allow your 
use of my checklists as you outlined. All I ask is that you send to me a copy of the revised 
checklists. I would also love to get a copy of the results of your eventual studies- would 
make me happy to see my work being expanded upon. 
Best wishes and congratulations on your Doctorate. 
Dr. B 
  
Joseph J. Burrascano Jr. M.D. 
Water Mill, NY, USA 
Sent from my LapTop 






Vicki A. Stanavitch 
Inbox 





You forwarded this message on 4/28/2015 10:27 AM. 
Good news. You can use the ROSS with our name on the scale. 
Dr. Cameron 
On 4/28/15 9:59 AM, Vicki A. Stanavitch wrote: 
Hi Dr. Cameron, 
  





I am working on the IRB approval for data collection here at Keystone College so that I 
can increase the control population for my study. 
  
I need your permission to use the ROSS Scale to collect control data here at the College. 
The IRB requires your written permission for use. I know you had given me verbal 
permission at the clinic, but I have to provide that permission in writing. I can remove 
your name from the scale if you prefer. 
  
An email stating that it is fine to use the scale is all I need…nothing more formal is 
required. Let me know as soon as you can.  
  




Vicki A. Stanavitch 
Assistant Professor of Biology, Chemistry, and Public Health 
Faculty Coordinator of Undergraduate Research 
Keystone College 
One College Green 
Capwell Hall 





Permission to publish the ROSS Scale as part of my dissertation 
ROSS Scale Permission 
 
 






Vicki A. Stanavitch 
Attachments: 
‎(2)‎Download all attachments 










  You have my permission to include the modified ROSS scale in your 
final dissertation.  I would appreciate being a contributor to your 
outstanding research. 
Dr. Cameron 
 
